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Zusammenfassung 
Beta-Laktamasen mit erweitertem Wirkungsspektrum (ESBLs) 
Das Auftreten von Resistenzen gegen Beta-Laktam Antibiotika ist ein Problem von 
zunehmender Bedeutung weltweit. Das Vorkommen von Beta-Laktamasen mit 
erweitertem Wirkungsspektrum (Extended Spectrum Beta-Lactamases, ESBL) ist 
hierbei besonders problematisch. Die am häufigsten vertretenen Enzyme dieser Art 
in klinischen Isolaten sind Varianten von TEM-1 oder SHV-1 Beta-Laktamasen. 
Diese zahlreichen Varianten unterscheiden sich von den Urtypen durch 
Aminosäureaustauschmutationen, die zu einer Erweiterung des Substratspektrums 
führen und auch Resistenzen gegen neuere Generationen der Beta-Laktam 
Antibiotika (Cephalosporine der 3. und 4. Gruppe) vermitteln. Sie werden durch so 
genannte Beta-Laktamase Inhibitoren (z. B. Clavulansäure oder Tazobactam) 
gehemmt. Es treten aber auch Varianten der TEM- oder SHV-Familie auf, die 
Resistenzen gegen eben diese Inhibitoren vermitteln, jedoch nicht gegen 
Cephalosporine der neueren Generation. Diese Enzyme gehören daher nicht zur 
Gruppe der ESBLs und werden als IRTs (ursprünglich für Inhibitor Resistant TEM) 
bezeichnet. Sequenzen von über 120 TEM- und 50 SHV-Varianten sind bisher 
veröffentlicht. ESBLs und IRTs sind plasmidkodiert und treten in vielen 
verschiedenen Spezies der Gattung Enterobacteriacae, hauptsächlich in Klebsiella 
pneumoniae und Escherichia coli, aber auch in Pseudomonas aeruginosa, 
Haemophilus influenzae, und Neisseria gonorrhoe auf (16). In den letzten Jahren hat 
die Häufigkeit von Enterobacteriacae mit Resistenz gegen Cephalosporine der 3. 
Gruppe deutlich zugenommen (181). Laut einer von 1997-1999 durchgeführten 
Studie treten resistente Stämme inner- und außerhalb des Krankenhauses mit einem 
für ESBL charakteristischen Phänotyp bei K. pneumoniae zu 45 % in Lateinamerika, 
zu 25 % in der Region des westlichen Pazifik, zu 23 % in Europa und zu 8 % in den 
USA auf (180). 
 
Phänotypischer Nachweis von ESBLs 
ESBL produzierende Organismen stellen ein besonderes Problem im klinischen 
Alltag dar, da sie mit herkömmlichen phänotypischen Screening-Methoden schwierig 
nachzuweisen sind. Die bisher aufgetretenen Enzymvarianten unterscheiden sich 
durch eine Vielfalt von Mutationspositionen, die zu stark unterschiedlichen 
Substratspektren führen. Die Auswahl des zu testenden Antibiotikums ist daher 
kritisch, z.B. kann ein Enzym Ceftazidim gut hydrolysieren mit einer Minimalen 
Hemmkonzentration (MHK) von bis zu 256 µg/ml, während es Cefotaxim nur 
unzureichend umsetzt, mit einer MHK von nur 4 µg/ml (95). Um einen zuverlässigen 
Nachweis aller ESBLs zu gewährleisten, muss die Empfindlichkeit der Isolate daher 
gegen eine Auswahl verschiedener Antibiotika getestet werden. Eine nicht 
nachgewiesene Resistenz kann zum Therapiemisserfolg führen und außerdem zu 
einer Verbreitung der Resistenz beitragen. Ein weiterer Grund für die 
Unzuverlässigkeit der bisherigen Methoden zum Nachweis von ESBLs ist die 
Abhängigkeit der Minimalen Hemmkonzentration von der eingesetzten Startmenge 
der Bakterien im Test, dem so genannten Inokulum-Effekt (108,132,168). Eine 
unzureichende Menge eingesetzter Bakterien kann somit zu falsch-negativen 
Ergebnissen führen. Hinweis darauf, dass dieser Inokulum-Effekt auch bei klinischen 
Infektionen auftritt, geben Berichte über Therapiemisserfolge und suboptimale 
klinische Ergebnisse, sowie eine erhöhte Sterblichkeitsrate von Patienten bei der 
Zusammenfassung 
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Behandlung von ESBL-Infektionen mit Cephalosporinen, obwohl die festgestellten 
MHK-Werte im empfindlichen Bereich lagen (89,124,142,149).  
 
Um die Zuverlässigkeit der Ergebnisse des ESBL Screenings zu erhöhen, ist die 
Durchführung von zusätzlichen phänotypischen Tests zur Bestätigung des ESBL-
Verdachts unerlässlich (115). Da die üblichen phänotypischen Testverfahren auf dem 
Nachweis der Hemmung des Wachstums von Bakterien in Anwesenheit 
verschiedener Antibiotikakonzentrationen beruhen, sind diese Verfahren sehr 
zeitaufwendig (98). Es kann bis zu drei Tagen dauern, bis der Verdacht auf Infektion 
mit einem ESBL-produzierenden Organismus bestätigt werden kann. Da eine 
effiziente Antibiotikatherapie jedoch so früh wie möglich einsetzen muss, wird die 
bisherige Resistenzdiagnostik eher retrospektiv denn predikitiv eingesetzt. Um 
Therapiemisserfolge zu vermeiden, werden daher mehr Breitbandantibiotika als 
notwendig verschrieben. Dies fördert die Verbreitung neuer Resistenzen. Infektionen 
mit ESBL produzierenden E. coli und K. pneumoniae werden mit längeren 
Krankenhausaufenthalten und höheren Behandlungskosten in Verbindung gebracht 
(85). Daher ist die Entwicklung präziserer und schnellerer Testmethoden zum 
Nachweis von ESBLs notwendig.  
 
Genotypischer Nachweis von ESBLs 
Die Mikroarray Technologie erlaubt die genotypische Identifizierung von Resistenzen 
innerhalb einer Analysezeit von weniger als einem Tag. Hierbei können, im 
Gegensatz zur phänotypischen Diagnostik und auch zu vielen anderen 
genotypischen Nachweisverfahren, alle relevanten Mutationspositionen erkannt und 
somit auch verschiedene ESBL-Typen differenziert nachgewiesen werden. Für viele 
ESBL-Varianten wurde bereits ein spezifisches Substratspektrum definiert (21,130), 
welches nach der eindeutigen Identifizierung auf der molekularen Ebene zu Rate 
gezogen werden kann, um eine spezialisierte, prediktive Diagnostik zu ermöglichen. 
Weiterhin kann die genotypische Identifizierung, im Gegensatz zum phänotypischen 
Nachweis, für eine zuverlässige Überwachung der Verbreitung bestimmter 
Resistenzmerkmale oder multiresistenter Bakterien im klinischen Umfeld eingesetzt 
werden. 
 
Nachweis von ESBLs per DNS-Mikroarrayanalyse 
In dieser Arbeit wurde ein diagnostischer Mikroarray entwickelt für den schnellen und 
spezifischen Nachweis der Mutationen der meisten zurzeit bekannten TEM und SHV 
Beta-Laktamase Varianten, die verantwortlich für die Ausprägung eines ESBL oder 
IRT Phänotyps sind. Die Allel-spezifische Hybridisierung auf dem DNS-Mikroarray 
erlaubt nun den Nachweis und die Identifizierung von 41 Mutationspositionen der 
TEM Beta-Laktamase Familie (entspricht 99 % der veröffentlichten Positionen) und 
37 Mutationspositionen (entspricht 100 % der veröffentlichten Positionen) relevant für 
SHV. Dies ermöglicht die Identifizierung von 96 % der bis jetzt bekannten TEM 
Varianten und 100 % der SHV Varianten. Konsensus-Primer, die homolog zu den 
veröffentlichten Sequenzen der Varianten sind, wurden entwickelt und erlaubten die 
Vervielfältigung der Resistenzgene per PCR.  
 
Entwicklung des Systems 
Anfänglich wurde der Array auf einer Poly-L-Lysin Oberfläche hergestellt, welche 
jedoch unzureichende Ergebnisse lieferte in Bezug auf Sensitivität und 
Zusammenfassung 
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Reproduzierbarkeit der Analyse. Durch Einsatz einer Epoxid-Oberfläche zur 
Immobilisierung der Sonden und eines phosphatsalzhaltigen Druckpuffers, sowie 
durch Optimierung des Druckprozesses konnte die anfänglich festgestellte hohe 
Varianz zwischen Signalintensitäten von Replika von 68 % im Mittel (für vier Replika 
innerhalb eines Arrays auf Poly-L-Lysin) auf durchschnittlich 18 % (für 9 Replika 
innerhalb von drei Arrays auf Epoxid) reduziert werden. Diese Varianz liegt innerhalb 
der technischen Grenzen für durch Kontaktdruckverfahren hergestellte Mikroarrays 
(157,185). Weiterhin konnten die erhaltenen Fluoreszenzsignalintensitäten um 
mindestens den Faktor 3 gesteigert werden und somit die Sensitivität des Systems 
durch den Einsatz der neuen Oberfläche erhöht werden. Dies kann entweder auf 
eine bessere Immobilisierungseffizienz (55) oder auf bessere Zugänglichkeit der 
Sonden auf der Epoxid-Oberfläche zurückgeführt werden. 
 
Entwicklung einer neuen Methode des Sondendesigns 
Für fünf SHV-Polymorphismen konnten keine üblichen Sondensets zur Allel-
spezifischen Hybridisierung entwickelt werden, da die zur getesteten Ziel-DNS 
komplementären Sonden starke Sekundärstrukturen aufwiesen. Dies kann zu 
Unzugänglichkeit der Sonden für die Hybridisierung der Ziel-DNS führen (111,112). 
Für diese Positionen wurden neue Sonden entwickelt, bei denen die vorhandene 
Sekundärstruktur durch Einfügen einer ungepaarten Base geschwächt, bzw. 
aufgehoben wurde. Für vier der fünf Positionen konnte auf diese Art ein spezifischer 
Nachweis der korrekten Mutationspositionen ermöglicht werden. 
 
Validierung mit Referenzstämmen und klinischen Isolaten 
Die Sensitivität, Reproduzierbarkeit und die Spezifität der Identifizierung der 
unterschiedlichen Varianten per Mikroarrayanalyse wurde anhand von 
Referenzstämmen (für TEM: blaTEM-3,-7,-8,-116; für SHV: blaSHV-1,-2,-3,-4,-5,-7,-8) 
nachgewiesen. Hierbei wurden alle untersuchten Mutationspositionen eindeutig und 
reproduzierbar identifiziert. Weiterhin wurde der TEM-Array validiert durch die 
Mikroarrayanalyse von 72 klinischen Isolaten, die aus unterschiedlichen Institutionen 
in Deutschland, Kroatien und Russland stammten. Zur Validierung des SHV-Arrays 
wurden 30 klinische Isolate aus Kroatien getestet. Siebzig TEM-Varianten und 29 
SHV-Varianten konnten bei diesen Tests eindeutig identifiziert werden. Drei Proben 
wurden aufgrund von Fehlern bei der Vorbereitung der Ziel-DNS von der Analyse 
ausgeschlossen. Die Ergebnisse der Mikroarray-Analyse wurden durch Resultate 
einer Standard-DNS-Sequenzierung bestätigt. 
 
Nachweis gemischter Resistenzmerkmale 
Das Vorkommen unterschiedlicher Beta-Laktamase Varianten derselben Familie 
innerhalb eines einzigen Stammes wurde sowohl im Fall von TEM (17), als auch von 
SHV (43) Beta-Laktamasen schon nachgewiesen. Die nicht-ESBL Varianten TEM-1 
(95) und SHV-1 (8) sind weit verbreitete Enzyme und es kann nicht ausgeschlossen 
werden, dass eine nicht-ESBL Variante und eine ESBL Variante koexistieren (64). 
Ein genotypischer Test muss daher in der Lage sein zwei Varianten simultan zu 
identifizieren. Die Möglichkeit zwei Varianten (blaTEM-116 und blaTEM-8) der gleichen 
Laktamase-Familie nachzuweisen, wurde für TEM in einem Modell-System bis zu 
einem Verhältnis von 1 zu 10 gezeigt. Für SHV wurde das gleichzeitige Vorkommen 
unterschiedlicher Varianten (blaSHV-1 in Kombination mit blaSHV-5 oder blaSHV-12) in den 
getesteten klinischen Isolaten nachgewiesen. Die genotypische Identifizierung mittels 
DNS-Mikroarrays einer ESBL Variante in Gegenwart einer nicht-ESBL Variante 
Zusammenfassung 
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wurde somit sowohl im Modellsystem, als auch in realen klinischen Proben 
nachgewiesen. 
 
Optimierung der Hybridisierung 
Für den klinischen Einsatz eines Testverfahrens spielt der Zeitaspekt eine große 
Rolle. Die entscheidenden Zeit verbrauchenden Schritte der DNS-Mikroarrayanalyse 
nach der DNS-Isolation sind hierbei die Vervielfältigung der Ziel-DNS mit zwei 
Stunden, der Hybridisierungsschritt mit anfangs drei Stunden, sowie die 
Waschschritte mit insgesamt 30 Minuten. Die Vervielfältigung der Ziel-DNS erfolgte 
bisher nach der Isolation des Krankheitserregers durch eine Vorkultur, was im Zuge 
weiterer Entwicklungen jedoch durch ein zeitsparendes Kultur-unabhängiges 
Anreicherungsverfahren ersetzt werden soll. Die Optimierung des 
Vervielfältigungschrittes sollte daher in Adaption an das Anreicherungsverfahren 
erfolgen. Da die Kombination beider Schritte sich jedoch noch in der 
Entwicklungsphase befindet, wurde das Augenmerk in dieser Arbeit zunächst auf 
eine Optimierung des Hybridisierungsverfahrens, sowie der Waschschritte gerichtet. 
Hierfür wurden umfangreiche Testreihen mit vier verschiedenen Geräten 
(ArrayBooster, Lucidea Slide Pro, Tecan HS400, Thermomixer mit 
Hybridisierungsaufsatz) durchgeführt, die durch Agitation der Hybridisierungslösung 
eine Verbesserung der Hybridisierungskinetik (151) und Homogenität der 
Signalverteilung versprachen, wobei die Geräte neben verschiedenen Verfahren zur 
Agitation auch unterschiedliche Automatisierungsgrade der einzelnen Schritte boten. 
Die Beurteilungskriterien umfassten die Steigerung der 
Fluoreszenzsignalintensitäten, die Spezifität der Identifizierung der Mutationen, die 
Reproduzierbarkeit der Daten, sowie niedrige und einheitliche 
Hintergrundsignalintensitäten. Die Sensitivität und die Reproduzierbarkeit konnten 
durch Automatisierung der Hybridisierung und des Waschvorgangs gesteigert 
werden. Die überzeugendsten Verbesserungen der Qualität und Reproduzierbarkeit 
der Hybridisierungsergebnisse, sowie den höchsten Grad an Automatisierung lieferte 
hierbei die Tecan HS400, mit der eine Reduktion der Hybridisierungzeit von 
anfänglich drei Stunden auf bis zu 15 Minuten gezeigt werden konnte. Das verkürzte 
die Analysezeit nach der DNS-Isolation von ehemals sechs Stunden auf weniger als 
3.5 Stunden. Da jedoch bei allen getesteten Verfahren eine starke Verkürzung der 
Hybridisierungszeit auch eine Verminderung der Spezifität und Sensitivität der 
Identifizierung zur Folge hatte, wurde als Kompromiss zwischen optimalen 
Analyseergebnissen und möglichst kurzer Testdauer eine Hybridisierungszeit von 
einer Stunde für alle folgenden Versuche festgelegt. Somit betrug die Analysezeit 
nach der DNS-Isolation etwa vier Stunden.  
 
Einfluss von Eigenschaften der Ziel-DNS 
Weiterhin wurde der Einfluss von Eigenschaften der Ziel-DNS, wie der 
Fragmentlänge und der Einbaurate der Fluoreszenzmarkierung untersucht. Die 
Fragmentierung der Ziel-DNS wurde durchgeführt, um eine Verminderung der 
Sekundärstrukturen zu erreichen, die die Zugänglichkeit der Ziel-DNS für die 
Hybridisierung an die Oligonukleotid-Sonden erschweren. Außerdem erlaubt eine 
Fragmentierung die unhabhängige Hybridisierung verschiedener Abschnitte der Ziel-
DNS an unterschiedliche Sonden (78). Hierbei wurde festgestellt, dass die 
Hybridisierungseffizienz abhängig ist von der Länge der Ziel-DNS Fragmente und 
von der Position der Sonde in Bezug auf die Ziel-DNS Sequenz. Je länger das zu 
hybridisierende Ziel-Fragment war, desto schwächer waren die 
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Hybridisierungsergebnisse für Sonden, die komplementär zu dem 3’ Ende des Ziel-
DNS-Strangs waren. Mögliche Erklärungen hierfür waren eine niedrige 
Zugänglichkeit des 3’ Endes des Ziel-DNS-Strangs wegen vorhandener 
Sekundärstrukturen, oder eine Verminderung der Hybridisierungseffizienz durch 
Interaktionen zwischen den komplementären Ziel-DNS-Strängen (127), da 
doppelsträngige DNS zur Hybridisierung eingesetzt wurde. Wie erwartet wurden die 
besten Hybridisierungsergebnisse bezüglich Spezifität und Sensitivität der 
Identifizierung der Mutationsposition mit Fragmentlängen erreicht, bei denen laut 
festgestellter Einbaurate die Mehrzahl der Fragmente eine Fluoreszenzmarkierung 
trägt (etwa 25 - 500 bp). Obwohl noch kleinere Fragmente eine bessere 
Zugänglichkeit ermöglichen, konnte für kleinere Fragmentlängen (< 50 bp) eine 
Verminderung der Sensitivität der Mutationsidentifizierung festgestellt werden. Dies 
wurde auf eine erhöhte Anzahl an unmarkierten Fragmenten zurückgeführt, welche 
in Kompetition mit den markierten Fragmenten stehen und somit die Sensitivität der 
Analyse negativ beeinflussen. 
 
Weiterführende Entwicklungen 
Kombination des Resistenznachweises mit einer Kultur-unabhängigen Isolation 
Die Identifizierung der TEM und SHV Varianten erfolgte in dieser Arbeit aus 
klinischen Isolaten, d.h. es wurde eine Isolierung des Krankheitserregers durch eine 
Vorkultur vorgenommen, bevor die DNS-Extraktion und danach die DNS-
Mikroarrayanalyse stattfand. Dieser Schritt ist bisher notwendig, um die Resistenz 
eindeutig dem Krankheitserreger zuzuordnen, ansonsten könnte ein nichtpathogener 
Resistenzträger zu falsch positiven Ergebnissen führen. Diese Isolation ist der 
zeitaufwendigste Schritt bei der kompletten Analyse. Um die Ausschöpfung des 
vollen Potenzials eines genotypischen Resistenznachweises zu ermöglichen, 
insbesondere des Zeitvorteils, ist eine Kultur-unabhängige Methode notwendig. An 
der Technischen Universität München wurde ein Verfahren entwickelt bei dem eine 
speziesspezifische Anreicherung durch den Einsatz von Polynukleotidsonden 
stattfindet. In Zusammenarbeit wurde festgestellt, dass nach einer Anreicherung von 
E. coli Bakterien aus einer klinischen Urinprobe das vorhandene blaTEM -
Resistenzgen durch die Mikroarrayanalyse identifiziert werden konnte. Somit wurde 
der Nachweis erbracht, dass die Entwicklung eines komplett Kultur-unabhängigen 
genotypischen Resistenznachweises möglich ist. 
 
Ausweitung des Nachweisspektrums 
Der Vorteil der phänotypischen Analyse bleibt, dass ein großes Spektrum 
unterschiedlicher Resistenzdeterminanten nachweisbar ist. Um einen zu dieser 
Standardmethode konkurrenzfähigen Test zu entwickeln, muss daher die große 
Mehrheit der klinisch relevanten Resistenzmerkmale für ESBL und ähnlicher 
Resistenzphänotypen nachweisbar sein. Die Ergänzung der bisher entwickelten TEM 
und SHV-Arrays zu einem Komplettsystem zum Nachweis aller Merkmale klinisch 
relevanter Laktamasefamilien (z.B. auch CTX-M (13) und AmpC (169)) ist möglich 
und derzeit in Arbeit. Ein Prototyp-Array, der unter den für den TEM- und SHV-Array 
festgelegten Versuchsparametern eine Auswahl von CTX-M-Varianten nachweisen 
kann, wurde bereits von M. Rubtsova (National Research Center for Antibiotic 
Resistance, Moskau, Russland) entwickelt.  
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Entwicklung eines marktreifen Systems 
Die Entwicklung eines marktreifen Systems aus den in dieser Studie entwickelten 
Prototypen ist nur in Verbindung mit einer patentrechtlich zugänglichen Methodik 
möglich. Da das Standard Arrayformat von kovalent immobilisierten 
Oligonukleotidsonden von Patenten von Oxford Gene Technology (u. a. 
Patentnummer EP0373203B1) abgedeckt ist, kann es nicht lizenzfrei angewendet 
werden. Durch die Kooperation mit einem Industriepartner (Eppendorf Array 
Technology) war ein alternatives (jedoch nicht offen gelegtes) 
Immobilisierungsverfahren zugänglich. In einem ersten Anwendungsversuch konnte 
gezeigt werden, dass die Identifizierung der relevanten Mutationspositionen auch in 
diesem Format erfolgen kann, aber noch der weiteren Optimierung bedarf. 
 
Fazit 
Die entwickelten DNS-Mikroarrays zur Identifizierung von TEM und SHV ESBL und 
IRT Varianten bieten ein viel versprechendes System für den Einsatz in der 
klinischen Mikrobiologie dar. Der schnelle Nachweis von resistenten Bakterien durch 
genotypische Resistenztestung zu einem kompetitiven Preis sollte das Auftreten 
neuer Resistenzen vermindern. Durch die frühzeitige und spezifische Identifizierung 
des Resistenzmerkmals kann die Verschreibung von Antibiotika spezialisierter und 
somit effektiver erfolgen, da bekannte Substratspektren vom genotypischen Profil 
abgeleitet und vor Therapiebeginn berücksichtigt werden können. Der Einsatz von 
Breitbandantibiotika könnte eher auf schwere Infektionen beschränkt werden und 
eine weitere Verbreitung der Resistenzen durch frühzeitige Erkennung und Isolierung 
von betroffenen Patienten erschwert werden. Weiterhin kann die Verbreitung von 
bestimmten Resistenzmerkmalen im klinischen Umfeld verfolgt werden, was die 
Sammlung bedeutender epidemiologischer Daten zur Resistenzentwicklung 
ermöglicht. Die Entwicklung von genotypischen Methoden zur Resistenztestung kann 
daher große Auswirkungen haben auf die klinische Behandlung von 
Infektionskrankheiten und deren Kosten. 
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Abstract 
Among the most important types of resistances to be detected are the extended 
spectrum beta-lactamases (ESBLs). ESBLs are found in many different species of 
the family Enterobacteriacae. Most ESBLs are mutants of TEM- or SHV-type beta-
lactamases. The TEM- and SHV- subtypes are derived from parental sequences 
(TEM-1, SHV-1) and differ from them by a variable number of amino acid 
substitutions. These mutations lead to an extended spectrum of activity against 
newer lactams, especially against 3rd generation cephalosporins. Other derivatives of 
the classical TEM or SHV enzymes also show an inhibitor resistant TEM (IRT) 
phenotype conferring resistance to beta-lactamase inhibitors. ESBL producing 
organisms are difficult to detect in standard phenotypic screening tests, mainly 
because of their widely varying levels of activity against various cephalosporins. For 
an improved accuracy confirmatory susceptibility tests have to be performed resulting 
in a response time of three days until the ESBL phenotype can be identified 
unequivocally. Since infections with ESBL producing organisms are registered with 
increased prevalence and are associated with significantly longer hospital stays and 
higher costs, more accurate tests to detect ESBLs in clinical isolates are necessary. 
The microarray technology allows the genotypic identification of resistance traits in 
less than one day of analysis time. Furthermore, the identification of the beta-
lactamase variant on a molecular level will define for most ESBL isolates a specific 
substrate pattern, which can be considered for the determination of the appropriate 
antibiotic treatment. Additionally, the genotyping of resistances can be used for the 
reliable surveillance of multiresistant bacteria in wards or hospitals.  
 
In the present study a diagnostic microarray was developed for the rapid 
identification of mutations of the majority of the currently known TEM or SHV beta-
lactamase variants, which are related to the ESBL and/or IRT phenotype. The assay 
enabled the detection and identification of 99 % of the relevant polymorphisms for 
TEM beta-lactamases and 100 % of the mutations of SHV beta-lactamases. This 
allows the detection of 96 % of the currently known TEM-variants and 100 % of the 
known SHV-variants. Consensus primers were developed and used for target 
amplification covering the majority of the known variant sequences. The sensitivity, 
reproducibility and identification capability of the developed arrays was determined 
with a set of reference samples. Furthermore, the TEM-array was validated by testing 
72 clinical isolates collected in diverse institutions in Germany, Croatia and Russia. 
The SHV-array was validated by testing 30 clinical isolates collected in Croatia. The 
simultaneous detection of an extended spectrum-variant in presence of a narrow 
spectrum-variant was shown in a model system for TEM up to a ratio of 1:10, as well 
as in clinical isolates for SHV. Starting from the isolated DNA, the assay could be 
performed in less than 3.5 hours. The discrimination level, the sensitivity and the 
reproducibility were enhanced by automation of the hybridization procedure. The 
development of a marketable diagnostic ESBL microarray based on the presented 
prototypes and the extension of the developed system towards the detection of other 
relevant beta-lactamase families is in progress. In conclusion, the diagnostic test 
developed in this study offers a promising approach for the rapid identification and 
epidemiologic monitoring of TEM or SHV ESBL and IRT beta-lactamases. 
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1 Introduction 
1.1 Antibiotic Resistance 
 
The discovery of penicillin by Alexander Fleming in 1928 was a first step towards the 
development of modern antibiotics and is still one of the most outstanding 
achievements of modern medicine. Since the world war II era these drugs became 
widely used, allowing the treatment of the most serious infections by pathogenic 
microorganisms. However, over fifty years of extensive use of antibiotics have led to 
the emergence of multiple defense mechanisms developed by the targeted bacteria. 
Although the sort, action and number of currently available antibiotics is astounding, 
the options for treatment of serious infections within the clinical setting become more 
and more limited, and at the beginning of the 21st century the current methods of 
applying existing and developing new antibiotics have to be reviewed (91). 
 
Drug resistance is especially problematic in hospitals, since patients with serious 
diseases are impaired regarding their immune defense system and present an easy 
target for pathogenic organisms. The extensive use of antibiotics to treat those 
infections increases the selective pressure for the development of new mutations 
promoting bacterial survival. Therefore, the hospital environment is the major point of 
origin of the spread of multiple resistant organisms. According to statistics from the 
Centers for Disease Control and Prevention in the US nearly two million patients get 
an hospital acquired infection each year. About 90,000 of these patients die because 
of this cause. The risk to acquire such an infection has risen steadily in recent 
decades. The incidence of blood and tissue infections (sepsis) has almost tripled 
from 1979-2000. More than 70 % of the bacteria causing infections in hospitals are 
resistant to at least one of the antibiotics most commonly used to treat them 
(http://www.niaid.nih.gov/factsheets/antimicro.htm). The infections with drug resistant 
organisms prolong the hospital stays and increase health care costs. Even 
organisms which are resistant to the most powerful antibiotics available (methicillin 
and vancomycin) are emerging presenting physicians and patients with serious 
problems (141).  
 
The mode of action of antibiotics is targeted towards different components of the 
bacterial life cycle and organism. The antibiotics can interfere with the biosynthesis 
and function of the genetic material, proteins and the cell wall. Bacteria are single cell 
organisms with a compact genetic material and short reproduction times. Therefore, 
new mutations with an impact on bacterial survival can evolve rapidly. Three major 
defense mechanisms against antibiotics emerged: (i) inhibition of the import or fast 
export of the antibiotic by change of the membrane permeability, (ii) modification of 
the binding domain of the target structure or (iii) enzymatic inactivation of the 
antibiotic (177). These defense mechanism are often transmittable between 
microorganisms, because they can be encoded on transferable genetic elements, 
such as plasmids (34) or transposons (6), or are propagated by phages.  
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1.1.1 Beta-lactam resistance 
Beta-lactams account for approximately 50 % of the global antibiotic consumption 
(96). They interact with enzymes responsible for the final step of the bacterial cell 
wall synthesis: the cross-linking of the peptidoglycan layer. Loss or damage of this 
peptidoglycan layer destroys the rigidity of the bacterial cell wall, resulting in death of 
the cell in a hypertonic environment. The peptidoglycan layer consists of a 
carbohydrate backbone of alternating units of N-acetyl glucosamine and N-acetyl 
muramic acid. The N-acetyl muramic acid residues are cross-linked via a 
transpeptidase reaction: by cleavage of a terminal D-alanyl-D-alanin bond the C-
terminus of a peptide side chain is linked to a free amino group of another peptide 
chain (see figure 1). This reaction is inhibited by β-lactam antibiotics (177).  
The four-membered beta-lactam ring is 
the common basic structure of all beta-
lactam antibiotics. Beta-lactams applied 
in human medicine are derived from 
natural products generated by fungi, 
such as Penicillium chrysogenum or 
Acremonium chrysogenum. The different 
groups of β-lactam antibiotics are the 
penicillins, cephalosporins (including 
oxacephems and cephamycins), 
thienamycins (carbapenems), and 
aztreonam (monobactam) (see figure 2). 
Penicillins and cephalosporins are widely 
used to inhibit gram-positive and gram-
negative bacilli. Monobactams inhibit 
only aerobic gram-negative bacilli, 
clavulanic acid acts as a beta-lactamase 
inhibitor and thienamycin inhibits a wide 
range of aerobic and anaerobic species 
(10). 
NH2
O
O
Ser
 
NH2 NH2
NH2 NH2
NH
O
OH
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-
TPase
TPase
Figure 1. Schematic view of the transpeptidase (TPase) reaction for cross-linking of the 
peptidoglycan layer. By cleavage of a terminal D-alanyl-D-alanin bond the C-terminus of a 
peptide side chain is linked to a free amino group (e.g. from L-lysine) of a neighboring peptide 
chain. 
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Figure 2. Basic structures of beta-lactam 
antibiotics. R and R1 represent various 
carbon groups. X can be either a hydrogen 
or a methoxy group. 
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The beta-lactam ring is a 
structural analog to the D-
alanyl-D-alanin terminal peptide 
bond, so that it undergoes an 
acylation reaction with the 
transpeptidases (also called 
Penicillin Binding Proteins 
PBPs) that cross-link the 
peptidoglycan layer (see figure 
3). The hydrolysis of the lactam-
bound transpeptidases is very 
slow, so that the cross-linking 
reaction is inhibited resulting in 
a mechanically labile cell wall 
(47). 
 
The resistance mechanisms to beta-lactam antibiotics are various. One mechanism 
consists of an alteration of the target site of the agent, the transpeptidase PBPs. In 
gram-positive bacteria a preexisting low affinity of the targeted transpeptidase 
towards the antibiotic (e.g. for Enterococci) was observed. In gram positive and gram 
negative bacteria an alteration of the transpeptidase structure (e.g. Streptococcus, 
Neisseria) or the coexpression of an alternative enzyme with a decreased affinity for 
the antibiotic (e.g. PBP2a for Staphylococcus) can be a cause of this resistance type. 
In gram-negative bacteria deletion of a porin protein can cause the impermeability of 
the membrane for the beta-lactam antibiotic (47,60,156).  
 
In gram-negative and -positive bacteria the expression of beta-lactamases, which 
inactivate the beta-lactam antibiotic by cleavage of the beta-lactam ring, is one of the 
clinically most relevant resistance mechanisms (95).  
 
A few beta-lactamases utilize Zinc ions to disrupt the beta-lactam ring (metallo-beta-
lactamases of molecular class B (2)), but the far greater number of class A (2), C 
(73), and D (67) enzymes bear a serine residue at the active site. The enzyme first 
associates noncovalently with the antibiotic to yield a noncovalent Michaelis complex. 
The beta-lactam ring is then attacked by the free hydroxyl of the serine residue, 
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Figure 3. Schematic representation of the inactivation 
reaction of the transpeptidase by penicillin. The hydrolysis 
of the lactam-bound transpeptidases is a very slow 
process. 
Figure 4. Mechanism of the hydrolysis of penicillin by a beta-lactamase. One beta-lactamase 
molecule can hydrolyze app. 1000 penicillin molecules per second (177). 
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yielding a covalent acyl ester. Hydrolysis of the ester finally liberates the active 
enzyme and the inactivated drug, since the opened beta-lactam ring can no longer 
be recognized by the transpeptidases as a substrate (176) (see figure 4). This 
mechanism is very effective, since one beta-lactamase molecule can hydrolyze about 
1000 penicillin molecules per second (177).  
 
 
 
Table 1. Classes of beta-lactam antibioticsa 
Cephalosporins Antibiotic 
1st Generation Cefazolin 
Cephalexin 
Cephalothin 
Cephadrine 
  
2nd Generation Cefuroxime 
Cefamandole 
Cefaclor 
  
2nd Generation (cephamycines)  Cefoxitin 
Cefotetan 
  
3rd Generation  Cefotaxime 
Ceftriaxone 
Ceftazidime 
Cefpodoxime 
  
4th Generation Cefepime 
Penicillins  
Beta-lactamase sensitive penicillins  Benzylpenicillin 
Phenoxymethylpenicllin 
Propicillin 
Azidocillin 
  
Beta-lactamase resistant penicillins Flucloxacillin 
Dicloxacillin 
Oxacillin 
  
Extended-spectrum penicillins Amoxicillin 
Ampicillin 
Bacampicillin 
Mezlocillin 
Piperacillin 
Other beta-lactams  
Thienamycins/Carbapenems Imipenem 
Meropenem 
  
Monobactam Aztreonam 
  
Beta-lactamase inhibitors Clavulanic acid 
Sulbactam 
Tazobactam 
aOnly a selection of the most common antibiotics of the displayed 
groups is listed. 
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1.1.2 Extended Spectrum Beta-Lactamases (ESBLs) 
In 2001 more than 340 different beta-lactamase types were known (20). A major part 
of these enzymes constitute plasmid mediated serine beta-lactamases in gram-
negative bacilli. The most common of these enzymes in Enterobacteriacae is TEM-1, 
which has been reported in about 50-80 % of plasmid mediated lactam resistances 
(106,134,146). SHV-1 is also a prevalent enzyme and was first described as a 
chromosomally encoded beta-lactamase in members of the genus Klebsiella. 
Subsequent work demonstrated that SHV-1 is also encoded by transposons or 
plasmids (62).  
 
TEM-1, TEM-2 and SHV-1 are the point of origin of a vast number of TEM- and SHV-
variants, which differ from the parental TEM and SHV beta-lactamases by a variable 
number of amino acid substitutions. The classical TEM-1, TEM-2 or SHV-1 enzymes 
attack the narrow spectrum cephalosporins and all the anti-gram-negative penicillins 
except temocillin, but they have minimal activity against newer cephalosporins (other 
than cefamandole and cefoperazone) and monobactams or carbapenems (69,72). A 
major number of the new enzyme variants mediate resistance to extended spectrum 
(third generation) cephalosporins and monobactams, as well as narrow spectrum 
(first or second generation) cephalosporins and anti-gram negative penicillins (71) 
(see table 1). These enzymes are designated Extended Spectrum Beta-Lactamases 
(ESBLs) in reference to their extended spectrum of activity against newer beta-
lactam antibiotics. They do not affect cephamycins or carbapenems and are usually 
susceptible to inhibitors of beta-lactamases like clavulanic acid. There are also 
derivatives of the classical TEM or SHV enzymes showing an IRT (which originally 
stands for Inhibitor Resistant TEM) phenotype, conferring resistance to inhibitors of 
beta-lactamases like clavulanic acid, but which do not confer an ESBL type 
phenotypic resistance pattern (95). 
 
ESBLs are found in many different species of the family Enterobacteriacae, 
predominantly in Klebsiella pneumoniae and Escherichia coli, but also in 
Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoe. Most 
ESBLs are mutants of TEM-1, TEM-2 or SHV-1, but there are also derivatives 
belonging to the CTX-M- or OXA-family of beta-lactamases. Few ESBLs are not 
closely related to the established families, these lactamases are designated PER, 
VEB, GES, TLA, FEC, CME, SFO and BES (16). The nomenclature of these 
enzymes is not standardized: The TEM-1 enzyme was originally found in a single E. 
coli strain isolated from a patient named Temoniera (33), hence the designation 
TEM. SHV denotes a variable response to sulfhydryl inhibitors (107). OXA is derived 
from oxacillin resistant (20), CTX-M was designated in reference to its hydrolytic 
activity against cefotaxime (13).  
 
The TEM- and SHV- subtypes are derived from parental sequences (TEM-1, TEM-2, 
SHV-1) and differ from them by a variable number of amino acid substitutions (for 
amino acid sequences of TEM and SHV beta-lactamases see 
http://www.lahey.org/Studies/). Their degree of activity against different beta-lactam 
antibiotics is depending on the combination of different amino acid substitutions 
surrounding the active site of the enzyme. The amino acid positions are numbered in 
the literature according to a beta-lactamase alignment proposed by Ambler in 1991 
(3). The most important substitution positions for an extension of the substrate 
spectrum are situated for TEM beta-lactamase at Ambler position 164, for SHV at 
position 179 and for both families in position 238, which result in an expansion of the 
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substrate binding site. Amino acid substitutions in position 104 and 240 in TEM and 
SHV enhance the interaction with oxyimino side-chains of ceftazidim and aztreonam. 
Mutation in amino acid 237 in TEM enzymes reduces the activity toward ceftazidime 
and aztreonam, while increasing it towards cefotaxime and cephalotin. In some TEM 
and SHV enzymes ESBL-type mutations have been found together with those that 
determine resistance to inhibitors (positions 69, 130, 275, 276). Some positions are 
considered as neutral (e.g. position 21 in TEM), however it is possible, that some of 
these mutations could reveal a modulation in enzyme activity in context of other 
mutations (51,82). Neutral mutations can also constitute genetic markers for 
specifying genealogic lineages of ESBL genes and their analysis is very useful in 
evolutionary as well as epidemiologic investigations. Up to date there are more than 
120 different TEM and more than 50 different SHV variants known.  
 
1.1.3 Prevalence of ESBLs 
The occurrence of plasmid encoded resistance against 3rd generation cephalosporins 
is reported since 1983 (80,81). Epidemic outbreaks of those resistances within the 
clinical setting were observed in France (148), the US (109) and other European 
countries (52,160,174) since then continuously. Whether these outbreaks were 
caused by ESBLs or AmpC-type enzymes was not investigated consistently. The 
existing epidemiologic data up to date suggests that the prevalence and type of 
ESBL resistance is highly variable and depends on the geographic area and the 
investigated institution. However, a trend of an increase of the resistance against 3rd 
generation cephalosporins can be observed (181). In the Sentry antimicrobial 
surveillance program the prevalence of ESBL producing isolates of E. coli, P. 
mirabilis, Salmonella spp. and K. pneumoniae was evaluated originating from 
institutions situated in the US, Canada, Europe, Latin America and the Western 
Pacific region. As displayed in figure 5 the highest percentage of ESBL phenotypes 
was detected among K. pneumoniae isolates from Latin America (45 %) followed by 
those from the Western pacific region (25 %) and Europe (23 %), the US (8 %) and 
Canada (5 %) (180).  
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Figure 5. Percentage of ESBL phenotypes detected among K. pneumoniae, E. coli, P. mirabilis and 
Salmonella species isolated in Europe, the Americas and the Western Pacific Region as a part of the 
Sentry project from 1997-1999 (180). 
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A study conducted in 1994 in 35 different intensive care units (ICUs) situated in 10 
southern and western European countries reported an ESBL prevalence of 22.8 % of 
all tested isolates and of 28.6 % for K. pneumoniae (7). In a study from 2001 
evaluating the resistance situation in Germany, Austria and Switzerland 
(accomplished by the Paul Ehrlich Gesellschaft) among 1.3 % of K. oxytoca and  
0.8 % of E. coli isolates an ESBL-type resistance was detected. In comparison to a 
study from 1998 the rate of ESBL producing K. pneumoniae increased from 4.7 to 
8.2 %. The prevalence of different genetic variants was only investigated in selected 
studies. The most reported ones belong to the TEM and SHV beta-lactamase 
families, in terms of variant numbers and number of producer strains (51). In a recent 
publication from 2003 a considerable increase in the occurrence of CTX-M producing 
strains was reported: in 455 bloodstream isolates of K. pneumoniae collected in the 
US, Taiwan, Australia, South Africa, Turkey, Belgium and Argentina 67.1 % of the 
ESBL producers carried an SHV-type, 23.3 % of CTX-M type and 16.4 % of TEM-
type lactamase (123). 
 
1.1.4 Phenotypic ESBL detection 
Clinical standard procedures for resistance detection are based on growth inhibition 
in dilution or disc diffusion tests. For the detection of the minimum inhibitory 
concentration (MIC) a dilution series of the investigated antibiotic in a culture medium 
is prepared, the isolated bacteria are inoculated and the samples are incubated for a 
defined time period. The lowest concentration inhibiting bacterial growth is defined as 
the MIC. The MIC itself has no therapeutic relevance, because it is detected under in 
vitro conditions and does not reflect the pharmacological properties of the tested 
agent. Therefore, breakpoint concentrations are defined, corresponding to serum 
levels obtainable at the half time of the application interval. Considering these 
benchmark parameters a prediction whether the organism is susceptible to a certain 
agent can be made. In disc diffusion testing an agar plate is inoculated with the 
tested isolate and paper discs containing defined concentrations of antibiotics and/or 
inhibitors are applied and the discs are incubated overnight. The zones of bacterial 
growth inhibition are measured and interpreted.  
 
The detection of ESBL producing organisms is especially difficult, because of their 
widely varying levels of activity against various cephalosporins. The choice of the 
right antibiotic to test is critical, e.g. one enzyme may actively hydrolyze ceftazidime 
with an MIC of 256 µg/ml, while having a poor activity on cefotaxime with MICs of 
only 4 µg/ml (95). Therefore, the NCCLS (National Committee for Clinical Laboratory 
Standards) has defined broth microdilution and disk diffusion screening tests with 
several selected antibiotics and low MICs of 2 µg/ml to be tested to determine a 
potential ESBL producer (see table 2). If an ESBL is detected, all penicillins, 
cephalosporins and aztreonam should be reported as resistant, except the 
cephamycins, which should be reported according to their test results (115). Even 
though these tested MICs are still in the susceptible range as defined by the 
breakpoint analysis (< 8 µg/ml), it was shown that they are clinically important, 
because treatment failures can occur, if they are not considered before treatment 
(124). Another problem of phenotypic ESBL detection is the occurrence of an 
inoculum effect. In vitro, the MICs of cephalosporins rise as the inoculum increases 
(108,132,168). Thus ESBL producing organisms might remain undetected, if the 
inoculum is not sufficient. The occurrence of this inoculum effect in clinical infections 
is indicated by reports of treatment failures, suboptimal clinical outcome and the 
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increased mortality of patients infected with ESBL-producing strains, that have MICs 
in the susceptible range and were treated with cephalosporins (89,124,142,149).  
 
Table 2. NCCLS screening parameters for ESBL detection (115) 
Disk diffusion MICs 
cefpodoxime < 22 mm cefpodoxime > 2 µg/ml 
ceftazidime < 22 mm ceftazidime > 2 µg/ml 
aztreonam < 27 mm aztreonam > 2 µg/ml 
cefotaxime < 27 mm cefotaxime > 2 µg/ml 
ceftriaxone < 25 mm ceftriaxone > 2 µg/ml 
 
 
According to recommendations issued by the NCCLS a phenotypic confirmatory test 
for potential ESBL producing isolates of K. pneumoniae, K. oxytoca and E. coli 
should be performed by testing cefotaxime and ceftazidime alone and in combination 
with clavulanic acid. A decrease of > 3 doubling dilutions in an MIC for either agent 
tested in combination with clavulanic acid versus its MIC when tested alone confirms 
an ESBL producer. For disc diffusion testing a > 5 mm increase in the zone diameter 
for cefotaxime or ceftazidime with clavulanic acid versus its zone diameter when 
tested alone confirms the presence of an ESBL producing organism (115).  
A standard confirmatory test for ESBL detection is also the double disc test. Discs 
containing ceftazidime and cefotaxime and amoxicillin/clavulante are placed on 
inoculated agar plates. An ESBL is detected, when the cephalosporin zone is 
expanded by the clavulanate. Etest ESBL strips use a strip containing a ceftazidime 
gradient at the one end and a ceftazidime plus clavulanate gradient at the other end 
(see figure 6). The MICs can be directly read off the paper strip scale: if the ratio of 
the MIC of ceftazidime to the MIC of ceftazidime/clavulanate is ≥ 8, ESBL production 
is inferred. The combined discs method depends on comparing the zones given by 
discs containing an extended spectrum cephalosporin with and without clavulanic 
acid. If an ESBL is produced, the zones are enlarged for the discs containing the 
inhibitor (97). To read out the inhibition zones in all these tests is not always 
straightforward and interpretation of the test results can be highly subjective. 
 
a b
Figure 6. Detection of ESBL production in an E. coli 
producing TEM-5 enzyme (a) in a double disc test. Left, 
ceftazidime, 30 µg; centre, amoxicillin + clavulante, 20 + 10 
µg; right cefotaxime 30 µg, (b) in a Etest ESBL. The strip 
has a ceftazidime gradient at both ends, with clavulanate in 
the right hand gradient only (97). 
Introduction 
 18 
Furthermore, these phenotypic confirmatory tests can not detect all ESBLs. In 
organisms with multiple beta-lactamases the phenotype of for example an AmpC or 
IRT type beta-lactamase can mask a present ESBL phenotype and lead to a false 
negative test result. Currently the presence of multiple lactamases can only be 
confirmed by isoelectric focusing or DNA sequencing, which is labor intensive and 
time consuming. ESBLs can also occur in other Enterobacteriacae, such as 
Salmonella species, Proteus mirabilis or Pseudomonas aeruginosa, but the methods 
defined by the NCCLS for ESBL producing isolates of K. pneumoniae, K. oxytoca 
and E. coli are not applicable for those species. So far no phenotypic screening and 
confirmatory tests were defined by the NCCLS for those kind of isolates (143). 
 
In summary, the phenotypic screening tests are, though cost-effective, time 
consuming (app. 2 days) (99). Furthermore, serious difficulties in interpretation of the 
test results are associated with treatment failures (95,97). For an improved accuracy 
and confirmation of the ESBL detection it is indispensable to test isolates on multiple 
antibiotics in combination with beta-lactamase inhibitors (115). This prolongs the 
specific response time to 3 days, so that treatment often has to start before the 
phenotype is determined unequivocally. The fast and accurate identification of the 
resistance is crucial for the outcome of the antimicrobial therapy and significantly 
influences following procedures, such as isolation of patients for preventing the 
spread of antibiotic resistances.  
 
1.1.5 Genotypic ESBL detection 
Genotypic analysis of putative ESBL strains is a promising alternative for ESBL 
detection. The genetic testing can be performed directly from the clinical sample as it 
is drawn from the patient (e.g. blood, urine) without preisolation or cultivation. This 
shortens the response time considerably and makes a specified antibiotic therapy 
possible. Unambiguous identification of the ESBL variant, as determined by 
genotyping, will define for most ESBL isolates a specific substrate pattern, which can 
be considered for the choice of antibiotic treatment. Furthermore, the time of contact 
between hospital staff and potentially infective organisms is minimized in comparison 
to phenotypic methods, so that the risk of cross contamination could be diminished. 
Genetic testing is much less prone to subjective interpretation, as for example the 
analysis of growth inhibition zones in phenotypic tests, so that more user-
independent test results can be generated. Also resistances from organisms not 
targeted by NCCLS ESBL confirmatory tests, or from uncultivable organisms, or 
resistances, which are not detected in vitro, can be determined by genetic resistance 
testing. Additionally, the genotyping of resistances can be used for the reliable 
surveillance of the multiresistant bacteria within wards or hospital. For genotypic 
ESBL detection the genetic traits characterizing the diverse ESBL variants have to be 
detected. The ESBL subtypes are derived from different beta-lactamase families. 
Within certain families multiple mutations (mostly single nucleotide polymorphisms 
(SNPs)) in the otherwise highly conserved sequences characterize the different 
subtypes. Therefore, a method for the parallel analysis of multiple genes, SNPs and 
other mutations has to be chosen. 
 
A number of molecular methods for determining ESBL resistances have already 
been developed (48). Biotinylated oligonucleotide probes (167) or radiolabeled 
primers (5) were used to discriminate between a limited number of ESBL variants. 
Restriction fragment length polymorphism analysis (PCR-RFLP) (4) and single strand 
conformation polymorphism analysis (PCR-SSCP) (100), real time PCR (129), ligase 
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chain reaction (117) or minisequencing (64) have also been used to identify some of 
the relevant point mutations. The major drawback of all these assays is that they 
distinguish just between a few variants of the TEM and SHV beta-lactamases due to 
limited multiplexing capability, so that the full potential of the genotypic analysis is still 
not exploited. Multiple more advanced methods for SNP detection have already been 
developed, but have not been applied so far for the detection of ESBL or IRT 
polymorphisms. 
 
1.2 Genotyping of single nucleotide polymorphisms 
The analysis of DNA sequence variations is of major interest, in particular since the 
sequencing of the human genome was completed. The high frequency of SNPs and 
their use as genetic markers for genome mapping studies, medical diagnostics and 
identity testing has driven the development of multiple methods for detection and 
identification of SNPs.  
 
1.2.1 SNP discrimination methods 
SNP assay methods usually apply hybridization to specific oligonuleotides to 
discriminate between perfectly matched and non-perfectly matched duplexes. Assays 
based on direct hybridization use complementary oligonucleotide sequences, which 
are annealed under stringent conditions to differentiate between sequence variations. 
Enzymatic reactions can be used to enhance the specificity and sensitivity of the 
reaction. Hereby DNA ligase, nucleases or DNA polymerase can be applied (75). In 
DNA ligase based assays SNPs are discriminated by the enzymatic joining of two 
oligonucleotides, if they are both complementary to the template at the position of the 
joining (136).  
 
Site-specific endonucleases are used in restriction fragment length polymorphism 
analysis (RFLP) to produce DNA fragments of different length, due to presence or 
absence of specific restriction sites at polymorphism positions (152). To achieve 
better sensitivity PCR amplified products are used in PCR-RFLP as the sample. The 
Flap endonuclease used in the Invader assay (Third Wave Technologies, Madison, 
WI) recognizes and cleaves specific overhang structures formed by the tandem 
hybridization of a signal probe and an Invader probe. The cleaved off overhang is 
used to drive a universal cleavage reaction for fluorescence signal generation (65). 
The 5’ to 3’ exonuclease activity of DNA polymerase and allele specific reporter 
probes are employed in a PCR reaction for SNP discrimination in the TaqMan assay. 
The allele specific reporter probes are labeled with a fluorescence dye and a 
quencher and anneal during PCR to the complementary polymorphism site. During 
the extension step the 5’ reporter dye and the quencher are cleaved off, so that the 
energy transfer from the reporter to the quencher is stopped and fluorescence is 
generated (77).  
 
The primer extension assay utilizes an oligonucleotide primer annealing immediate 
upstream from the polymorphic site of a PCR amplified fragment. The primer is 
extended in presence of appropriate dNTPs or ddNTPs (159). The products can be 
distinguished through fragment size determination or fluorescence detection, if 
labeled nucleotides are used. In allele specific PCR primers with discriminating bases 
at the 3’ ends are employed, they are only extended if they are fully complementary 
to the template sequence (116). One amplification reaction is run for each allele to be 
tested and the generation of PCR products can be analyzed by gel electrophoresis. 
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In the Amplifluor system (Serologicals Corp., Norcross, GA) the discriminating 
primers are labeled with two different fluorescent dyes, which are quenched initially 
by close proximity to a quencher molecule in a hairpin structure. The hairpin structure 
of the primer is unfolded during PCR and a fluorescent signal is generated depending 
on the present allele (172).  
 
Direct sequencing of polymorphic regions by incorporation of fluorescently labeled 
nucleotides and analysis of reaction products by gel or capillary electrophoresis in an 
automated process is still viewed as the gold standard for SNP genotyping, since the 
presence and identity of any polymorphism can thus be confirmed (84). However, the 
process is still laborious, expensive and speed as well as throughput are still low for 
the analysis of multiple samples and multiple polymorphic regions. A minimized 
sequencing process was developed by Pyrosequencing (Pyrosequencing AB, 
Uppsala, Sweden). The successful incorporation of a nucleotide is visualized through 
a chemilumenescent reaction. The process allows the sequencing of up to 20 bases 
for 96 samples in 10 minutes (133). 
 
1.2.2 SNP detection methods 
The detection of SNPs is based in most aforementioned assays either on size 
differention or on the detection of generated fluorescence signal. The identification of 
molecular size be performed by gel or capillary electrophoresis, mass spectrometry 
or high performance liquid chromatography (HPLC). Gel electrophoresis can be used 
as a detection method for RFLP, PCR, sequencing, primer extension and ligation-
based SNP assays. However, gel electrophoresis is laborious and generally not 
applicable for high-throughput analysis (75). Capillary electrophoresis significantly 
shortens hands-on time and enhances throughput, but is still labor intensive and 
expensive compared to other methods.  
 
Mass spectometry based SNP detection can be done through matrix assisted laser 
desorption/ionization and time-of-flight detectors (MALDI-TOF). The analytes are 
deposited with a matrix on a metal plate and are desorbed into the gas phase by a 
laser pulse. After the analytes are ionized by collision, allele specific products are 
discrimiated by recording the time of flight of a product towards a detector, which can 
be related to its mass (59). Fully automated MALDI-TOF systems allowing a high-
throughput of samples are available, but the need of expensive equipment and highly 
purified DNA analytes is disadvantagous for a clinical application. 
 
Fluorescence-based genotype detection in solution can be performed in microtiter 
plates using fluorescence readout systems. These systems are for example 
applicable for ligation or primer extension, TaqMan, molecular beacons, Amplifluor or 
Invader assay. This detection format allows higher throughput of samples, however, 
the number of simultaneously analysable features remains limited, because for 
multiple analysable polymorphism usually multiple separate reactions have to be 
performed.  
 
An alternative method based on the detection of SNPs by flow cytometry increasing 
the number of simultaneously analysable features was developed by Luminex 
(Austin, TX). Two different fluorescent dyes combined at ten different concentration 
ratios integrated in microspheres provide a set of 100 distinguishable markers, which 
can be coupled to capture probes. Single-base extension, allele-specific primer 
extension (ASPE), oligonucleotide ligation, and direct hybridization have been used 
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in this format for SNP detection (87). Flow cytometry is already used in the clinical 
environment for immuno-based analysis, so that the equipment would be available 
for genotypic analyses. However, although the number of parallel analysable features 
is significantly enhanced compared to other methods, it’s number is still limited, so 
that depending on the necessary number of SNPs, which need to be analysed, it can 
still be insufficient. Furthermore, the sensitivity of the method is limited, since a 
certain population size of present microspheres is necessary for a reliable detection. 
 
A promising genotyping method with a high multiplexing power is provided by DNA 
microarray technology. DNA microarrays for the detection and identification of ESBL 
and IRT gene variants have not been reported so far.  
 
1.3 DNA microarrays 
 
1.3.1 Development 
DNA microarrays allow a highly parallel analysis of genetic information. Since 
microarray technology was first described in the 1990s the number of technical 
developments and the fields of application of microarray technology have exploded. 
The underlying principle of a nucleic acid hybridization assay are reported since the 
1960s. The vast potential of this principle could only be exploited through the 
development of solid-phase synthesis of nucleic acids and the introduction of the use 
of a solid support, which allowed a site-specific attachment and arraying of multiple 
nucleic acids (153). The first assays reported of this kind were designated dot blots 
(76) or reverse dot blots (135) using immobilized targets or probes on porous 
supports respectively. The term probe is used for nucleic acids of known sequence 
which are applied to analyze the unknown target sequences. The first arrays using in 
situ synthesized short oligonucleotides on impervious supports were described by 
Maskos and Southern in 1993 (103,104). These experiments established the basis of 
the current DNA microarray analysis technology. One of the major applications of 
DNA microarray analysis is the analysis of gene expression (19,40) as first reported 
by Schena et al. in 1995 (140). The other major application is the analysis of the 
genetic background, so called genotyping, for identification of species (12,57) or 
genetic variations (55,58) or to identify the phenotypic effect of genetic variations 
(24). 
 
1.3.2 Principle 
The basic principle of the DNA microarray analysis consists of DNA probes 
immobilized on an impermeable carrier in a highly parallel addressable format. 
Labeled target nucleic acids are synthesized and hybridized on the immobilized 
probe DNA. Unbound target DNA is washed off and the hybrids are detected via the 
label. The basic principle of a genotyping microarray analysis is displayed in figure 7. 
Probes can include synthetic oligonucleotides, amplicons or larger DNA/RNA 
fragments, as well as peptide nucleic acids. The probes are immobilized covalently or 
non-covalently on the support consisting of e.g. glass, silicon or plastic substrates 
usually coated with reactive groups. The microarray can have from a hundred up to 
106 test sites with a size range from 10-500 µm in a 1-2 cm2 area. The test sites can 
be constructed by in situ synthesis of oligonucleotides or by deposition of 
presynthesized oligonucleotides or other probe molecules on the solid support by 
contact printing or by inkjet or microjet deposition technology. Devices allowing 
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electronic addressing, immobilization and hybridization at specific test sites have also 
been developed (61). The target nucleic acid to be analyzed can be RNA or DNA, 
which should preferably be labeled, so that hybrids can be directly detected. It can be 
synthesized by Polymerase Chain Reaction or in vitro transcription. For labeling 
fluorescent dyes, radioactive markers (153), silver precipitation on gold conjugates 
(1), etc. can be used. The hybridization can be carried out under standard cover slips 
or in flow cells or specially designed hybridization chambers. Also hybridization 
stations for automation of the hybridization and washing steps are available. 
Commercial scanners for fluorescence image acquisition apply either 
photomultipliers (PMTs) or charged coupled device (CCD) cameras for detection. 
Most current systems include two lasers for Cy3 or Cy5 excitation and two filters for 
the separate detection of the emitted fluorescence signals. 
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Figure 7. Schematic representation of a genotypic DNA microarray method. After DNA 
isolation from the sample the targeted genes are amplified and fluorescently labeled by 
PCR. The target DNA is then hybridized on the immobilized target-specific oligonucleotide 
probes. After washing off unbound target DNA the probe/target duplex are detected via 
fluorescence imaging. 
clinical sample 
fluorescenctly labeled 
target DNA 
DNA microarray with 
oligonucleotide probes 
hybridization 
fluorescence imaging
1. DNA extraction 
2. amplification and fluorescence 
labeling of target genes by PCR 
wash off unbound 
target DNA 
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1.3.3 Array based genotyping methods 
In case of the detection of TEM or SHV extended spectrum beta-lactamases the 
single nucleotide polymorphisms (SNPs) relevant for the identification of the different 
variants have to be detected. Therefore, a discrimination between a perfectly 
matched hybrid and a non-perfectly matched hybrid between a probe and target 
molecule has to be achieved. For array based genotyping of single nucleotide 
polymorphisms (SNPs) three major reaction principles were derived for this purpose: 
primer extension, ligation reaction and allele specific hybridization. For the primer 
extension and ligation reaction enzymatic reaction steps for discrimination of the 
different allelic variants are performed.  
 
Multiple array based primer extension methods have been developed. The 
underlying principle is the extension of an immobilized primer in a primer/target 
duplex by DNA Polymerase. In the single nucleotide extension assays the 
discriminating base is located one base upstream of the 3’ end of the immobilized 
primer. The incorporation of a single labeled ddNTP complementary to the base 
present in the target DNA at the concerned position is used for allele discrimination 
(83,92,121). Single nucleotide primer extension in solution followed by capturing of 
extended primers using tag microarrays has also been described (44,63). In the array 
based allele specific primer extension at least two immobilized primers (one wild 
type, one mutation specific) are used, because the discriminating base is located at 
the 3’ end of the immobilized primer. The primer strand is only elongated if the 3’ end 
base is perfectly complementary to the target DNA strand (122). The possible 
incorporation of several labeled dNTPs during extension leads to an increased 
sensitivity of the assay compared to the single nucleotide extension assay. 
 
Ligation reactions are exploited for allelic discrimination in a microarray format using 
immobilized oligonucleotide probes (54) or stem loop ligation probes (18). In other 
methods the ligation is performed in solution followed by hybridization and detection 
of the ligation products on tag or zipcode microarrays (37,50). Circularisable 
oligonucleotide ligation probes, so called padlock probes have also been used in a 
tag microarray format for SNP analysis and enhanced signal amplification (9,32). 
 
Differential hybridization with allele specific oligonucleotide probes is the most 
commonly used reaction principle in microarray format (122). In the allele specific 
hybridization the discrimination is achieved by exploiting the destabilizing effect of the 
mismatched base in the DNA duplex. Usually four probes (termed A, G, C, and T 
probes) are designed to interrogate a single position in the target sequence. One is 
designed to be perfect complementary to the investigated sequence stretch (so 
called perfect match (PM) probe), the other three are identical to the first, except at 
the interrogated position, where one of the other three bases are substituted (so 
called mismatch (MM) probes). Upon hybridization with the labeled reference 
sequence, the probe perfectly complementary to the reference sequence will obtain 
the highest signal intensity. If a sample with a different base (a substitution variant) at 
the interrogated position is hybridized, the probe complementary to this variant will 
obtain the highest fluorescence intensity (94). The probes are designed with the 
polymorphism in the center-most position for optimal perfect match mismatch 
discrimination, since the destabilizing effect of the mismatched base is enhanced the 
more centralized the polymorphism position is in the probe/target duplex (58). The 
degree of the discrimination is strongly influenced by the hybridization conditions, 
such as pH, temperature, ionic strength, as well as the position of the polymorphism 
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in the probe sequence, the sequence surrounding the SNP position, and probe and 
target secondary structures (154). Therefore, the probe design and the reaction 
conditions for this method have to be thoroughly optimized. In the experimental 
approach of this work the allele specific hybridization method was applied for the 
development of the diagnostic microarray for resistance detection. 
 
1.3.4 Microarray preparation 
1.3.4.1 Probe design 
For the development of an array of allele specific hybridization probes the probes 
have to be selected and tested for an application under the same hybridization 
conditions allowing a specific identification of all tested polymorphisms. One option is 
to use oligos with identical length in combination with hybridization buffers, which 
diminish the effect of diverging melting temperatures of the oligonucleotide probes 
(105). Problematic is that the thermodynamic background of these effects is missing, 
making it impossible to predict the effects of further factors on the behavior of a given 
oligo probe (12). 
 
The approach used in this work consists of a calculation of the melting temperatures 
of the central oligonucleotide duplexes and to design sets of oligonucleotides with 
similar melting temperatures but different length. Furthermore, probe secondary 
structures such as hairpins or dimers, which decrease the accessibility of the probe 
for the target DNA, were if possible excluded or minimized by in silico probe design 
analysis. There is a variety of programs on the market, which allow the automated 
calculation of Tms and all oligonucleotide secondary structures facilitating the choice 
of the appropriate oligonucleotide probe.  
 
1.3.4.2 In situ synthesis and printing 
In situ synthesis of oligonucleotides allows the production of high density 
oligonucleotide arrays with a high and consistent yield of probe molecules over the 
surface of the support and permits the fabrication of large arrays of oligonucleotide 
probes in few coupling steps. The Affymetrix in situ process combines DNA synthesis 
chemistry with photolithography techniques from the microelectronic industry. 
Oligonucleotide probes are synthesized attached to a glass substrate. Light is 
directed through a mask to remove photolabile reactive groups at selected sites. 
Subsequently chemical building blocks are added, which form the nascent DNA 
strand (94). The use of micromirrors for light directed synthesis (147) or ink jet 
delivery of nucleotide precursors (11) to the surface have also been described. 
 
A more generally applicable procedure of manufacturing of oligonucleotide 
microarrays is to deposit presynthesized oligonucleotides on the surface. This can be 
done by mechanical printing using pins with a capillary slot or a pin-and-ring system 
or by non-contact printing using an inkjet dispensing system comparable to traditional 
inkjet printers. In this work a Microgrid II (Biorobotics) high throughput printer was 
used for contact printing of presynthesized oligonucleotide probes on a chosen 
surface. To print the oligonucleotide probes, wolfram pins with a capillary slot were 
applied. The probes are dissolved in spotting buffer and the solution is drawn into the 
split of the submerged pin by capillary force. The force generated from the downward 
movement and the surface tension of the slide draws a small amount of the solution 
out of the split (27). The printing process involving the pins, the slide surface, the 
spotting buffer as well as spotting parameters such as the surrounding humidity has 
to be optimized empirically. Hereby the following effects have to be considered: The 
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spot size and shape as well as the regularity is depending on the pin specifications, 
the acceleration of the pin towards the slide, the surface tension of the deposited 
solution and the slide surface. The surrounding humidity during the printing process 
is especially important for a uniform drying of the spot, otherwise a concentration 
gradient inside the drying spot might occur, causing a not uniform probe and thus 
signal distribution after hybridization (e.g. donut shaped signal patterns). Different 
pins exhibit mostly diverging printing characteristics. To minimize variation inherent in 
the spotting process a set of multiple pins should be tested empirically for almost 
equal performance and replicate spots should be spotted with the same pin. 
 
1.3.4.3 Surface and binding chemistry 
Today there is a variety of carriers for microarray applications commercially available, 
differing in the kind of active groups used for covalent or non-covalent coupling of the 
probe DNA, as well as the nature and structure of the surface. For an accurate 
location, a precise spot shape in a µm size range and a facilitated automated image 
acquisition and processing, dimensional stabile and rigid glass or plastic supports are 
mostly used today. Furthermore, such a flat and impermeable surface permits a good 
accessibility of the probe, so that the diffusion limitation due to steric hindrances in 
the hybridization process is decreased (153).  
 
Glass as a solid support is easy to derivatize for immobilization of chemically 
modified or unmodified oligonucleotides. The most commonly used surface 
chemistries for DNA microarrays are planar poly-L-lysine, aldehyde or epoxy groups. 
The probe DNA is bound covalently to these surfaces via reactive groups of the 
bases itself or via additionally synthesized exposed reactive groups (e.g. NH2), which 
allow a directed immobilization (see figure 8). Tethering one end of the probe to the 
surface is especially advantageous for short oligonucleotide probes, since the base 
involved in the coupling to the surface can not take part in base pairing and thus the 
full-length probe sequence is not accessible for target hybridization. The effect is 
naturally the more pronounced the shorter the probe sequence is. In case of an allele 
specific hybridization, where the duplex destabilizing effect of a single base mismatch 
is determined, these effects have to be considered. Generally, the bases nearest to 
the surface are less accessible for hybridization of the target (151). Therefore, spacer 
molecules can be introduced between the probe sequence and the surface, so that 
the probe molecules are more exposed to the target molecules in solution. Spacers 
can be made of of polynucleotide strands (e.g. polyT (55)) or different chemical 
building blocks attached to the probe sequence. Hybridization yields can be 
increased up to two orders of magnitude by introduction of spacers (144). In this work 
poly-L-lysine and epoxy coated glass slides with unmodified oligonucleotide probes 
or oligonucleotide probes with a 5’ amino group and a polyT spacer were used. 
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Figure 8. Immobilization chemistries for microarray surfaces. The (a) aldehyde or (b) epoxy 
groups are covalently attached to the glass surface. The DNA probes are bound via exposed 
amino-groups coupled at the 5‘ or 3‘ end or amino groups of the bases itself. (c) On poly-L-lysine 
surfaces the DNA probes are absorbed electrostatically. The probes are bound via an UV-
induced radical reaction between a thymine and an amino group of the surface. 
(a) (b) 
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1.3.4.4 Target preparation 
In general, for reduced sequence complexity and improved sensitivity of the assay an 
amplification of the target sequence is necessary. Amplification by PCR is therefore a 
standard part of the target preparation. The target DNA can be produced single 
stranded or double stranded. A commonly used method to produce single stranded 
targets from PCR products is to include a promoter for RNA Polymerase in one of the 
primers, from which RNA is transcribed. Single stranded DNA can be produced either 
in an asymmetric PCR or one strand of the double stranded amplicon is removed by 
exonuclease treatment, while the other strand is protected from exonuclease 
digestion by a resistant group (phosphorthioates (118) or dendritic caps (145)) 
annealed to one of the primers (153).  
 
During amplification by PCR also the labeling for signal detection can be performed. 
Fluorescence labels are utilized in the majority of microarray experiments, because 
they allow high resolution imaging and a sensitive detection. Such dyes absorb light 
energy at a higher energetic (short) wave length and reemit light at a lower energetic 
(longer) wavelength. The use of fluorescent labels with differing absorption and 
emission spectra enables the simultaneous detection of different dyes, which is 
applied in microarray experiments using comparative analysis (e.g. gene expression 
analysis (19), loss of signal analysis (58)). The most commonly used fluorescent 
dyes are Cy3 or Cy5 (see figure 9). The labeling of the target DNA can be carried out 
via direct incorporation of fluorescently labeled nucleotides during PCR amplification 
or via indirect coupling: the incorporated nucleotides bear reactive groups, which can 
be used to couple the fluorescent label in a subsequent reaction (e. g. streptavidin-
biotin or amino-allyl coupling). The labeling can also be performed during 
fragmentation of the target DNA (78). 
 
For microarrays with oligonucleotide probes with a size range between 15-30 nt, it is 
important to apply randomly fragmented nucleic acid targets (12). This minimizes 
steric hindrance during hybridization due to target secondary structures and 
increases the diffusion rate of the targets. Furthermore different regions of the target 
molecule can hybridize independently from each other to each of the immobilized 
oligonucleotides (78). Therefore, an enhanced sensitivity and specificity of the 
analysis especially for SNP detection can be achieved. The random fragmentation 
can be performed enzymatically (by DNaseI) (31,54) or chemically (78).  
 
Figure 9. Structure of Cy3-dCTP and excitation- and emissions spectra of Cy3 and Cy5.  
Cy3: Exmax: 550 nm, Emmax: 570 nm, Molar extinction coefficient: 150 000 M-1·cm-1,  
Cy5: Exmax: 649 nm, Emmax: 670 nm, Molar extinction coefficient: 250 000 M-1·cm-1 
[Amershambiosciences]. 
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1.3.4.5 Hybridization 
Duplex formation is a multistep process that is believed to begin with an initial pairing 
of a small number of bases in a transient intermediate. If the two strands are 
complementary, duplex formation propagates from the initiation site in a process 
known as zippering (151). Whether a labeled target DNA fragment finds an 
immobilized complementary probe molecule, is depending on the diffusion of the 
molecule through the solution phase. In the allele specific hybridization format the 
discrimination between a perfectly matched probe/target duplex and a non-perfectly 
matched duplex has to be achieved. For maximal PM/MM discrimination the 
hybridization reaction has to reach an equilibrium state. This is strongly dependent 
on the number of probe/target meeting events and therefore the hybridization time. 
To accelerate this process, shorter target DNA fragments, which are less affected by 
diffusion limitation, and additional agitation of the solution phase can be applied. 
Further already mentioned factors influencing the discrimination level include ionic 
strength, pH, Tm of the duplexes and the hybridization temperature as well as the 
stringency of the following washing steps. All these parameters have to be optimized 
empirically. 
 
Hybridization should be carried out in a closed compartment or a humid environment 
to avoid evaporation and drying of the hybridization solution resulting in high 
background signal intensities. Furthermore hybridization should be carried out in the 
dark for avoiding photobleaching of the fluorescent dyes. Multiple manual and 
automated methods exist for carrying out the hybridization and washing steps. In this 
work the major focus was to develop a highly reproducible and sensitive assay, 
therefore a variety of hybridization devices offering different strategies to address the 
aforementioned problems was tested. 
 
1.3.5 Transfer to a marketable array format 
The application of microarray technology for diagnostic purposes and the 
development of marketable array formats is rapidly advancing. Here only few 
examples for the fast growing number of arrays, which are currently developed for 
diagnostic applications will be given. 
 
In January 2005 Roche announced that its first microarray-based test, the AmpliChip 
CYP450 Test (36), has been cleared by the US Food and Drug Administration (FDA) 
for diagnostic use in the United States. The microarray is based on Affymetrix 
microarray technology (high density in situ synthesized oligonucleotide probe chips) 
and analyses a patient's Cytochrome P450 2D6 and 2C19 genotypes from genomic 
DNA extracted from a blood sample. The test results allow physicians to consider 
genetic information from patients for the selection of medications and doses of 
medications for a wide variety of common conditions such as cardiac diseases, pain 
and cancer. 
 
Nanogen developed in 1999 an automated electronic microchip for fast detection of 
single nucleotide polymorphisms (SNPs), short tandem repeats (STRs), insertions, 
deletions and other mutation analyses (45). The chip allows the electronic addressing 
of biotinylated amplicons to selected pads, where they remain embedded through 
interaction with streptavidin in the permeation layer. The DNA at each test site is then 
hybridized to a mixture of fluorescently labeled wild-type or mutant probes. This 
platform has already been applied for the automated detection of mutations involved 
in beta-thalassemia disease (49) or in familial Mediterranean fever (FMF) (113). 
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Furthermore, the simultaneous in situ amplification and genotyping of single 
nucleotide polymorphism involved in Factor V Leiden (FVL) disease has been shown 
(66). This method combines strand displacement amplification (SDA) with 
electrophoretic movement and concentration of DNA on an electronic microarray to 
provide a single platform for DNA amplification and analysis.  
 
The Austrian Research Center Seibersdorf concentrates on the development of 
microbial diagnostic microarrays. A prototype microarray has been developed for the 
detection and community analysis of methanotrophic bacteria (12). The method 
involves oligonucleotide probes based on 16S rRNA or other genes, which can be 
used as phylogenetic markers. These probes are applied in a standard hybridization 
microarray format. 
 
Since specific features of the DNA microarray technology are covered by patents, 
alternative strategies for the development of a marketable diagnostic array have to 
be found. The standard array format of oligonucleotide probes immobilized on coated 
glass slides is currently covered by the patent filed by Edwin Southern and Oxford 
Gene Technology covering the application of oligonucleotide probes immobilized on 
impermeable substrates (patent number EP0373203B1). Through the cooperation 
with Eppendorf Array Technology (EAT, Namur, Belgium) an alternative 
immobilization method was provided, which is not covered by this patent. 
Furthermore, this company provides a post-hybridization labeling technique based on 
the precipitation of silver on gold particles, which are bound to the target DNA via 
incorporation of biotinylated nucleotides. A streptavidin-gold conjugate is used in the 
signal development step (1). The applicability of this format for the developed arrays 
should be evaluated in this study. 
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1.3.6 Link of the resistance to the pathogenic bacteria 
For a complete clinical application of the genotypic resistance detection the 
assignment of the resistance to the pathogenic bacteria is a crucial step, since the 
human body harbors a wide variety of non-pathogenic microorganisms, which might 
also carry resistance determinants. Only if the resistance can be linked to the 
pathogenic bacteria, a proposition for an effective antimicrobial therapy is possible. 
Currently this was achieved by a culture dependent preisolation of the pathogenic 
organism, but this is time consuming and hinders the exploitation of the full 
advancement potential of a genotypic diagnostic. A new approach, which was 
developed by coworkers at the TU-Munich, uses genetic markers for designing 
polynucleotide probes for a species-specific enrichment of pathogenic bacteria in 
microtiterplate wells (46). Afterwards a PCR with resistance gene specific primers 
can be carried out and the amplicon is analyzed by the resistance microarrays. The 
proof of principle of the method (as shown in figure 10) for the detection of 
resistances by microarray analysis should be shown in this work. 
 
Figure 10. Schematic representation of species-specific enrichment and microarray analysis of 
resistance genes. The bacteria (in clinical samples such as urine, blood,..) are pretreated with 
detergents, so that the cell walls are permeabilized for probe hybridization to the targeted 16S or 
23S rRNA or DNA structures. The hybridization to species-specific polynucleotide probes is carried 
out in solution. Afterwards the hybridized cells are separated from non-target cells via binding to 
microtiter cavities coated with complementary nucleic acids (46). After denaturation, the resistance 
gene is amplified by PCR performed in the microwells and is identified by microarray analysis. 
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1.4 Objectives 
This work was accomplished within the scope of the GenoMik (Genome research on 
microorganisms) project funded by the BMBF (Bundesministerium für Bildung und 
Forschung). This project promotes research targeting the genomic and metabolic 
features of bacteria important for agriculture, environmental protection, biotechnology 
and the health care sector. The focus of our group at the Institute of Technical 
Biochemistry (University of Stuttgart, Germany) is the development of rapid genotypic 
assays for antibiotic resistance detection in pathogenic bacteria. This work was done 
in cooperation with academic and industry partners. At the Robert-Bosch Hospital in 
Stuttgart the phenotypic testing was performed, the strain collection was supported 
and advice concerning the clinical microbiology point of view was provided. The 
Wernigerode branch of the Robert Koch Institute (the central federal institution 
responsible for disease control and prevention in Germany) delivered reference 
strains and knowledge regarding importance and prevalence of diverse antibiotic 
resistance traits. In a cooperation with the TU-Munich a method for the species-
specific enrichment of pathogenic bacteria was provided for a combination with the 
resistance arrays. The industry partner Eppendorf AG supported this work with 
technical equipment and promotes the transfer of the developments to a marketable 
format. Our group also cooperates with the National Research Center for Antibiotics 
in Moscow, Russia for an early monitoring of emerging antibiotic resistances in 
eastern Europe.  
 
The ultimate goal in this project was the development of an ESBL-Chip for the rapid, 
sensitive and reliable detection and identification of the clinically relevant ESBL and 
IRT producing beta-lactamases for application in clinical microbiology diagnostics as 
well as epidemiologic studies. Since their first appearance, the most reported ESBL 
genes belong to the TEM and SHV beta-lactamase families regarding variant 
numbers and producer strains. Therefore, the focus of this work was directed 
towards the establishment of an assay system for the detection of these variants, 
which is still extendable towards other beta-lactamase families (e.g. CTX-M, OXA). In 
summary, the major objectives of this work were (i) the ability of the assay system to 
detect relevant single nucleotide polymorphisms and other mutations, (ii) the 
unambiguous identification of all parental, ESBL and IRT variants of the TEM and 
SHV beta-lactamase family, (iii) the use of consensus primers for target amplification, 
(iv) maximal sensitivity and (v) reproducibility of the procedure, (vi) minimal assay 
time, (vii) validation of the assay system using clinical samples compared to clinical 
standard procedures, (viii) the possibility to extend the developed system for 
detection of other ESBL causing gene variants.  
 
Material and Methods 
  33
2 Material and Methods 
2.1 Material 
 
2.1.1 Biological reagents 
Supplier Product 
Amersham Pharmacia Biotech (Freiburg, Germany) FluoroLink Cy3-dCTP, Cy5-dCTP 
Applied Biosystems (Darmstadt, Germany) Big-dye Terminator Cycle Sequencing Kit 
Eppendorf (Hamburg, Germany) Taq DNA-Polymerase 
Gibco BRL Life Technologies (Eggenstein, Germany) 1Kb DNA Ladder, 1Kb Plus DNA Ladder 
Invitrogen (Karlsruhe, Germany) dNTPs 
Promega (Mannheim, Germany) RQ1 RNase-free DNase Kit 
Qiagen (Hilden, Germany) QIAquick PCR Purification Kit 
 
2.1.2 Chemical reagents 
Supplier Product 
Gibco BRL Life Technologies Technologies 
(Eggenstein, Germany) 
Agarose  
Merck (Darmstadt, Germany) LiChrosolv ( HPLC Water) 
Sigma-Aldrich (Deisenhofen, Germany) acetic acid, bromphenol blue, DMSO, EDTA, 
ethanol (100% or 95%), ethidium bromide, 
ethylene glycol, glycerol, HCl, KCl, 1-methyl-2-
pyrrolidinon, SDS, sodium acetate, sodium borate, 
sodium citrate⋅2H2O, NaCl, Na2EDTA, NaH2PO4, 
NaOH, succinic acid, Tris , Triton X-100,  
 
2.1.3 Equipment 
Supplier Designation Equipment 
Advalytix (Brunnthal, 
Germany) 
hybridization compartment arraybooster 
Affymetrix (Santa Clara, US) array-scanner GMS 418 Array Scanner 
Applied Biosystems 
(Darmstadt, Germany) 
DNA-sequencer ABI Prism 377-DNA-Sequencer 
Amersham Pharmacia Biotech 
(Freiburg, Germany) 
hybridization station Lucidea Slide Pro 
Biometra (Göttingen, 
Germany) 
hybridization oven 
UV-crosslinker 
OV5 hybridization oven 
Stratalinker UV Crosslinker 1800 
Biorobotics (Cambridge, 
England) 
spotter Microgrid II Microarrayer 
Corning (New York, US) hybridization chamber Corning Hybridization Chamber 
Eppendorf (Hamburg, 
Germany) 
centrifuge 
thermomixer 
thermomixer slide adapter 
PCR Cycler  
Automatic Pipette  
5417R, 5810R and MiniSpin 
Thermomixer Comfort 
Thermomixer Slide Adapter 
MasterCyler Gradient,  
Research, Research Pro  
Fujifilm (Düsseldorf, Germany) gel documentation system Image Reader Las-1000 Plus 
Memmert (Schwabach, 
Germany) 
drying compartment Universal Oven (Model U) 
NanoDrop Technologies spectrophotometer ND-1000 Spectrophotometer 
Scientific Industries (New 
York, US) 
vortex Vortex-Genie 2 
Tecan (Crailsheim, Germany) hybridization station HS 400 Hybridization Station 
WTW (Weiheim, Germany) pH-meter pH500 
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2.1.4 Consumables 
Supplier Product 
Eppendorf (Hamburg, Germany) CreativeChip® Oligo Slides, in situ frames (65 µl), 
safe-lock tubes 
Greiner bio-one (Frickenhausen, Germany)  384 well polystyrol (PS)-microtiterplates (U-form), 
pipette tips 
Invitrogen (Karlsruhe, Germany) oligonucleotide probes for TEM-array (desalted 
purity grade), PCR primers (desalted) 
Metabion (Planegg-Martinsried, Germany) 5’ C6-amino-modified oligonucleotide probes for 
SHV-array, oligonucleotide probes with 5‘ 
Cy3/Cy5-modification (controlled by MALDI_TOF) 
Sigma-Aldrich (Deisenhofen, Germany) oligonucleotide probes for TEM-array (desalted 
purity grade), PCR primers (desalted) 
 
2.1.5 Clinical isolates 
Isolate 
No. 
Identifier 
Number 
Sample Species Phenotype Hospital 
Samples collected in Germany 
1 421196 swab E. cloacae ESBL Robert Bosch Hospital 
2 474273 urine E. cloacae ESBL Robert Bosch Hospital 
3 477997 swab E. cloacae ESBL Robert Bosch Hospital 
4 479803 blood E. amnigenus ESBL Robert Bosch Hospital 
5 405339 swab E. cloacae ESBL Robert Bosch Hospital 
6 406551 urine Enterobacter spp. ESBL Robert Bosch Hospital 
7 410147 vaginal swab E. cloacae ESBL Robert Bosch Hospital 
8 431859 dialysate E. cloacae ESBL Robert Bosch Hospital 
9 431196 BAL E. cloacae ESBL Robert Bosch Hospital 
10 431389 urine E. cloacae ESBL Robert Bosch Hospital 
11 432697 urine E. cloacae ESBL Robert Bosch Hospital 
12 435727 tracheal swab Klebsiella spp. ESBL Robert Bosch Hospital 
13 445421 vaginal swab E. coli ESBL Robert Bosch Hospital 
14 445437 cervix swab E. cloacae ESBL Robert Bosch Hospital 
15 429457 urine K. pneumoniae ESBL Robert Bosch Hospital 
16 456789 decubitus 
swab 
Klebsiella spp. ESBL Robert Bosch Hospital 
17 442766 tracheal swab E. sakazakii ESBL Robert Bosch Hospital 
Samples collected in Russia 
25 361 n.s. E. coli ESBL Moscow City Clinic 
26 932 n.s. E. coli ESBL Moscow City Clinic  
31 n.s n.s. P. mirabilis ESBL/ 
AmpC 
Moscow City Clinic 
37 14451 n.s. K. pneumoniae ESBL Moscow City Clinic 
39 47a n.s. Klebsiella spp. ESBL Moscow City Clinic 
41 241 n.s. E. coli no ESBL Moscow City Clinic 
43 1140 n.s. E. coli ESBL Moscow City Clinic 
50 15935 n.s. K. pneumoniae ESBL Central Russian Military Hospital 
52 18721 n.s. E. aerogenes ESBL Central Russian Military Hospital 
55 20426 n.s. E. coli ESBL Central Russian Military Hospital 
57 20585/2 n.s. E. coli ESBL Central Russian Military Hospital 
59 129 n.s. K. pneumoniae ESBL Moscow City Clinic 
64 1949/2 n.s. K. pneumoniae ESBL Moscow City Clinic 
67 361 n.s. C. freundii ESBL/ 
AmpC 
Tomsk City Hospital 
68 n.s n.s. M. morganii ESBL Tomsk City Hospital 
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75 52 n.s. K. pneumoniae ESBL National Research Center for 
Pediatric Diseases 
77 212 n.s. E. coli not pure Moscow City Clinic 
79 161 n.s. E. coli ESBL Moscow City Clinic 
83 571 n.s. E. coli ESBL Tomsk City Hospital 
86 622 n.s. C. freundii ESBL/ 
AmpC 
Tomsk City Hospital 
87 533 n.s. E. coli ESBL Tomsk City Hospital 
90 271 n.s. P. vulgaris ESBL Tomsk City Hospital 
92 73 n.s. K. pneumoniae ESBL National Research Center for 
Pediatric Diseases 
93 771 n.s. E. coli ESBL/ 
AmpC 
Tomsk City Hospital 
94 358 n.s. E. coli ESBL Tomsk City Hospital 
95 358 n.s. K. pneumoniae ESBL Tomsk City Hospital 
96 797 n.s. C. freundii ESBL/ 
AmpC 
Tomsk City Hospital 
98 896 n.s. C. freundii ESBL Tomsk City Hospital 
99 761 n.s. C. freundii ESBL Tomsk City Hospital 
100 813 n.s. E. coli no ESBL Tomsk City Hospital 
Samples collected in Croatia 
1 32193/03 urine K. pneumoniae ESBL Zadar Hospital 
2 31300/03 wound swab K. ornithinolytica CTX-M Zadar Hospital 
3 37254/03  E. coli ESBL Zadar Hospital 
4 30164/03 urine K. pneumoniae ESBL Zadar Hospital 
5 30903/03 urine K. pneumoniae ESBL Zadar Hospital 
6 28505/03 urine K. pneumoniae ESBL Zadar Hospital 
7 19445/03 urine K. pneumoniae ESBL Zadar Hospital 
8 34136/03 n.s. K. pneumoniae ESBL Zadar Hospital 
9 28390/03 urine K. terrigena ESBL Zadar Hospital 
10 20214/03 urine E. coli ESBL Zadar Hospital 
11 18945/03 n.s. K. pneumoniae ESBL Zadar Hospital 
12 31015/03 wound swab K. pneumoniae ESBL Zadar Hospital 
13 30953 n.s. K. pneumoniae no ESBL Zadar Hospital 
14 19586/03 blood K. pneumoniae ESBL Zadar Hospital 
15 34640/03 urine E. coli ESBL Zadar Hospital 
16 32199/03 urine K. pneumoniae ESBL Zadar Hospital 
18 15 urine E. coli ESBL Zadar Hospital 
19 34601/03 urine K. pneumoniae ESBL Zadar Hospital 
20 33913/03 urine K. pneumoniae ESBL/ 
AmpC 
Zadar Hospital 
21 35710/03 urine E. coli no ESBL Zadar Hospital 
22 14 blood E. coli ESBL Zadar Hospital 
23 28 vaginal swab E. coli ESBL Zadar Hospital 
24 16 n.s. E. coli ESBL Zadar Hospital 
25 32929/03 urine K. pneumoniae ESBL Zadar Hospital 
26 31696/03 urine K. oxytoca K1 Zadar Hospital 
27 2 n.s. E. coli ESBL Zadar Hospital 
28 32198/03 urine K. pneumoniae ESBL Zadar Hospital 
29 34078/03 urine K. pneumoniae ESBL Zadar Hospital 
30 35646/03 n.s. K. pneumoniae ESBL Zadar Hospital 
31 28504/03 urine K. pneumoniae ESBL Zadar Hospital 
32 29933/03 urine K. pneumoniae no ESBL Zadar Hospital 
33 30350/03 urine K. pneumoniae ESBL Zadar Hospital 
34 29332/03 n.s. K. pneumoniae ESBL Zadar Hospital 
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35 29843/03 n.s. K. pneumoniae ESBL Zadar Hospital 
36 19415/03 n.s. E. coli not clear Zadar Hospital 
n.s. = no specification 
 
2.1.6 Software 
Supplier Product 
Biodiscovery (Los Angeles, USA) ImaGene™ (Version 3.0)  
DNAStar (Madison, USA) SeqMan™ II (Version 5.0) 
Molecular Biology Insights (Cascade, USA) Oligo (Version 6.65) 
PREMIER Biosoft International (Palo Alto, Canada) Array Designer (Version 2.0) 
freeware (ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX/) ClustalX (Version 1.81) 
freeware (http://www.ncbi.nlm.nih.gov/BLAST) nucleotide - nucleotide BLAST (blastn) 
 
2.2 Solutions 
Name Composition 
Blocking solution for poly-L-lysine-slides 0.18 M succinic acid anhydride, 44 mM sodium 
borate (pH 8.0) in methyl-pyrrolidinone 
Spotting buffer for poly-L-lysine-slides 50 % DMSO (v/v) in ddH2O 
Spotting buffer for epoxy slides 160 mM Na2SO4, 130 mM Na2HPO4 in ddH2O 
Betaine spotting buffer 3 x SSC, 1 M betaine 
Rinse solution 1 for epoxy slides 0.1 % (v/v) Triton x 100 in ddH2O 
Rinse solution 2 for epoxy slides 0.5 µl conc. HCl per ml ddH2O 
Rinse solution 3 for epoxy slides 100 mM KCl 
Blocking solution for epoxy slides 25 % (v/v) ethylene glycol, 0.5 µl conc. HCl per ml 
ddH2O 
20 X SSPE 
 
175.3 g NaCl, 88.2 g NaH2PO4.1H2O, 7.4 g 
Na2EDTA, 800 ml H2O, 10 M NaOH (pH 7.4) ad 1l 
ddH2O 
20 X SSC 
 
175.3 NaCl, 88.2 g Na3Citrat.2H2O, HCl (pH 7.0) 
ad 1l ddH2O 
Wash solution 1 for PLL-slides 2 x SSC, 0.1% SDS  
Wash solution 2 for PLL-slides 0.2 x SSC 
Wash solution 1 for epoxy slides 2 x SSC, 0.2% SDS 
Wash solution 2 for epoxy slides 2 x SSC 
Wash solution 3 for epoxy slides 0.2 x SSC 
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2.3 Methods 
2.3.1 Identification of SNP positions 
To identify the SNP (single nucleotide polymorphism) positions data was extracted 
from web resources containing published amino acid exchanges 
(http://www.lahey.org/Studies/) and a multisequence alignment of all available blaSHV 
and blaTEM nucleotide sequences was established using ClustalX (Version 1.81, 
freeware). 
 
2.3.2 Probe design  
2.3.2.1 TEM-array 
For 41 SNP positions (ESBL, IRT, or both; see table 3) oligonucleotide probes were 
designed with variable lengths (17 - 27 bases) (see table 4 and 5). For maximum 
perfect match/mismatch discrimination during hybridization the probes were designed 
with the SNP at the central base within the probe sequence. For each SNP a probe 
set of 4 probes was designed with identical sequence except the central base, which 
is either A, T, G, or C. The SNP probes are named after the position of the amino 
acid substitution within the TEM sequence, that means probe number 161 defines 
the polymorphism at position 161 in the TEM amino acid sequence. For seven amino 
acid substitution positions there are two polymorphisms within one triplet. For these, 
two SNP probe sets (2 x 4 probes) were designed (e. g. 162, 162.2).  
 
The probe length, the melting temperature (Tm °C), GC content (GC %), free energy 
of hairpin bonds (hairpin ∆G kcal/mol), the number of bases forming the hairpin bond 
(hairpin bond), free energy of dimers (dimer ∆G kcal/mol), the number of bases 
forming the dimer bond (dimer bond) as displayed in table 4 were calculated by 
ArrayDesigner 2.0 software software (Premier Biosoft International, Palo Alto, US) 
using default values: 0.25 nM DNA, 50 mM monovalent ions, 1.5 mM free Mg2+, 
temperature for free energy calculation: 25°C. In this program Tm is calculated based 
on nearest neighbor thermodynamic theory using SantaLucia values. Entropy and 
enthalpy calculations are based upon the thermodynamic library of all 10 Watson-
Crick DNA nearest-neighbor interactions determined by SantaLucia et al. (139). 
 
2.3.2.2 SHV-array 
For 37 mutation positions (ESBL, IRT, table 8) oligonucleotide probes were designed 
with variable lengths (15 - 25 bases) (see tables 9 - 12). Secondary structure’s ∆G 
values and the melting temperatures were calculated by ArrayDesigner 2.0 software 
(see above). As for the TEM-array the probes were designed with the mutation at the 
central position within the probe sequence. For each SNP a probe set of 4 probes 
was designed with identical sequence except the central base, which is either A,T, G, 
or C. The probes are named for the position of the amino acid substitution within the 
SHV sequence, that means probe No 03 defines the polymorphism at position 03 in 
the SHV amino acid sequence. For amino acid substitution position 175 there are two 
polymorphisms within one triplet. For this, two SNP probe sets (2 x 4 probes) were 
designed (e. g. 175.1, 175.1). For the neighboring amino acid position 234 and 235 
multiple amino acid exchanges occur. For each naturally occurring SHV-mutant 
sequence one perfect match probe was designed. These probes are designated by 
the targeted amino acids at position 234/5 (GE, SE, SK, AE, AK) and the nucleotide 
at the third codon position for amino acid 235 (GEa or GEg). At three amino acid 
positions more than one neighboring nucleotide differs in the mutant sequence from 
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the wildtype sequence (for amino acid position 135/6: GGCC to CCGG, 188/9: GC to 
CG, 163: insertion of 15 nucleotides), here for each position one probe (136WILDTYPE, 
188/9WILDTYPE, 163WILDTYPE) matching the wildtype sequence (SHV-1) and one probe 
(136MUTANT, 188/9MUTANT, 163MUTANT) matching the mutant sequence were designed.  
 
2.3.3 Oligonucleotide array fabrication on poly-L-lysine-sides  
The array layout (shown in figure 11) was spotted in 4 replicates, each one with a 
different pin. The probes were dissolved in spotting buffer (50 % DMSO) to a final 
concentration of 20 µM and spotted with a MicroGrid II using MicroSpot 2500 pins 
(BioRobotics, Cambridge, UK) on poly-L-Lysine-slides (Sigma-Aldrich, Deisenhofen, 
Germany). For covalent immobilization the oligonucleotide array was irradiated with 
120 mJ/m2 in a UV crosslinker (Stratalinker, Biometra, Göttingen, Germany). For 
blocking, the slides were incubated in blocking solution (0.18 M succinic acid 
anhydride, 44 mM sodium borate (pH 8.0) in methyl-pyrrolidinone) for 15 min under 
agitation in a glass container. For cleaning, the slides were rinsed shortly in ddH2O 
and 95 % ethanol and then dried by nitrogen flow. The spot size was estimated to be 
150 µm and the spot to spot distance was 320 µm. The processed slides were stored 
for maximally 20 days dry at room temperature in the dark until further use.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.4 Oligonucleotide array fabrication on epoxy slides  
2.3.4.1 Setting up the system 
In the initial spot test a spotting control and a probe set were spotted with a MicroGrid 
II using MicroSpot 2500 pins (BioRobotics, Cambridge, UK) at a final concentration of 
20 µM in DMSO- (50 % DMSO), betaine- (3 x SSC, 1 M betaine) or phosphate-based 
(160 mM Na2SO4, 130 mM Na2HPO4) spotting buffer on epoxy slides. The spotting 
control was spotted in 32 replicates, the probe set in four replicates for each of eight 
pins. For covalent immobilization the oligonucleotide array was incubated at 120 °C 
for 30 min in a drying compartment (Memmert, Schwabach, Germany). For blocking, 
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Figure 11. One probe set layout of the TEM-microarray on poly-L-lysine slides is displayed. The 
TEM-array was spotted in 4 identical replicate layouts with four different pins. In the layout the SNP 
position is indicated above each probe set. The central base in the probe sequence is indicated on 
the left side of the row as A, G, C or T. Blue spots designate perfect match positions for blaTEM-116 
gene, white spots refer to mismatch positions. The spotting controls (indicated in red) frame each 
replicate layout spotted by a different pin.  
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the slides were rinsed for 5 min in 0.1 % (v/v) Triton x 100 in ddH2O, 4 min in 0.5 µl 
conc. HCl per ml ddH2O, for 10 min in 100 mM KCl solution while constantly stirring. 
Subsequently, the slides were incubated in blocking solution (25 % (v/v) 
ethylenglycol, 0.5 µl conc. HCl per ml ddH2O) with the spotted side upwards at 50 °C 
in a heating compartment (OV5, Biometra, Göttingen, Germany). For cleaning, the 
slides were rinsed in ddH2O for 1 min and then dried by nitrogen flow.  
 
2.3.4.2 TEM-array 
Oligonucleotide arrays were constructed with 168 oligonucleotide capture probes. 
The oligonucleotides were purchased from Invitrogen (Karlsruhe, Germany) at a 
desalted purity grade. The capture and control probe sequences are given in table 5. 
Each SNP probe was spotted in triplicate. The array layout is shown in figure 12. The 
probes were dissolved in spotting buffer (160 mM Na2SO4, 130 mM Na2HPO4) to a 
final concentration of 20 µM and spotted with a MicroGrid II using MicroSpot 2500 
pins (BioRobotics, Cambridge, UK) on epoxy coated glass slides (Elipsa, Berlin, 
Germany). The immobilization and blocking procedure was identical to the 
parameters described in section 2.3.4.1. The spot size was estimated to be 150 µm 
and the spot to spot distance was 320 µm. The processed slides were stored for 
maximally 20 days dry at room temperature in the dark until further use.  
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Figure 12. The SNP capture probe layout of the TEM microarray on epoxy-coated slides is 
shown. All SNP capture probes were spotted in triplicates. The SNP position is indicated above 
each triplicate. The central base in the probe sequence is indicated on the left side of each row 
as A, G, C or T. Blue spots indicate perfect match positions for blaTEM-116 gene, white spots 
indicate mismatch positions. Negative and positive hybridization controls are indicated as neg. 
hyb. and pos. hyb controls respectively.  
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2.3.4.3 SHV-array 
Oligonucleotide arrays for SHV were constructed with 151 oligonucleotide capture 
probes. The array layout is shown in figure 13. The oligonucleotides were purchased 
from Metabion (München, Germany) with a desalted purity grade. The capture and 
control probe sequences are given in table 12, all probes were equipped with a 13 
thymidine spacer and a C6-aminomodification. Further production parameters were 
identical to fabrication of the TEM-array. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.5 Controls 
Several controls were included on the array: a spotting control  
(5’-ttttttttttttttctagacagccactcata-Cy3/Cy5 3’), a positive hybridization control  
(5’-tttttttttttttgattggacgagtcaggagc-3’) complementary to a labeled oligonucleotide 
target (5’-Cy3/5-gctcctgactcgtccaatc-3’), which was spiked in during hybridization, 
and a negative hybridization control (5’-ttttttttttttttctagacagccactcata-3’). All these 
controls consisted of sequences unrelated to bacterial species and were equipped 
with a C6-aminomodification at the 5’ end. The process control  
(5’-NH2-ttttttttttttttttaaagtagtgctctgcggc-3‘ for blaSHV; and 5’-agaaacgctggtgaaagt-3‘ for 
blaTEM) corresponded to a conserved sequence within the blaSHV or blaTEM gene 
family. The spotting controls were set at the corner positions of each subgrid, which 
was spotted by a different pin. The positive and negative hybridization controls 
appeared alternately at the side borders of each subgrid. The process controls were 
spotted in two lines bordering the central SNP probe sets of each subgrid (figure 12 
and 13). 
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Figure 13. The spotting layout of the mutation capture probes of the SHV microarray is displayed. All 
mutation specific capture probes were spotted in triplicate. The mutation position is indicated above 
each triplicate. For the SNP specific probes the nucleotide at the central base is indicated on the left 
side of each row as A, G, C or T. For probe No. 234/5 the probes are designated by the targeted 
amino acids at position 234/5 (GE, SE, SK, AE, AK) and the nucleotide at the third codon position for 
amino acid 235 (GEa or GEg) as indicated in the legend. For position 136, 188/9, 163 one probe triplet 
(WT) matching the wild type sequence (blaSHV-1) and one probe triplet (MT) matching the mutant 
sequence (blaSHV-X) are spotted. Negative and positive hybridization controls are indicated as neg. hyb. 
and pos. hyb controls respectively.  
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2.3.6 Bacterial strains 
As TEM reference samples two EARSS (European Antibiotic Resistance 
Surveillance System) reference strains and two strains carrying ESBL-type TEM 
variants were provided by the Robert Koch Institute in Wernigerode. As SHV 
reference samples E. coli DH5α transformed with blaSHV target genes in a pCCR9 
target vector were used, which were kindly provided by H. Hächler (Institute of 
Medical Microbiology, University of Zurich, Switzerland). The bacterial strains were 
inoculated in 5 ml LB with 50 µg ampicillin per ml and incubated overnight at 37°C. 
Clinical samples were taken during the daily routine of the cooperating hospitals (see 
section 2.1.5) and processed following standard operation procedures. Prior to 
microarray analysis, the isolated bacterial strains were inoculated on Müller-Hinton 
agar plates at 37°C over night. Plasmid DNA was extracted according to the QIAprep 
Spin Miniprep Kit protocol (Qiagen, Hilden, Germany). 
 
After isolation, bacterial strain identification was performed according to NCCLS 
standard operation procedures at the Robert Bosch Hospital (RBK) in Stuttgart. 
Antibiotic resistance determination and confirmation of ESBL phenotypes was also 
performed at the RBK by agar diffusion testing with ceftazidime, cefotaxime and 
cefpodoxime with and without clavulanic acid, as well as cefoxitin and aztreonam 
according to NCCLS standard operation procedures. Automated species 
identification and ESBL screening were performed at the RBK using an automated 
microdilution test system (WalkAway 5105, Neg Breakpoint Combo Panel Type 30, 
Dade MicroScan, West Sacramento, US) according to the manufacture’s protocol. 
 
2.3.7 Preparation of target DNA 
2.3.7.1 Amplification and labeling 
 
TEM  
The target DNA for hybridization on the oligonucleotide arrays was synthesized by 
PCR. The sequences of the amplification primers for the blaTEM gene (with an 
expected amplicon length of 861 bp) were for the forward primer "temforw":  
(5‘-atgagtattcaacatttccg-3‘) and reverse "temrev" (5‘-ttaatcagtgaggcacctat-3‘). For 
PCR amplification and labeling 1 – 75 ng of plasmid DNA was supplemented with  
0.4 µM forward and reverse primer, PCR-buffer (2.5 mM Mg(OAc)2, 50 mM KCl,  
10 mM Tris-HCl pH 8.3) containing 50 µM dATP, dGTP, dTTP, 30 µM dCTP, 20 µM 
Cy5- or Cy3-dCTP (Amersham Biosciences, Freiburg, Germany) and 10 U Taq DNA 
Polymerase (Eppendorf, Hamburg, Germany) in a total volume of 100 µl. The 
amplification was performed in a Mastercycler Gradient (Eppendorf, Hamburg, 
Germany). An initial denaturation step (94°C for 1 min) was followed by 30 cycles 
(94°C for 30 s, 55°C for 30 s, 72°C for 1 min) and a final extension step at 72°C for 
4 min. 
 
SHV 
The sequences of the amplification primers for the blaSHV gene (with an expected 
amplicon length of 932 bp) were for the forward primer "shvforw":  
(5‘-gcaaaacgccgggttattc -3‘) and reverse "shvrev" (5‘-ggttagcgttgccagtgct-3‘). For 
PCR amplification and labeling 30-80 ng of plasmid DNA was supplemented with  
0.4 µM forward and reverse primer, PCR-buffer (2 % DMSO, 2.5 mM Mg(OAc)2,  
50 mM KCl, 10 mM Tris-HCl pH 8.3) containing 50 µM dATP, dGTP, dTTP, 30 µM 
dCTP, 20 µM Cy3-dCTP (Amersham Biosciences, Freiburg, Germany) and 10 U Taq 
DNA Polymerase (Eppendorf, Hamburg, Germany) in a total volume of 100 µl. The 
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amplification was performed in a Mastercycler Gradient (Eppendorf, Hamburg, 
Germany). An initial denaturation step (94°C for 1 min) was followed by 30 cycles 
(94°C for 1min, 54°C for 1 min, 72°C for 1 min) and a final extension step at 72°C for 
4 min.  
 
2.3.7.2 Purification  
The PCR product was purified with the Qiaquick® Spin PCR Purification Kit (Qiagen, 
Hilden, Germany) according to the manufacture’s protocol. The DNA was eluted in 
30 µl ddH2O.  
 
2.3.7.3 Determination of incorporation ratio 
The concentration of DNA and fluorescent dye was determined using 1 µl purified 
target DNA by measuring the absorption of DNA at 260 nm, Cy3 at 550 nm and Cy5 
at 650 nm with the ND-1000 Spectrophotometer (NanoDrop Technologies, Rockland, 
USA) and by calculating the concentrations by Lambert Beer’s law. The incorporation 
ratio of Cy3- or Cy5-dCTP, expressed as number of nucleotides/incorporated 
fluorescent dye (NT/F) was determined by the following formula: 
F
A
DNA
C
M
C
R
1000×
=  
R: incorporation ratio of Cy3 or Cy5 in NT/Cy3 or NT/Cy5 
CDNA: DNA concentration in ng/µl 
CF: Cy3 or Cy5 concentration in pmol/µl 
MA: average molecular weight of one nucleotide in g/mol (app. 330g/mol) 
 
2.3.7.4 Fragmentation  
The amplified and labeled target DNA was diluted to a concentration of 30 ng/µl in 
reaction buffer (40mM Tris-HCl, pH 8, 10 mM MgSO4, 1 mM CaCl2) and fragmented 
with DNaseI (11.5 mU/µl) (Promega, Mannheim, Germany) at room temperature for  
5 min to fragment sizes of about 15 to 150 bp. The reaction was stopped by the 
addition of 3 mM EGTA and incubation at 65°C for 10 min.  
 
2.3.7.5 Determination of fragment sizes 
Fragment sizes were estimated by lab-on-a-chip electrophoresis (Bioanalyzer 2100 
and DNA 1000 LabChip kit, Agilent, Böblingen, Germany) using 1 µl of fragmented 
target DNA. The analysis was performed according to the manufacture’s protocol.  
 
2.3.8 Hybridization  
2.3.8.1 Preparation 
If not stated otherwise, the hybridization solution consisted of fragmented target DNA 
with addition of control DNA (5’-Cy3- or Cy5-gctcctgactcgtccaatc-3’, 0.05 pmol) in  
6 x SSPE. All hybridizations were carried out at 45°C. The amount of target DNA  
(25-400 ng) was depending on the experiment and the incorporation ratio  
(50 - 150 NT/F). The duration of the hybridization (10 min - 3 h) and the total volume 
(30 - 65 µl) of the hybridization sample depended on the experiment and the applied 
hybridization method. 
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2.3.8.2 Hybridization without agitation 
 
Cover glass hybridization 
The hybridization sample was hybridized with the DNA microarray under a  
18 x 18 mm cover glass (Knittel Gläser, Braunschweig, Germany) in a total volume of 
30 µl, while incubating in hybridization chambers (Corning, New York, USA), which 
were placed in a hybridization oven (OV5, Biometra, Göttingen, Germany) for 3 
hours. 
 
Hybridization in sealing frames 
The hybridization sample was hybridized with the DNA microarray in in situ frames 
(Eppendorf, Hamburg, Germany) in a total volume of 65 µl, while incubating in a 
hybridization oven (OV5, Biometra, Göttingen, Germany) for 15 min - 1 hour. 
 
2.3.8.3 Hybridization with agitation  
 
ArrayBooster 
The hybridization sample was hybridized with the DNA microarray in the 
ArrayBooster (Advalytix, Brunnthal, Germany) under a special cover glass 
(AdvaCardTM-micro agitation chip card for 40 µl) with 50-65 ng DNA in a total 
volume of 40 µl for 30 min - 3 hours with a medium agitation intensity as defined by 
the manufacturer. 
 
Thermomixer 
The hybridization sample was hybridized with the DNA microarray in in situ frames 
(Eppendorf, Hamburg, Germany) in a total volume of 65 µl, while incubating in a 
thermomixer slide adapter for 15 min - 1 hour at 45 °C under agitation at 1200 rpm. 
 
Wash and dry 
When a non-automated hybridization was carried out, the washing steps were as 
follows: After hybridization the poly-L-lysine-slides were washed for 15 min in wash 
solution 1 (2 X SSC, 0.1 % SDS) and 3 min in wash solution 2 (0,2 x SSC) with 
agitation in a glass container. For epoxy slides: the slides were washed with 2 x SSC, 
0.2 % SDS then 2 x SSC and finally 0.2 x SSC, each time for 10 minutes at room 
temperature with agitation in a glass container. Finally the slides were dried with N2. 
 
2.3.8.4 Automated hybridization and washing 
 
HS4800 or HS400 
These hybridizations were carried out with the hybridization station HS 400 or HS 
4800 (Tecan, Crailsheim, Germany) with an initial wash step at 45°C with 6 x SSPE 
for 30 s, followed by the injection of the hybridization sample in a total volume of  
65 µl and hybridization under medium agitation intensity (as defined by the 
manufacturer) for 15 min - 3 hours. The slides were then washed at room 
temperature 2 times for 2 min in 2 x SSC, 0.2% SDS and for 1.5 min in 0.2 x SSC. 
The slides were dried with N2 for 2 min. 
 
Lucidea Slide Pro 
These hybridizations were carried out with the hybridization station Lucidea Slide Pro 
(Amersham Pharmacia Biotech, Freiburg, Germany) starting with the injection of the 
hybridization sample containing 75 ng DNA in a total volume of 250 µl and 
hybridization for 15 min (mixing cycles: 5 cycles of 3 min); 30 min (mixing cycles: 10 
cycles of 3 min); 1h (mixing cycles: 10 cycles of 6 min) (mixing cycles as defined by 
Material and Methods 
 44 
the manufacturer). The slides were then washed at room temperature for 2 min in  
2 x SSC, 0.2 % SDS, 2 min in 2 x SSC and for 2min in 0.2 x SSC. The slides were 
dried with N2 for 2 min. 
 
2.3.9 Data acquisition and processing 
Data from oligonucleotide arrays after the hybridization reaction were extracted by 
acquisition of fluorescence signals with a 418 Array Scanner (Affymetrix, Santa 
Clara, US) at laser power and gain settings to 100 %. The image processing and 
calculation of signal intensities was performed using Imagene, Version 3.0 
(Biodiscovery, Los Angeles, US). For the calculation of the individual net signal 
intensities the local background was subtracted from the raw spot intensity. To 
calculate the mean net signal intensity of one oligo probe on all arrays tested under 
identical conditions (each carrying three replicate spots of one oligo probe), n 
replicates of one spot were used (n = number of analyzed spots), herein referred to 
as "net signal intensity" (NI) (see figure 14a).  
 
Within each oligo set related to one SNP, the highest signal intensity was taken as 
potential perfect match (PM). The remaining three oligo probes having a lower signal 
were considered as mismatch (MM). For comparison of inter array variation, mean 
intensity ratios were calculated by forming the ratio of the mismatch or perfect match 
signal intensity to the perfect match signal intensity within one SNP probe set and 
calculating the mean between n probe sets, herein referred to as "relative intensity" 
(RI) of one oligo probe [RIMM = NIMM/NIPM and RIPM=NIPM/NIPM] (n = number of 
analyzed spots) (see figure 14b). Accordingly, the perfect match relative intensities 
RIPM should correspond to a value of 1, the mismatch relative intensities RIMM should 
be below 1. The efficiency of the mismatch to perfect match discrimination was 
analyzed in detail by reviewing the distribution of all mismatches in dependency of 
the mismatch to perfect match ratio. 
 
The efficiency of the mismatch to perfect match discrimination was estimated in total 
by calculating the average of the specific intensities of all probe sets. The “specific 
intensity” (SI) was hereby defined as the ratio of the perfect match signal intensity 
over a mean of the three mismatch signal intensities (see figure 14c). 
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2.3.10 DNA sequencing 
The blaTEM (861 bp)  and blaSHV (932 bp) amplicons were produced by PCR as 
described in section 2.3.7.1 with two exception: instead of the denoted dNTP-mix 
containing Cy3- or Cy5-dCTP, 50 µM dNTPs (Invitrogen (Karlsruhe, Germany) were 
used and only 5 U of Taq DNA polymerase instead of 10 U. After purification (as 
described in “purification of target DNA”) 200 ng of the purified DNA were used in a 
sequencing reaction containing 10 pmol of either a forward or a reverse primer (the 
same primers as used for amplification reaction) and 4 µl of a premix solution from 
the big-dye terminator cycle sequencing kit (Applied Biosystems, Darmstadt, 
Germany) in a total volume of 20 µl. The premix comprises the AmpliTaq DNA 
polymerase, dNTPs, as well as the fluorescently labeled ddNTPs. The sequencing 
reaction was performed in a Mastercycler Gradient (Eppendorf, Hamburg, Germany). 
An initial denaturation step (95°C for 4 min) was followed by 25 cycles (95°C for 40 s, 
55°C for 30 s, 60°C for 4 min) and a final extension step at 60°C for 4 min. The 
sequencing was carried out in an ABI Prism 377A-DNA-sequencer. The data were 
analyzed by SeqMan II software. 
 
 
Figure 14. (a) To calculate the "net signal intensity" (NI) - the local background is subtracted from 
the raw spot intensity. The mean signal intensity of one oligo probe is calculated by averaging the 
individual intensities of n replicates (n = number of replicate spots analyzed under the same 
conditions). (b) Individual relative intensities (RI) of one oligo probe were calculated by forming the 
ratio of the net mismatch or perfect match signal intensity to the net perfect match signal intensity 
within one SNP probe set. The “specific intensity” (SI) was defined as the ratio of the net perfect 
match signal intensity over a mean of the three net mismatch signal intensities. The probes or 
probe sets, for which an example of calculating a mean (NI, RI, or SI) value is displayed, are 
shaded in gray.   
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 RIMM’ = NIMM/NIPM  
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3 Results 
3.1 Results TEM-array 
3.1.1 Probe design 
In the present study an oligonucleotide microarray was developed for genotyping of 
TEM beta-lactamases from bacteria isolated from real clinical samples. A first subset 
of probes for the TEM-array was designed by Satoshi Ezaki at the Institute of 
Technical Biochemistry, University of Stuttgart. Based on this, the complete probe set 
for the TEM microarray was developed and validated in this study. The whole probe 
set used for the array design covers 99 % of the amino acid substitution positions 
published up to date (see table 3) except the end-standing positions of amino acids 
number 2, 3 and 285 of TEM beta-lactamase. Probes for amino acid position 4 were 
included, but the probe sequence was partially overlapping the primer sequence, so 
that the polymorphism detection at this position was not possible with the used 
primer set. The design of a different primer set outside the open reading frame (ORF) 
to circumvent the problematic of the detection of end-standing SNPs was currently 
not advisable, since for a considerable part of the published TEM variants no ORF 
flanking sequences were available.  
 
In table 4 the results of the probe design for the probes complementary for blaTEM-1 
and the mutant blaTEM-X are displayed. The probe length was between 17-27 bases, 
the Tm values varied from 46.4 to 64.7 °C and the GC content between 27.3 to and 
76.5 %. Due to the necessity to exclude unfavorable probe secondary structures and 
to gain sufficient perfect match net signal intensity for analysis, it was determined in 
first experiments, that a narrow Tm range could not be realized for the complete 
probe set (data not shown). Probes with stable secondary structures should be 
excluded, because of non-optimal accessibility. The applied probe design parameters 
of the software excluded probes with a hairpin ∆G value of less than - 3 kcal/mol and 
self dimer ∆G values of < - 6 kcal/mol. All probes met these criteria for the hairpin 
secondary structures with ∆G values between 0 and - 2.5 kcal/mol. Probes 40C, 90A, 
102G, 182C and 235.1A shared self dimer secondary structures with ∆G values of 
more than - 6 kcal/mol. For all other probes self dimer ∆G values were within the 
default limits (0 to - 6 kcal/mol). Since the dimer forming bases were in close 
proximity to the central SNP position, alternate probe sequences were not applicable. 
The concept of this array was defined to include all mutation positions, which were 
relevant for unambiguous identification of the different TEM variants, so that also 
probes with ∆G values violating these limits were accepted and tested in 
hybridization experiments. For the probe performance in hybridization experiments 
see results below.  
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Table 3. TEM beta-lactamase polymorphism sites and corresponding mutants 
Nucleotide Amino acida TEM -X  phenotypeb 
Codon in: Amino acid in:  
Positionc blaTEM-1 blaTEM-X 
 
Ambler 
position 
 
Position TEM-1 TEM-X 
 
ESBL 
 
IRT 
 
ESBL+ 
IRT 
 
Not defined 
3-6 AGT GAT 4 2 S D    97, 98, 99, 102, 108 
7-9 ATT CCT 5 3 I P    97, 98, 99, 102, 108 
10 CAA AAA 6 4 Q K    87, 92 
55 CTT TTT 21 19 L F 4, 9, 25, 48, 49, 53, 63 73, 74  75, 85, 86, 94, 110 
55 CTT ATT 21 19 L I    67 
109 
 
CAG 
 
AAG 
 
39 
 
37 
 
Q 
 
K 
 
3, 7, 8, 11, 16, 18, 21, 22, 
24, 42, 46, 56, 60, 61, 66, 
72 
44, 59, 65 
  
2, 67, 89, 101 
 
119 GCA GTA 42 40 A V 42    
146 CTC CCT 51 49 L P 60    
199 ATG GTG 69 67 M V  34, 36, 38, 78, 82  97 
199 
 
ATG 
 
CTG 
 
69 
 
67 
 
M 
 
L 
  
33, 35, 39, 45, 50, 77, 
80, 81   
199 ATG TTG 69 67 M L  45   
201 ATG ATT 69 67 M I  32, 37, 40, 83   
233 GTA GAA 80 78 V E    108 
244 GTT ATT 84 82 V I    116 
269 GGT GAT 92 90 G D 57, 66    
304 
 
 
GAG 
 
 
AAG 
 
 
104 
 
 
102 
 
 
E 
 
 
K 
 
 
3, 4, 6, 8, 9, 13, 15, 16, 17, 
18, 21, 22, 24, 26, 43, 46, 
52, 56, 60, 63, 66 
 
50 
 
 
87, 88, 89, 92, 94, 106, 
107, 111 
 
338 GAT GGT 115 113 D G    90 
365 AGT AAT 124 122 S N    105 
373 ATA GTA 127 125 I V  80, 81   
382 AGT GGT 129 127 S G  59, 76  89 
427 CCG GCG 145 143 P A    95 
452 CAC CGC 153 151 H R 21, 56    
482 GAT GGT 163 161 D G    96 
484 
 
CGT 
 
AGT 
 
164 
 
162 
 
R 
 
S 
 
5, 7, 8, 9, 10, 12, 24, 26, 
46, 53, 60, 63   
85, 86, 102 
 
484 CGT TGT 164 162 R C    87, 91 
485 CGT CAT 164 162 R H 6, 11, 16, 27, 28, 29, 43, 61   107, 118 
487 TGG CGG 165 163 W R  39, 78   
489 TGG TGT 165 163 W C  83   
539 
 
ATG 
 
ACG 
 
182 
 
180 
 
M 
 
T 
 
20, 43, 52, 63, 72 
 
32 
  
87, 88, 91, 92, 93, 94, 
106, 107 
545 GCA GTA 184 182 A V    116 
580 GGC AGC 196 194 G D    88 
581 GGC GAC 196 194 G S    108 
605 CGG CAG 204 202 R Q    70 
647 GGA GAA 218 216 G E 55    
703 GCC ACC 237 235 A T 5, 24    86 
704 GCC GGC 237 235 A G 22    
706 
 
GGT 
 
AGT 
 
238 
 
236 
 
G 
 
S 
 
3, 4, 8, 15, 19, 20, 21, 22, 
25, 42, 47, 48, 49,52, 66, 
68, 72 
 50  
71, 88, 89, 92, 93, 94, 
101, 107 
707 GGT GAT 238 236 G D    111 
709 
 
GAG 
 
AAG 
 
240 
 
237 
 
E 
 
K 
 
5, 10, 24, 27, 28, 42, 46, 
47, 48, 49, 61, 72  
68 
 
71, 85, 86, 91, 93, 101 
 
721 CGC AGC 244 241 R S 58 30, 44, 74, 77  99 
721 CGC TGC 244 241 R C  31, 65, 73   
721 CGC GGC 244 241 R G  79   
722 CGC CAC 244 241 R H  51   
722 CGC CTC 244 241 R L 54    
772 GTT ATT 262 258 V I    58 
782 
 
ACG 
 
ATG 
 
265 
 
261 
 
T 
 
M 
 
4, 9, 13, 25, 27, 42, 47, 48, 
49 
73, 74 
 
68 
 
85, 86, 94, 110, 111, 118
 
790 AGT GGT 268 264 S G    49 
812 CGA CTA 275 271 R L  38  68 
812 CGA CAA 275 271 R Q  45, 82, 83   
814 
 
AAT 
 
GAT 
 
276 
 
272 
 
N 
 
D 
  35, 36, 37, 39, 78, 80 
50 
 
84 
 
827 GCT GTC 280 276 A V    101, 104 
854 CAT CTT 289 285 H L    97, 98, 99 
aAmbler position: position of the polymorphism in the amino acid sequence of TEM 
(http://www.lahey.org/Studies/temtable.asp) according to Ambler et al (3). Position: position of the 
polymorphism according to the amino acid sequence of TEM (GenBank accession number 
AAB59737). The amino acids at the position in the TEM-1 sequence and the mutated TEM (TEM-X) 
sequence are also indicated.  
b The numbers in the table body are the TEM types with an amino acid substitution at the indicated 
position. The ESBL, IRT, ESBL-IRT phenotypes are as described by Bradford (16). 
c Position refers to the position of the polymorphism site in the nucleotide sequence of the blaTEM - 
gene (GenBank accession number J01749 region: complement (3293..4153)). 
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Table 4. Probe design results for the TEM-specific microarraya 
Probe 
name 
Probe sequence (5’-3’) Length
 
 
(nt) 
Tm 
 
 
(°C) 
GC 
 
 
(%) 
Hairpin 
∆G 
 
(kcal/mol) 
Hairpin 
bond 
 
(nt) 
Dimer 
∆G 
 
(kcal/mol) 
Dimer 
bond 
 
(nt) 
Run/ 
repeat 
length 
(nt) 
04C ATGAGTATTCAACATTTTCGTG 22 49.4 31.8 0 0 0 0 4 
04A ATGAGTATTAAACATTTTCGTG 22 47.2 27.3 -0.1 3 -0.7 4 4 
19C GCATTTTGCCTTCCTGTTTT 20 51.3 40 -1.9 3 -1.9 3 4 
19T GCATTTTGCTTTCCTGTTTT 20 49.5 35.0 -1.9 3 -1.9 3 4 
37C CTGAAGATCAGTTGGGTGC 19 51.4 52.6 0 0 -1.9 4 3 
37A CTGAAGATAAGTTGGGTGC 19 48.8 47.4 0 0 0 0 3 
40C  ATCAGTTGGGTGCACGAGTGGGTTA 25 62.8 52 0 0 -6.7 6 3 
40T  ATCAGTTGGGTGTACGAGTGGGTTA 25 60.1 48 0 0 -1.9 4 3 
49T ATCGAACTGGATCTCAACAGCGGTAAG 27 61.8 48.1 -1.1 3 -1.9 4 2 
49C ATCGAACTGGATCCTAACAGCGGTAAG 27 61.3 48.1 -1.1 3 -5.7 6 2 
67.1A CGTTTTCCAATGATGAGCACTTTTAA 26 56.3 34.6 0 0 0 0 4 
67.1G CGTTTTCCAATGGTGAGCACTTTTAA 26 58.1 38.5 0 0 -1.4 3 4 
67.2G TTTTCCAATGATGAGCACTTTTAA 24 52.3 29.2 0 0 -0.7 4 4 
67.2T TTTTCCAATGATTAGCACTTTTAA 24 50.2 25.0 0 0 -0.7 4 4 
78T ATGTGGTGCGGTATTATCCC 20 53.1 50 0 0 0 0 3 
78A ATGTGGTGCGGAATTATCCC 20 53.6 50 -1.3 3 -1.3 3 3 
82G TTATCCCGTGTTGACGCCG 19 55.9 57.9 -1.9 3 -1.9 3 3 
82A TTATCCCGTATTGACGCCG 19 52.9 52.6 -1.9 3 -1.9 3 3 
90G GCAACTCGGTCGCCGCA 17 58.4 70.6 -2.3 3 -2.3 3 2 
90A GCAACTCGATCGCCGCA 17 55.8 64.7 0 0 -6.5 6 2 
102G GACTTGGTTGAGTACTCACC 20 51.1 50 -1.4 3 -10.3 10 2 
102A GACTTGGTTAAGTACTCACC 20 48.7 45 -1.4 3 -4.3 6 2 
113A ATCTTACGGATGGCATGAC 19 50.2 47.4 -0.3 3 -2.2 4 2 
113G ATCTTACGGGTGGCATGAC 19 52.6 52.6 0 0 -2.2 4 3 
122G AGAATTATGCAGTGCTGCCATA 22 54.3 40.9 -1.9 3 -3.4 4 2 
122A AGAATTATGCAATGCTGCCATA 22 52.6 36.4 -1.9 3 -3.3 4 2 
125A GTGCTGCCATAACCATGA 18 50.1 50.0 -0.5 3 -2.2 4 2 
125G GTGCTGCCGTAACCATGA 18 52.8 55.6 0 0 -2.2 4 2 
127A  TGCCATAACCATGAGTGATAACACTG 26 58.2 42.3 -2.5 4 -2.5 4 2 
127G  TGCCATAACCATGGGTGATAACACTG 26 60.1 46.2 -2.4 4 -6 6 3 
143C CGGAGGACCGAAGGAGC 17 53.9 70.6 -2.3 3 -2.3 3 2 
143G CGGAGGAGCGAAGGAGC 17 54.4 70.6 0 0 0 0 2 
151A CCGCTTTTTTGCACAACATGGGGG 24 62.4 54.2 0 0 -3.3 4 6 
151G CCGCTTTTTTGCGCAACATGGGGG 24 64.7 58.3 0 0 -10.2 8 6 
161A CTCGCCTTGATCGTTGGGA 19 55.2 57.9 0 0 -1.9 4 3 
161G CTCGCCTTGGTCGTTGGGA 19 57.6 63.2 0 0 0 0 3 
162.1G GCCTTGATCGTTGGGAA 17 49.0 52.9 0 0 -1.9 4 3 
162.1A GCCTTGATAGTTGGGAA 17 45.2 47.1 0 0 0 0 3 
162.2G GCCTTGATCGTTGGGAACC 19 54.2 57.9 -0.6 3 -1.9 4 3 
162.2A GCCTTGATCATTGGGAACC 19 51.6 52.6 0 0 -4.7 6 3 
163.1T TTGATCGTTGGGAACCG 17 49.2 52.9 -0.6 3 -1.9 4 3 
163.1C TTGATCGTCGGGAACCG 17 51.4 58.8 -2.3 3 -2.3 3 3 
163.2G TGATCGTTGGGAACCGGAG 19 54.8 57.9 -0.6 3 -4.2 4 3 
163.2T TGATCGTTGTGAACCGGAG 19 52.9 52.6 -0.6 3 -4.2 4 2 
180T CACCACGATGCCTGTAG 17 49.4 58.8 0 0 0 0 2 
180C CACCACGACGCCTGTAG 17 52.3 64.7 0 0 0 0 2 
182C CGATGCCTGCAGCAATGGC 19 58.2 63.2 -2.4 3 -6.3 6 2 
182T CGATGCCTGTAGCAATGGC 19 54.8 57.9 -2.4 3 -2.4 3 2 
194.1G AACTATTAACTGGCGAACTACTT 23 52.0 34.8 0 0 -0.7 4 2 
194.1A AACTATTAACTAGCGAACTACTT 23 49.4 30.4 -0 3 -1.5 4 2 
194.2G ACTATTAACTGGCGAACTACTT 22 51.1 36.4 0 0 -0.7 4 2 
194.2A ACTATTAACTGACGAACTACTT 22 48.5 31.8 0 0 -0.7 4 2 
202G CTAGCTTCCCGGCAACAATTA 21 54.3 47.6 0 0 -4.2 4 3 
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Table 4. continued 
 
202A CTAGCTTCCCAGCAACAATTA 21 51.8 42.9 -1.7 3 -2.9 4 3 
216G AGTTGCAGGACCACTTCT 18 50.6 50 -0.8 3 -3.3 4 2 
216A AGTTGCAGAACCACTTCT 18 48.6 44.4 -1.7 4 -3.3 4 2 
235.1G AAATCTGGAGCCGGTGAGC 19 55.4 57.9 0 0 -4.2 4 3 
235.1A AAATCTGGAACCGGTGAGC 19 53.1 52.6 0 0 -7.0 6 3 
235.2C ATCTGGAGCCGGTGAGC 17 53.4 64.7 0 0 -4.2 4 2 
235.2G ATCTGGAGGCGGTGAGC 17 53.4 64.7 0 0 0 0 2 
236.1G CTGGAGCCGGTGAGCGT 17 56.6 70.6 0 0 -4.2 4 2 
236.1A CTGGAGCCAGTGAGCGT 17 53.7 64.7 -1.1 3 -2.9 4 2 
236.2G CTGGAGCCGGTGAGCGTG 18 58.3 72.2 0 0 -4.2 4 2 
236.2A CTGGAGCCGATGAGCGTG 18 55.8 66.7 0 0 0 0 2 
237G GAGCCGGTGAGCGTGGGT 18 59.8 72.2 0 0 -4.2 4 3 
237A GAGCCGGTAAGCGTGGGT 18 57.1 66.7 0 0 -4.2 4 3 
241.1C GTGGGTCTCGCGGTATC 17 51.6 64.7 0 0 -5.1 4 3 
241.1A GTGGGTCTAGCGGTATC 17 48.0 58.8 0 0 -1.5 4 3 
241.2G GTGGGTCTCGCGGTATCAT 19 54.7 57.9 0 0 -5.1 4 3 
241.2A GTGGGTCTCACGGTATCAT 19 51.6 52.6 -1.2 3 -1.2 3 3 
258G CCGTATCGTAGTTATCTACACG 22 52.1 45.5 -1.7 4 -1.7 4 2 
258A CCGTATCGTAATTATCTACACG 22 50.5 40.9 -0.2 3 -2.4 6 2 
261C TTATCTACACGACGGGGA 18 49.3 50.0 0 0 0 0 4 
261T TTATCTACATGACGGGGA 18 46.4 44.4 0 0 -2.2 4 4 
264A CGACGGGGAGTCAGGCA 17 55.8 70.6 -1.1 3 -1.1 3 4 
264G CGACGGGGGGTCAGGCA 17 58.6 76.5 -1.1 3 -1.1 3 6 
271G ATGGATGAACGAAATAGACAG 21 49.4 38.1 0 0 0 0 3 
271A ATGGATGAACAAAATAGACAG 21 47.5 33.3 0 0 0 0 4 
272A GGATGAACGAAATAGACAGAT 21 49.1 38.1 0 0 0 0 3 
272G GGATGAACGAGATAGACAGAT 21 50.3 42.9 0 0 0 0 2 
276C TAGACAGATCGCTGAGATAGGTG 23 55.3 47.8 -1.1 3 -1.9 4 2 
276T TAGACAGATCGTCGAGATAGGTG 23 55 47.8 -1.1 3 -3 4 2 
a For each polymorphism site one probe complementary to blaTEM-1 (upper line) and one probe 
complementary to the mutated blaTEM-X (lower line) are displayed. The additional two mismatch probes 
of one complete probe set are not displayed. The probes are named for the position in the amino acid 
sequence of TEM and the nucleotide at the central base position (either A, G, C, or T). The probe 
length, the melting temperature (Tm), GC content (GC), free energy of hairpin bonds (hairpin ∆G), the 
number of bases forming the hairpin bond (hairpin bond), free energy of dimers (dimer ∆G), the 
number of bases forming the dimer bond (dimer bond) were calculated by ArrayDesigner 2.0 software.  
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Table 5. Oligonucleotide probe sequences used in the TEM-specific microarraya 
Tm 
(°C) 
Length 
(nt) 
Probe name Probe sequence (5’-3’)b 
49.4 22 04 ATGAGTATTNAACATTTCCGTG 
51.3 20 19 GCATTTTGCNTTCCTGTTTT 
51.4 19 37 CTGAAGATNAGTTGGGTGC 
62.8 25 40 ATCAGTTGGGTGNACGAGTGGGTTA 
61.8 27 49 ATCGAACTGGATCNCAACAGCGGTAAG  
56.3 26 67 CGTTTTCCAATGNTGAGCACTTTTAA 
52.3 24 67.2 TTTTCCAATGATNAGCACTTTTAA 
53.1 20 78 ATGTGGTGCGGNATTATCCC 
55.9 19 82 TTATCCCGTNTTGACGCCG 
58.4 17 90 GCAACTCGNTCGCCGCA 
51.1 20 102 GACTTGGTTNAGTACTCACC 
50.2 19 113 ATCTTACGGNTGGCATGAC 
54.3 22 122 AGAATTATGCANTGCTGCCATA 
50.1 18 125 GTGCTGCCNTAACCATGA 
58.2 26 127 TGCCATAACCATGNGTGATAACACTG 
53.9 17 143 CGGAGGANCGAAGGAGC 
62.4 24 151 CCGCTTTTTTGCNCAACATGGGGG 
55.2 19 161 CTCGCCTTGNTCGTTGGGA 
49.0 17 162 GCCTTGATNGTTGGGAA 
54.2 19 162.2 GCCTTGATCNTTGGGAACC 
49.2 17 163 TTGATCGTNGGGAACCG 
54.8 19 163.2 TGATCGTTGNGAACCGGAG 
49.4 17 180 CACCACGANGCCTGTAG 
58.2 19 182 CGATGCCTGNAGCAATGGC 
52.0 23 194.2 AACTATTAACTNGCGAACTACTT 
51.1 22 194 ACTATTAACTGNCGAACTACTT 
54.3 21 202 CTAGCTTCCCNGCAACAATTA 
50.6 18 216 AGTTGCAGNACCACTTCT 
55.4 19 235.2 AAATCTGGANCCGGTGAGC 
53.4 17 235 ATCTGGAGNCGGTGAGC 
56.6 17 236 CTGGAGCCNGTGAGCGT 
58.3 18 236.2 CTGGAGCCGNTGAGCGTG 
59.8 18 237 GAGCCGGTNAGCGTGGGT 
51.6 17 241 GTGGGTCTNGCGGTATC 
54.7 19 241.2 GTGGGTCTCNCGGTATCAT 
52.1 22 258 CCGTATCGTANTTATCTACACG 
49.3 18 261 TTATCTACANGACGGGGA 
55.8 17 264 CGACGGGGNGTCAGGCA 
49.4 21 271 ATGGATGAACNAAATAGACAG 
49.1 21 272 GGATGAACGANATAGACAGAT 
55.3 23 276 TAGACAGATCGNTGAGATAGGTG 
52.3 18 process control AGAAACGCTGGTGAAAGT 
46.0 18 negative hybridization control TCTAGACAGCCACTCATA 
53.1 19 positive hybridization control GATTGGACGAGTCAGGAGC 
46.0 18 spot control TCTAGACAGCCACTCATA-Cy3 
a For the SNP specific probes, four probes for each SNP position were used. The 
probes are named for the position in the amino acid sequence of blaTEM. The four 
probes had either A, G, C, or T at the central base position (designated N in the probe 
sequence). The probe length and the melting temperatures (calculated for the probes 
matching the blaTEM-1 sequence by Arraydesigner 2.0 software) are also provided. 
bThe triplet with the amino acid substitution is underlined.  
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3.1.2 Setting up the system on poly-L-lysine slides 
The system was set up on low priced poly-L-lysine slides with a DMSO based 
spotting buffer. The probes were immobilized via non-directed covalent binding of a 
thymidine from within the probe sequence to the primary amino group of the lysine. 
The whole probe set was spotted in four replicates. Each replicate was spotted with a 
different pin. The array was hybridized with 260 ng of target DNA from a TEM-116 
sample, derived from a pure culture of Escherichia coli (E. coli) K12 bearing a pUC19 
plasmid. The target DNA had an incorporation ratio of fluorescence label, defined as 
the number of nucleotides/fluorophore (NT/F) = 90 and was hybridized for three 
hours in Corning hybridization chambers using standard cover glasses. The array 
layout and a corresponding fluorescence image of the hybridization are shown in 
figure 15. The aim of this experiment was to determine the performance and the 
reproducibility of the analysis under standard conditions and to assess if the 
identification of the correct perfect match positions was possible with the designed 
probe sets. 
 
All perfect match positions could be identified by the highest signal intensity within a 
SNP probe set. The resulting overall signal intensity was low: the net signal intensity 
varied between 400 and 2500 arbitrary units for the perfect match probes. Most of 
the spots showed a donut shaped signal due to inhomogeneous drying of the spot. 
The not uniform signal distribution on the spots, low signal to noise ratios and the use 
of different pins for spotting of replicate spots resulted in standard deviations of the 
net perfect match signal intensities of in average 68 % between replicate spots (see 
figure 16). 
Figure 15. On the left the SNP capture probe layout of the TEM-microarray, on the right the 
fluorescence image of a hybridization experiment with 260 ng of blaTEM-116 target DNA (NT/F = 90) 
for three hours is displayed. The TEM-array was spotted in 4 identical replicate layouts with four 
different pins. The upper left replicate is highlighted in the fluorescence image.  
In the layout the SNP position is indicated above each probe set. The central base in the probe 
sequence is indicated on the left side of the row as A, G, C, or T. Blue spots designate perfect 
match positions for blaTEM-116 gene, white spots refer to mismatch positions. The spotting controls 
(indicated in red) frame each replicate layout spotted by a different pin. In the fluorescence image 
the signal intensity is shown in false color. Blue corresponds to the lowest signal intensity, red to 
white depict the highest signal intensities (as output by ImaGene 3.0). 
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Multiple experiments indicated that low signal intensities, unfavorable background 
signals and low reproducibility of experiments seemed to be a problem associated 
with the used spotting buffer and the low quality of the surface (data not shown). Due 
to the high standard deviations and the low signal to noise ratios a reliable and 
sensitive analysis was impossible with this method and new experimental strategies 
had to be developed. This led to the conclusion that not only for the spotting layout, 
but also for the surface and the spotting buffer alternatives had to be found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 . Mean net signal intensities for each SNP position and corresponding probe (A, G, C or 
T refer to the central base position) from a hybridization experiment with 260 ng of  blaTEM-116 target 
DNA (NT/F = 90). The displayed standard deviation was calculated for the four replicate spots on 
one array.  
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3.1.3  Setting up the system on epoxy slides 
Epoxy-coated slides were chosen as a new carrier and three different spotting 
buffers (DMSO-, betaine-, and phosphate-based spotting buffers) were tested for 
optimal probe immobilization and reproducible signal pattern by spotting a 
fluorescently labeled probe (a spotting control) and one conventional probe set 
(probes A, G, C and T). The slides were scanned directly after immobilization and 
blocking. The corresponding fluorescence image is shown in figure 17.  
 
The DMSO-based buffer showed 
highest signal intensities, but the spot 
size and signal distribution was very 
inhomogeneous, which was unfavorable 
for data extraction. The spotting control 
spots with betaine based buffer showed 
homogeneous signal distribution and 
reproducible spot shapes, but on the 
probe spots A, G, C, T, where no signal 
should be observed, because no target 
DNA was hybridized, also fluorescence 
signals were detected. This was due to 
an incomplete immobilization of the 
spotting control in betaine buffer, which 
tended to attach to neighboring probe 
spots spotted with the same betaine-
based buffer.  
 
 
The phosphate based spotting buffer showed reproducible, but donut shaped 
spotting control spots. The first two buffers (DMSO and betaine) were excluded, 
because a reproducible and correct data analysis would not have been possible due 
to the observed problems regarding spot shape or incomplete immobilization. 
Therefore, the phosphate-based buffer was used for further experiments. The donut 
shaped spots with this buffer were not observed in following experiments (see proof 
of concept).  
DMSO betaine phosphate
spotting 
control
A
G
C
T
Figure 17. Fluorescence image of a spot 
test using a DMSO- betaine- or phosphate-
based spotting buffer on epoxy slides. The 
spotting control was an oligonucleotide 
probe labeled with Cy5. A, G, C, T refers to 
an unlabeled control probe set, which was 
spotted in four replicates.  
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3.1.4 Proof of concept 
To minimize the variability between replicate signals, in the new array layout a 
different spotting strategy was devised. Instead of spotting replicate spots with four 
different pins, replicate spots in the new layout were spotted directly one after the 
other by the same pin. To establish the TEM-array on the epoxy surface, and to show 
the feasibility of the method, the array was hybridized with 100 ng target DNA  
(blaTEM-116) in three repetitive experiments. The target DNA was hybridized for three 
hours in Corning hybridization chambers using standard cover glasses. It was the 
aim to analyze the performance of the designed probe sets regarding specificity of 
the perfect match identification and set a threshold indicating at which level all the 
perfect match positions for blaTEM-116 could be considered as correctly identified. 
Furthermore the reproducibility of the system was determined under standard 
conditions. The array layout and a fluorescence image of the hybridized array is 
shown in figure 18.  
The mean signal intensity values and standard deviations of all SNP positions are 
shown in figure 19. The net signal intensity values ranged from 1,500 to 20,000 for 
the perfect match probes (figure 19a). 40 of 41 SNP positions were correctly 
identified. Since perfect match position 182T showed spotting errors in this slide 
batch, it was not taken into account. To investigate the discriminatory power of the 
system, the relative intensities were calculated (figure 19b). The relative intensity is 
Figure 18. On the left, the SNP capture probe layout of the TEM microarray is shown. All 
SNP capture probes were spotted in triplicates. The SNP position is indicated above each 
triplicate. The central base in the probe sequence is indicated on the left side of each row 
as A, G, C, or T. Blue spots indicate perfect match positions for blaTEM-116 gene, white 
spots indicate mismatch positions.  
On the right, the fluorescence image of a hybridization experiment with 100 ng of blaTEM-116 
target DNA (incorporation ratio NT/F = 57) for three hours is displayed. The signal intensity 
is shown in false color. Blue corresponds to the lowest signal intensity, red to white depict 
the highest signal intensities (as output by ImaGene 3.0). 
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defined as the ratio of the net intensity of a given probe over the net intensity of the 
perfect match probe (the probe with the highest intensity within a SNP probe set). 
Thus, for a correctly identified perfect match the relative intensity (RIPM) should 
correspond to a value of 1, the relative intensity of a mismatch (RIMM) should be 
lower than 1. The lower the relative intensity of the mismatches is, the better the 
discrimination between a perfect match and a mismatch.  
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Figure 19. (a) Mean net signal intensities and (b) mean relative (rel.) signal intensities for each SNP 
position and corresponding probe (A, G, C or T refer to the central base position) from a hybridization 
experiment with 100 ng blaTEM from pUC19 (NT/F = 57). The displayed standard deviation was 
calculated for three replicate spots on each of three arrays (n = 9). (c) Percentage of mismatch 
probes depending on the MM/PM ratio (d) Percentage of mismatch probes depending on the 
standard error of the MM/PM ratio. 
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For a detailed analysis of the discrimination efficiency of all TEM-array probe sets the 
distribution all mismatch probes depending on their mismatch to perfect match ratio 
was plotted in figure 19c. Over 99 % of the relative intensity of mismatches remained 
below 0.4, only probe 82 showed higher RIMM values up to 0.52. The standard 
deviations for the mean RIMMs ranged between 0.01 and 0.12, over 98 % remained 
below 10 % of the perfect match intensity (figure 19d). A perfect match was further 
on considered as correctly identified ("ID limit"), if the relative intensity of any of the 
three mismatches of one probe set did not exceed 0.8.  
 
In comparison to the array spotted on the poly-L-lysine substrate the net perfect 
match signal intensities on the epoxy coated slides were at least three times 
increased, although 1.6 times less fluorescently labeled nucleotides were applied 
within the hybridized target DNA. This was a sign of an improved immobilization 
efficiency or accessibility of the probes. The signal distribution on the spots was 
mostly uniform. The standard deviations of the perfect match net signal intensities 
were reduced from 68 % in between one array spotted on poly-L-lysine to an average 
of 18 % spotted on epoxy coated slides in between three arrays (compare figure 16 
and figure 19a). The achievement of increased fluorescence signal intensities in 
combination with the more uniform signal distribution on the spot and the optimized 
spotting layout rendered the analysis more sensitive and reproducible, since 
discrimination of the specific signals from the background net intensity was facilitated 
and aberrations introduced through the spotting procedure were reduced. 
 
3.1.5  Probe performance analysis 
The perfect match to mismatch discrimination was feasible with all designed probes 
with varying efficiency. A linkage between optimal probe design parameters, such as 
no or only weak secondary structures (dimer ∆G > -1.9 kcal/mol) and optimal 
discrimination capabilities (RIMM < 0.1) could be observed for some probes (e.g. 37, 
67.2, 180, 194.2, 271), but not for all. When comparing the determined probe 
parameters (table 4) and the hybridization results (figure 19), it can be noticed, that 
even though for example perfect match probe 102G formed the most stable 
secondary structure within the whole TEM-array probe set with a ∆G value of  
- 10.3 kcal/mol (in contrast to mismatch probe 102A with a ∆G value of only - 4.2), 
the discriminatory power of the probe set 102 was optimal with all RIMM values below 
0.03. Perfect match probe 40C, which also contained a stable self dimer structure of 
∆G = - 6.7 kcal/mol, still remained accessible enough for target DNA hybridization to 
yield an efficient discrimination with all RIMM values below 0.12. The probe with the 
weakest discrimination capability in this experiment, probe 82, showed a hairpin as 
well as a dimer structure with a ∆G value of - 1.9 kcal/mol for both perfect match 
probe 82A and mismatch probe 82G, consequently both probes should be equally 
accessible for hybridization. 
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3.1.6 Reproducibility of the perfect match/mismatch discrimination 
In this experiment it should be determined, if the ratio of perfect match to mismatch 
signal intensity after hybridization with target DNA from a set of different 
amplification/labeling and fragmentation reactions was reproducible. The array was 
therefore hybridized with five different blaTEM-1 (400 ng target DNA) samples with 
varying incorporation ratios of fluorescence label (defined as the number of 
nucleotides per fluorophore: NT/F = 71 - 180) for three hours in the automated 
hybridization station HS4800 from Tecan. The net intensities of the same probes 
hybridized with different target DNA samples varied in some cases with a factor 
larger than three, due to the differences in the incorporation ratio or efficiency of 
fragmentation (data not shown). Since it should be determined, if the ratio of 
mismatch to perfect match signal intensity remained reproducible, the relative 
intensity was calculated. The mean and the standard deviation of the relative 
intensity values are given in figure 20.  
 
All 41 perfect match positions for blaTEM-1 could be identified correctly in every 
sample. The mean relative intensity of the mismatches (RIMM) varied, but 95 % 
remained below 0.4, only 4 % showed higher values of up to 0.6 (see figure 20b). 
Probe 161 showed the weakest discriminatory power with RIMM = 0.61. The standard 
deviations of the mean RIMM values varied from 0.01 to 0.21 (n = 15), but still 
remained for 79 % below 10 % of the perfect match intensity (see figure 20c). Thus, it 
was determined, that the identification of the perfect matches was reproducible, 
mainly independent from the diverse target DNA batches having varying 
incorporation ratios and which were prepared in different fragmentation reactions.  
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Figure 20. (a) Relative intensities of all TEM SNP positions averaged from five independent 
hybridizations with blaTEM-1 target DNA (n = 15). The four probes per  SNP are indicated by 
their central base (A, G, C, T) in the legend. The labeling efficiency (NT/F) of the hybridized 
sample DNA was 71-180; 400 ng of target DNA were applied. (c) Percentage of mismatch 
probes depending on the MM/PM ratio. (d) Percentage of mismatch probes depending on 
the standard error of the MM/PM ratio. 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
4 19 37 40 49
67
.1
67
.2 78 82 90 10
2
11
3
12
2
12
5
12
7
14
3
15
1
16
1
16
2.
1
16
2.
2
16
3.
1
re
l. 
in
te
ns
ity
 (R
I)
16
3.
2
18
0
18
2
19
4.
2
19
4.
1
20
2
21
6
23
5.
2
23
5.
1
23
6.
1
23
6.
2
23
7
24
1.
1
24
1.
2
25
8
26
1
26
4
27
1
27
2
27
6
A
G
C
T
0
10
20
30
40
50
60
70
<0.05 <0.1 <0.2 <0.3 <0.4 <0.5 <0.6 <0.7 <0.8 <0.9 >0.9
standard error RIMM = MM/PM
m
is
m
at
ch
 p
ro
be
s 
%
0
10
20
30
40
50
60
<0.1 <0.2 <0.3 <0.4 <0.5 <0.6 <0.7 <0.8 <0.9 >0.9
RIMM = MM/PM
 m
is
m
at
ch
 p
ro
be
s 
%
(a)
(b) (c)
probe set number 
Results  
  59
3.1.7 Testing of clinical isolates and reference strains 
To test the performance of the array, a set of 17 clinical isolates, which were 
phenotypically characterized as ESBLs, were collected at the Robert Bosch Hospital 
(Stuttgart, Germany) during the daily routine over a period of 12/2000 to 05/2002. 
Additionally, four ESBL reference strains were provided by the Robert Koch Institute 
(Wernigerode, Germany). The isolated plasmid DNA was prescreened for the 
occurrence of TEM beta-lactamase genes by PCR (without fluorescence label) and 
subsequent agarose gel electrophoresis. For 14 clinical isolates and three reference 
strains a PCR product could be generated with a size corresponding to the blaTEM -
amplicon (861 bp) (for agarose gel analysis of PCR products from clinical samples  
1-19 see figure 21). The isolated plasmid DNA from the positively prescreened 14 
clinical samples and the reference strains was amplified and fluorescently labeled 
during PCR with primers flanking the blaTEM -gene, yielding as expected a 861 bp 
fragment. The incorporation ratio NT/F varied between 50 to 150 NT/F depending on 
the quality of the template DNA.  
The PCR products were analyzed on the TEM microarray. In detail, the identified 
TEM-variants were: blaTEM-1, -3, -7, -8, and -116 as displayed in table 6. The fluorescence 
images of exemplary TEM-arrays hybridized with different blaTEM variants are 
displayed in figure 22. The blaTEM gene identified for reference strain EARSS  
UA1528 was blaTEM-8. For the other EARSS reference strain (EARSS UA1526) no 
amplicon could be obtained and no hybridization signals corresponding to a blaTEM 
variant were observed (data not shown), which is analog to the result of the PCR 
prescreening. For the reference strain designated as isolate number 21, the 
hybridization signals corresponded to a blaTEM-7 gene, in contradiction to the label on 
the sample tube indicating TEM-5. The correct identification of blaTEM-7 and all other 
variants by the TEM-array was confirmed by standard DNA sequencing.  
1    2    3   4    5    6   7   8   9    bla  0  1kb+   10  11 12  13  14  15 16 17 18 19  bla   0 1kb+
Figure 21. Agarose gel electrophoresis analysis of the PCR products of clinical isolates No. 1-19. 
The numbers designate the isolate number, which was applied on the corresponding lane. 0 and bla 
(for bla gene from pUC19) indicate the negative control and the positive control respectively. 1KB+ 
DNA ladder was used as a DNA size standard. The amplicon size of the target gene is 861 bp. 
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The results of the identification of blaTEM-1 (isolate 3, n = 6), blaTEM-3 (isolate 20,  
n = 6), blaTEM-7 (isolate 21, n = 6), blaTEM-8 (isolate 19, n = 9) and blaTEM-116 (isolate 9, 
n = 6) are displayed in figure 23 as relative intensity values. Only the polymorphism 
positions, which varied in comparison to blaTEM-1 are given. All of these positions 
were identified without ambiguity. Perfect match position 235 could not be identified 
for sample 10, blaTEM-3, blaTEM-7 and blaTEM-8 due to a spotting failure. 93 % of the 
analyzed mismatch positions remained below the relative intensity of the mismatches 
(RIMM) value of 0.4 (displayed in figure 24a). Only 7 % of the tested mismatch 
positions showed an RIMM of 0.4 - 0.7. The standard deviation of mean RIMM values 
varied from 0 to 0.36, but 95 % remained below 10% of the perfect match intensity 
(displayed in figure 24b). Two times the RIMM value of 0.7 was exceeded by probe 
49A with an RIMM of 0.76 for isolate 14 and by probe 143T with an RIMM of 0.72 for 
isolate 10.  
 
For both samples (isolate 10 and 14) and for isolate 1 (which could not be identified 
and therefore was omitted in the data evaluation) the overall discrimination was not 
optimal (data not shown), which was attributed to a suboptimal fragmentation of the 
target DNA due to handling problems and subsequent partial inactivation of DNaseI 
before starting the fragmentation. In summary, all detected blaTEM genes could be 
identified by the use of the TEM-array without ambiguity, except for the blaTEM gene 
of isolate 1. The results were confirmed by standard DNA sequencing of selected 
Table 6. Results of testing of reference strains and clinical isolates from the RBKa 
Isolate No. Sample Species Phenotype PCR
b Genotypec
(blaTEM-X) 
1. swab Enterobacter cloacae ESBL + (TEM-1) 
2. urine Enterobacter cloacae ESBL + TEM-1 
3. swab Enterobacter cloacae ESBL + TEM-1 
4. blood Enterobacter amnigenus ESBL + TEM-1 
5. swab Enterobacter cloacae ESBL + TEM-1 
6. urine Enterobacter spp. ESBL + TEM-1 
7. vaginal swab Enterobacter cloacae ESBL + TEM-1 
8. dialysate Enterobacter cloacae ESBL + TEM-1 
9. BAL Enterobacter cloacae ESBL + TEM-116 
10. urine Enterobacter cloacae ESBL + TEM-1 
11. urine Enterobacter cloacae ESBL + TEM-1 
12. tracheal swab Klebsiella spp. ESBL + TEM-1 
13. vaginal swab Escherichia coli ESBL -  
14. cervix swab Enterobacter cloacae ESBL + TEM-1 
15. urine Klebsiella pneumoniae ESBL -  
16. decubitus swab Klebsiella spp. ESBL -  
17. tracheal swab Enterobacter sakazakii ESBL + TEM-1 
18. ref. strain, EARSS, UA 1526 Escherichia coli  ESBL -  
19. ref. strain, EARSS, UA 1528 Escherichia coli ESBL + TEM-8 
20. ref.strain, TEM-3 Escherichia coli  ESBL + TEM-3 
21. ref. strain, TEM-5 Escherichia coli  ESBL + TEM-7 
a Sample collection, isolation of bacteria, species and phenotype determination was performed by 
standard procedures according to the NCCLS at the Robert Bosch Hospital (RBK) in Stuttgart.  
b PCR: result of the PCR prescreening for determination of blaTEM gene presence (+ visible band at 861 bp 
in agarose gel electrophoresis, - no visible band at 861 bp in agarose gel electrophoresis).  
c Result of TEM-array analysis, all blaTEM genes could be identified, except for isolate No. 1, which was 
identified by sequencing. All hybridizations were performed in duplicate (n = 6, n = number of analyzed 
spots), except for isolate No. 6 and 14 (n = 3) and isolate No. 19 (n = 9). 
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samples of the tested TEM variants and the blaTEM gene of isolate 1 was thereby 
identified as blaTEM-1 (data not shown).  
 
Apart from the reference strains all positively prescreened clinical isolates except 
isolate 9 contained a blaTEM-1 gene, which is a parental type and thus no ESBL. 
These isolates should contain other ESBL determinants, such as SHV, CTX-M or 
OXA causing the ESBL phenotype. These resistance genotypes were not determined 
for these isolates within the scope of this work. For the blaTEM-116 gene variant, as 
identified in isolate 9, the conferred phenotype, whether ESBL or not ESBL, was up 
to date not conclusively determined (74).  
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Figure 22. Fluorescence images of selected TEM-arrays hybridized 
with target DNA from different variants detected in clinical isolates 
collected at the RBK and reference strains. The varying SNP positions 
37, 82, 102, 162.1,182, 236.1 are highlighted. The identified variants 
were (a) blaTEM-1, (e.g. in isolate 3), (b) blaTEM-3  (isolate 20), (c) blaTEM-7 
(isolate 21), (d) blaTEM-8 (isolate 19) and (e) blaTEM-116 (isolate 9). The 
signal intensity is shown in false color. Blue corresponds to the lowest 
signal intensity, red to white depict the highest signal intensities (as 
output by ImaGene 3.0). In (f) the SNP capture probe layout of the 
TEM microarray is displayed (for details see also figure 4). 
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Figure 23. Relative intensities of selected 
SNP positions in dependency of applied 
target DNA. The perfect matches at SNP 
positions 37, 82, 102, 162.1, 182, 236.1 
were identified to determine the target DNA 
origin (a) blaTEM-1 (n = 6) and (b) blaTEM-3 
(n = 6), (c) blaTEM-7 (n = 6), (d) blaTEM-8 (n = 9) 
and blaTEM-116 (n= 6). The probe sets are 
indicated by their central base (A, G, C, T) in 
the legend. 
0
10
20
30
40
50
60
<0.1 <0.2 <0.3 <0.4 <0.5 <0.6 <0.7 <0.8 <0.9 >0.9
RIMM = MM/PM
m
is
m
at
ch
 p
ro
be
s 
%
0
10
20
30
40
50
60
70
80
90
100
<0.05 <0.1 <0.2 <0.3 <0.4 <0.5 <0.6 <0.7 <0.8 <0.9 >0.9
standard error RIMM = MM/PM
m
is
m
at
ch
 p
ro
be
s 
%
(a) (b)
Figure 24. (a) Percentage of mismatch probes depending on the MM/PM ratio and (b) percentage 
of mismatch probes depending on the standard error of the MM/PM ratio of all identified SNP 
positions from the target DNAs originating from in total 16 analyzed clinical isolates and reference 
strains. All hybridizations were performed in duplicate (n = 6), except for isolate 6 and 14 
(n = 3) and isolate 19 (n = 9).  
Results 
 64 
3.1.8 Influence of target DNA properties 
3.1.8.1 Quantity of target DNA and incorporation ratio of the fluorescence label 
This experiment was devised to determine the sensitivity of the detection concerning 
the amount of target DNA and the influence of the incorporation ratio of fluorescence 
label (number of nucleotides per fluorophore) under standard conditions. It was 
accomplished within the scope of a “Studienarbeit” from Christina Onaca at the ITB. 
For an optimal sensitivity of the array analysis every target DNA fragment should 
bear at least one fluorescence label, otherwise competition between labeled and 
unlabeled fragments can occur.  
 
Two target DNA batches with differing incorporation ratios of the fluorescence label 
(number of nucleotides per fluorophore: NT/F = 87 and 166) were prepared. The 
target DNA was fragmented to fragment lengths between 50 and 150 bp. For an 
incorporation ratio of 87 NT/F 60 % to 100 % of the fragments should bear at least 
one fluorescence label, whereas for an incorporation ratio of 166 NT/F only 30 to 90 
% of the fragments would bear a fluorescence label, so that an increased competition 
should occur. Increasing amounts of target DNA (25 - 200 ng) were hybridized in 
triplicate experiments.  
 
The analysis of the net signal intensity averaged from all SNP specific probes yielded 
an unexpected result. The average net intensity increased as expected with a higher 
target DNA amount, but the corresponding average net signal intensities for an 
incorporation ratio of 87 NT/F were continuously lower (except for a target DNA 
amount of 200 ng) than those of the target DNA with an incorporation ratio of 166 
NT/F (see figure 25).  
Figure 25. (a) Net intensity (NI) and (b) specific intensity (SI) averaged from all SNP 
positions for a hybridization experiment with 25 to 200 ng of blaTEM-116 with an 
incorporation ratio of 87 or 166 nucleotides/fluorophore for 3 hours under standard cover 
slips (n = 9). 
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This result suggested either an underestimation of the DNA concentration in the 
target DNA with an incorporation ratio of 166 NT/F or an overestimation of the DNA 
concentration in the target DNA batch with a NT/F of 87.  
 
However, the analysis of the specific intensities (defined as the ratio of the perfect 
match signal intensity over a mean of the three mismatch signal intensities) - 
averaged from all SNP specific probe sets - indicated that at least the tendency of the 
determined incorporation ratios was true. The average specific intensities for 87 NT/F 
were continuously higher (app. 14 – 42 %) in comparison to the corresponding 
signals for 166 NT/F. In case of the target DNA with an NT/F of 87 the signals 
increased for target DNA amounts from 25 ng towards 200 ng about 42 %. In 
contrast to that the average specific intensities for the DNA with an NT/F of 166 
remained for all applied target DNA amounts at the same level.  
 
A dependency of the mismatch to perfect match discrimination level of the applied 
target DNA amount could be observed for an incorporation ratio of 87 NT/F by 
analyzing the distribution of the relative intensities of the mismatches. The number of 
mismatches with an RIMM < 0.1 (optimal discrimination) increased steadily from 25 to 
50 % for target DNA amounts from 25 to 200 ng as displayed in figure 26. For the 
hybridization of 25 ng DNA (NT/F = 87) all analyzed perfect match positions could be 
identified correctly, although the perfect match net intensities were very low with 
values between 83 and 1169, but the lowest mean perfect match net intensity was 
still five times above background level. Also for all other tested DNA amounts (50 - 
200 ng) the perfect matches could be detected correctly.  
Figure 26. (a) Distribution of the relative intensities of the mismatch probes (RIMMs) and (b) 
distribution of the standard errors of the relative intensities of the mismatch probes depending on the 
amount of the target DNA from a hybridization experiment with 25 to 200 ng of blaTEM-116  with an NT/F 
of 87 (n = 9). (c) Distribution of the relative intensities of the mismatch probes (RIMMs) and (d) 
distribution of the standard errors of the relative intensities of the mismatch probes depending on the 
amount of the target DNA from a hybridization experiment with 25 to 200 ng of blaTEM-116  with an NT/F 
of 166 (n = 9). 
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The distribution of the RIMM standard errors was shifted towards higher values for 
lower amounts of target DNA, consistently to a decreased signal to noise ratio (see 
figure 26), but remained in an acceptable range of 0 - 0.4. In contrast to that, the 
level of discrimination for an incorporation ratio of 166 was decreased compared to 
all tested amounts of target DNA with an incorporation ratio of 87. The distribution of 
the relative intensities of the mismatches for 166 NT/F was almost independent from 
the amount of target DNA. Nevertheless, all analyzed perfect match positions could 
be correctly identified for all tested DNA amounts, with perfect match net intensities 
between 276 and 2613 for 25 ng DNA, whereby the lowest analyzed perfect match 
intensity was still 17 times above background level. The RIMM standard errors were 
between 0 and 0.32.  
 
In conclusion, the specificity of the perfect match detection was enhanced for 
increasing amounts of target DNA with a majority of target DNA fragments bearing a 
label (87 NT/F). In contrast to that, the level of discrimination for target DNA with a 
decreased content of fluorescently labeled fragments (NT/F of 166) was lower and 
seemed to be independent from the applied amount of target DNA. The sensitivity 
limit of the array was not fully exploited with this experiment, since the lowest perfect 
match signals with 25 ng target DNA were still five times above background level. 
However, the negative influence on the discrimination and the reproducibility of a low 
signal to noise ratio were already obvious. Therefore, it was determined that for an 
optimal specificity and reproducibility the incorporation ratio should amount to at least 
100 nucleotides per fluorophore, and at least 50 ng of target DNA should be applied. 
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3.1.8.2 Fragment length 
The fragmentation of the target DNA was a crucial step during target DNA 
preparation and array analysis. To analyze the 41 polymorphisms in parallel, which 
were distributed over the whole length of 861 bp of the target gene, all target DNA 
regions had to be equally accessible for hybridization with oligonucleotide probes. 
Due to secondary structures a long target DNA fragment is partly inaccessible, since 
during the hybridization step the formation of secondary structures is favored. 
Furthermore, the hybridizing target DNA fragments had to bear at least one 
fluorescent label, otherwise competition between labeled and unlabeled fragments 
might occur. For target DNA with an incorporation ratio of usually 50-150 nucleotides 
per fluorophore, fragment sizes between 50 and 150 bp should be the optimal 
compromise between target DNA accessibility and sensitivity of the detection. To 
verify these assumptions, target DNA was fragmented with four different 
concentrations of DNaseI.  
 
The fragment sizes were estimated using lab-on-a-chip electrophoresis (see figure 
27). The signal peaks, which were detected at 43 s and 105 s, represented no 
signals specific for the analyzed sample, but were internal standard peaks. For the 
unfragmented target DNA (DNaseI, 0 U/µl) a sharp signal peak was detected at  
100 s which corresponds to a fragment size - as determined by the DNA standard - 
of 850 to 1000 bp. The minor peak detected at 63 s corresponds most probably to an 
air bubble and thus was ignored. For the target DNA fragmented with 1.2 mU/µl 
DNaseI the major signal peak was starting at 88.5 s (500 bp), but the maximum 
fluorescence was detected at the time point corresponding to the unfragmented 
target DNA peak. The peak maximum was reduced by about 10 fluorescence units in 
comparison to the unfragmented target DNA (DNaseI, 0 U/µl). These observations 
indicated the target DNA was partly fragmented with 1.2 U/ml DNaseI to fragment 
sizes between 500 and 861 bp.  
Figure 27. Analysis of target DNA fragment sizes from DNA fragmentation reactions with four 
different concentrations of DNaseI (0 – 120 mU/µl) by lab-on-a-chip electrophoresis. The 
fluorescence signal is given in arbitrary units (a.u.). The fluorescence signal peaks of the ladder 
correspond to fragment sizes between 15 - 1500 bp as indicated in the legend. 
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For a DNaseI concentration of 12 mU/µl an increased fluorescence signal was 
detected between 45 and 88 s corresponding to fragment sizes between 25-500 bp. 
The target DNA was completely fragmented, since no signal was detected at time 
points above 90 s. For the target DNA fragmented with 120 mU/µl a fluorescence 
signal was detected between 38 and 48 s corresponding to fragment sizes between 
less than 15 and up to 50 bp. Since the detected signals were partly outside of the 
size range covered by the DNA standard (43-105 s), a distinct analysis was not 
possible. Due to the limited resolution at the start and end point of the detection, this 
method could only yield an estimation of the fragment sizes.  
 
To determine the effect of the different fragment lengths on the hybridization, the 
array was hybridized with 110 ng target DNA (NT/F = 76) from the different 
fragmentation reactions. The fluorescence images of the hybridized arrays are 
displayed in figure 28. Clearly visible is, that the distribution of the fluorescence 
signals is strongly dependent on the fragment size. In case of the target DNA 
fragmented with 0 or 1.2 mU/µl a major part of the fluorescence signals is below the 
detection limit. For the target DNA fragmented with 12 or 120 mU/µl the signals are 
distributed more evenly.  
0 U/µl 1.2 mU/µl 
12 mU/µl 120 mU/µl 
Figure 28. Fluorescence image of a hybridization experiment with 110 ng 
blaTEM target DNA from pUC19 (NT/F = 76) fragmented with 0 U/µl,  
1.2 mU/µl, 12 mU/µl and 120 mU/µl DNaseI as indicated in the lower right 
corner of the corresponding image. The signal intensity is shown in false 
color. Blue corresponds to the lowest signal intensity, red to white depict 
the highest signal intensities (as output by ImaGene 3.0). 
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The quantified data confirm these results (see figure 29). Especially the fluorescence 
signals on probe positions 19-182 for the target DNA fragmented with 0 or 1.2 mU/µl 
were so weak, that an accurate identification of the perfect matches was not 
possible. Apparently, no hybridization happened at these probe sets with mainly 
unfragmented target DNA. In contrast to that, the probe sets targeting the 5’ end of 
the target strand showed higher perfect match signal intensities, when hybridized 
with less fragmented target DNA.  
 
For the target DNA fragmented with 12 mU/µl all 41 perfect match positions for 
blaTEM-116 could be identified correctly. 98 % of the mean relative intensities of the 
mismatches remained below 0.6. Probe 82G showed values up to 0.79 (data not 
shown). The relative intensity standard deviations ranged from 0 to 0.24.  
For the target DNA fragmented with 120 mU/µl considerably lower net signal intensity 
for the majority of perfect match probes were detected (see figure 29) and only 40 of 
41 perfect match positions for blaTEM-116 could be identified by calculating the mean 
relative intensities. The perfect match of position 261 was misidentified. Although 
probes 67.1, 67.2, 258, 271, 272 had very low net perfect match signal intensities 
between 115 and 565 (which was still at least six times above net background signal 
intensity), 98 % of the mean relative intensities of the mismatches remained below 
0.6. Probe 182G showed values up to 0.71 (data not shown). The relative intensity 
standard deviations ranged from 0 to 0.38.  
 
In conclusion, the effect of long target DNA strands preventing target DNA 
accessibility could be observed for target DNA batches with mostly unfragmented 
target DNA. Hereby the 3’ end of the captured target strand seemed to be less 
accessible for hybridization than the 5’ end. The fragmentation with 12 mU/µl DNaseI 
produced fragments between 25-500 bp and performed best regarding sensitivity and 
specificity of the perfect match identification. As assumed, target DNA with smaller 
fragment sizes (15-50 bp), but with the same incorporation ratio, performed worse 
regarding sensitivity of the perfect match detection. In this case some of the net 
perfect match signal intensities approached the background level leading to 
increased standard deviations of the relative intensities and misidentification of one 
perfect match position.  
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Figure 29. Mean net signal intensities for each SNP position and corresponding probe (A, G, C or T 
refer to the central base position) from a hybridization experiment with 110 ng blaTEM target DNA from 
pUC19 (NT/F = 76) fragmented with (a) 0 U/µl, (b) 1.2 mU/µl, (c) 12 mU/µl and (d) 120 mU/µl DNase 
(n = 9). 
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3.1.9 Reduction of assay time and test of hybridization devices 
The hybridization method used to set up the system was performed under a standard 
cover slip. These were incubated in Corning hybridization chambers during 
hybridization, followed by washing steps in agitated solution in glass jars and a 
manually performed drying step. Several features of this method offered a potential 
for optimization. The hybridization of DNA microarrays is diffusion limited and the net 
signal intensity is depending on the number of target molecules reaching the probe. 
This is a notoriously slow process for relatively big molecules such as DNA, so that 
with shorter incubation time a reduced sensitivity and specificity is usually 
associated. The overall time to perform the molecular diagnostics assay was initially 
six hours, including two hours for DNA amplification and labeling, 30 minutes for 
purification and fragmentation, three hours for hybridization and 30 minutes for 
washing. Since this array should be finally applied in the clinical setting, it was tested, 
if the rate limiting hybridization time could be significantly reduced by applying 
different hybridization devices, while keeping the sensitivity and specificity at a 
sufficient level. Furthermore, the reproducibility of experiments and quality of the 
generated data should be improved, as well as the most frequent sources of error 
compromising the array analysis should be reduced, so that the reliability necessary 
for a clinical application will be ensured.  
 
The most frequent sources of error were the following: The hybridization under an 
unsealed cover glass could lead to evaporation and subsequent drying of the 
hybridization sample causing high background intensities. During washing the cover 
slip did not always dissociate right at the beginning, leading to an ineffective wash 
step, so that unspecific signals and high background intensities remained. The drying 
step had to be performed instantly (which was not always realizable when performing 
an experiment with several replicates) or remaining salt from the wash solution 
caused a high background intensity. Therefore, the application of different devices for 
improvement of hybridization conditions or partial automation of the hybridization 
process were evaluated.  
 
Not all devices could be tested at the same time, therefore each analyzed device was 
compared to a standard cover slip hybridization in Corning hybridization chambers. 
Since for these experiments large target DNA batches were necessary, they had to 
be prepared in advance and had sometimes to be frozen and thawed before use. 
This storage parameters and differing incorporation ratios of fluorescence label could 
introduce a variable performance of the different target DNA batches, especially 
regarding the observed net signal intensities. However, through comparison to a 
standard cover slip hybridization, variations in the resulting data introduced by 
different target DNA batches could be estimated. The evaluation criteria included the 
increase of the overall net fluorescence signal intensity, the specificity of the perfect 
match identification in total and in detail, the reproducibility of the generated data, as 
well as low and uniform background signal intensities. 
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3.1.9.1 ArrayBooster 
The first tested device was an ArrayBooster (Advalytix, Brunnthal, Germany) 
hybridization station, using surface acoustic waves to agitate the sample solution 
during incubation of the target DNA. After hybridization, the slides had to be washed 
and dried manually. Hybridization times from three hours to 30 min were analyzed 
with 65 ng target DNA (57 NT/F) per array. For each condition only one array was 
tested. The increase of the fluorescence signals by using the surface acoustic waves 
for sample agitation during hybridization was distinct, as visible in the fluorescence 
images displayed in figure 30. This was confirmed by the analysis of the net signal 
intensities averaged from all SNP specific probes. The net signal intensities were 
increased in average about 1.7 times for three hours incubation to up to 8.5 times for 
one hour incubation time (see figure 31), while retaining equal background net 
intensities (approximately 20-30 arbitrary units).  
An increase of the average net signal intensity was only advantageous in 
combination with an increase of the mismatch to perfect match discrimination, which 
was estimated in total by calculating the average specific intensities of all probe sets. 
The specific intensity was defined as the ratio of the net perfect match signal intensity 
over the mean of the three net mismatch signal intensities of each SNP probe set. 
The average specific intensity was clearly increased through agitation (see figure 31). 
The enhancement of the discrimination by the use of the ArrayBooster was the more 
pronounced the shorter the hybridization time.  
Figure 30. Fluorescence images of a hybridization experiment with 65 ng DNA (57 NT/F) 
used in a (a) diffusion dependent hybridization using standard cover slips in Corning 
hybridization chambers or (b) agitation dependent hybridization using suface acoustic waves 
produced by the ArrayBooster, for hybridization times of 30 min to 3 h. 
1   h 2 h 3 h 30 min
(b)
(a)
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All 41 perfect match positions could be identified at three hours, two hours and 30 
minutes. Only in the cover slip hybridization of one hour one perfect match was 
misidentified (data not shown). This was attributed to aberrations in the spotting 
process. 
The efficiency of the mismatch to perfect match discrimination was analyzed in detail 
by reviewing the distribution of all mismatches in dependency of the mismatch to 
perfect match ratio (defined as the relative intensity of the mismatch, RIMM =MM/PM) 
as displayed in figure 32. The discrimination is the more efficient the lower the 
mismatch to perfect match ratio. A perfect match is considered as not clearly 
identified if one or more of the three mismatches of one probe set have a relative 
intensity of > 0.8. 
 
 
 
 
The discrimination was clearly enhanced by agitation for hybridization times shorter 
than one hour. At one hour hybridization time, while using the ArrayBooster, over  
50 % of the relative intensities of the mismatches were below 0.1, corresponding to 
an optimal perfect match to mismatch discrimination. In contrast to that only 37 % of 
the mismatches presented such a discrimination efficiency in case of the cover slip 
Figure 32. (a) Percentage of mismatch probes depending on the MM/PM ratio for a diffusion 
dependent (cover slip) hybridization and (b) percentage of mismatch probes depending on 
the MM/PM ratio for an agitation dependent (Arraybooster) hybridization for 3 h to 30 min 
(n = 3).  
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Figure 31. (a) Net intensities (NIs) averaged from all SNP specific probes and (b) specific 
intensities (SIs) averaged from all SNP probe sets depending on the hybridization time for a 
diffusion dependent (cover slip) and agitation dependent (ArrayBooster) hybridization (n = 3). 
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hybridization. At 30 minutes hybridization time the divergent discrimination efficiency 
between the two methods was even more pronounced. By using the cover slip 
method, only 20 % of the RIMMs showed optimal discrimination efficiency with values 
below 0.1, in contrast to 37 % under agitation of the hybridization sample. Generally, 
the better the discrimination, the further the RIMM distribution was shifted towards 
lower RIMMs with the majority of the mismatch relative intensities below 0.1. If the 
discrimination was less optimal, the maximum of the distribution of the relative 
intensities of the mismatches was shifted from a mismatch to perfect match ratio of 
0.1 to higher values.  
 
To analyze the variability of the system in 
total, the standard errors of the relative 
intensities were averaged from all 
mismatch probes. The average RIMM 
standard errors are displayed in figure 
33. The decrease of the net intensities 
and the resulting decreased signal to 
noise ratio caused an increase of the 
RIMM standard errors as obvious for the 
cover slip hybridization of one hour and 
30 minutes (see figure 33). It has to be 
taken into account, that the analysis of 
the different hybridization times was 
performed with only one array for each 
condition. In an additional experiment the 
reproducibility in between three arrays 
was tested for a hybridization time of 
three hours. Here the ArrayBooster did 
yield an average RIMM standard error of 
2.4 % in contrast to 1.2 % for the cover 
slip hybridization. So in terms of 
reproducibility no improvement was 
observed for this condition, but it can be 
assumed that for shorter hybridization 
times the effect would be more 
pronounced, mainly by increasing the 
signal to noise ratio as indicated by the 
results of the variation of the 
hybridization time.  
 
In summary, it was determined that by using both methods hybridization times of 30 
minutes were sufficient for a correct identification of all perfect match positions. 
Although the ArrayBooster produced very convincing results considering the 
acceleration of the hybridization, more experiments were not performed, because 
several features of the tested device were disadvantageous. The application of the 
sample solution without air bubbles was problematic, because of the design of the fill 
nozzle of the hybridization chamber, so that several arrays had to be excluded from 
the analysis. Furthermore, removing of the hybridization chamber from the array after 
hybridization caused sometimes a smearing of the target DNA over the array surface, 
which could not be eliminated by subsequent washing. Even though these problems 
might be solved by a well trained user, it is a prerequisite to perform the assay user-
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Figure 33. Standard errors of relative 
mismatch intensities (RIMM) averaged from 
all SNP positions depending on the 
hybridization time for a diffusion dependent 
(cover slip) and agitation dependent 
(ArrayBooster) hybridization. (n = 3, if not 
stated otherwise). 
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independently, and since these facts reduced the amount of analyzable data 
considerably, this device was not further investigated. 
 
 
3.1.9.2 Lucidea Slide Pro  
Besides the diffusion limitation of the hybridization process another source of 
experimental aberrations were the washing and drying steps. The second tested 
hybridization device (Lucidea Slide Pro, Amersham Pharmacia Biotech, Freiburg, 
Germany) included a flow chamber using a pumping mechanism to actively distribute 
the sample on the microarray surface during hybridization and allowed also to 
perform the washing steps automatically. A final drying step was a projected feature 
of this hybridization station, but was not ready for application so far according to the 
supplier, so that the drying step had to be performed manually. In the precedent 
experiment it was determined, that for hybridization times below one hour the effect 
of the sample agitation on the hybridization results was most pronounced and that 
the generated data was sufficient for a sensitive data analysis. Therefore, the 
influence of hybridization times from one hour to 15 minutes on the hybridization 
signals using the Lucidea Slide Pro in comparison to using cover slips in Corning 
hybridization chambers was investigated.  
 
All experiments were performed in triplicate with 75 ng target DNA (75 NT/F) per 
array. The increase of the fluorescence signals after hybridization with the Lucidea 
Slide Pro in comparison to the cover slip hybridization was not as remarkable as for 
the ArrayBooster (see figure 34 for fluorescence images).  
30 min 1 h 15 min 
(b) 
(a) 
Figure 34. Fluorescence images of a hybridization experiment with 75 ng DNA  
(75 NT/F) used in a (a) diffusion dependent hybridization using standard cover 
slips in Corning hybridization chambers or (b) agitation dependent hybridization 
and wash in flow chambers of Lucidea Slide Pro, for hybridization times of 15 min 
to 1 h. 
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The resulting net signal intensities averaged from all SNP specific probes at one hour 
were comparable. At 30 minutes the hybridization station produced about two times 
higher net intensities. Using the hybridization station, the average net intensity 
observed at 30 min was surprisingly higher than the one determined with the same 
device at one hour hybridization time. This was attributed to problems associated 
with the sample injection. At 15 minutes the net intensities of one array of the cover 
slip hybridization were uncharacteristically high, resulting in a highly increased 
average net intensity. This might have been caused by inefficient washing due to a 
too late dissociation of the cover slip from the array during the wash steps. The effect 
of the differing hybridization times and devices was more comprehensible for the 
analyzed average specific intensities. Here the use of the Lucidea Slide Pro resulted 
in a clear increase of the average specific intensities, which was the better in 
comparison to the cover slip hybridization, the shorter the hybridization time (see 
figure 35).  
At one hour and 30 minutes hybridization time all 41 perfect match positions could be 
identified by analyzing the relative intensities resulting from both hybridization 
methods, but at 30 minutes in the cover slip hybridization one mismatch position 
exceeded the predefined ID limit of 0.8 (as defined in section 3.1.4) with a value of 
0.86. In the hybridization using the Lucidea Slide Pro at 15 minutes two perfect 
match positions were misidentified and for two others the predefined ID limit of 0.8 
was exceeded with RIMMs up to 0.86. At 15 min in the cover slip hybridization finally 
12 % of the mismatch positions exceeded the ID limit. For six polymorphism positions 
the perfect matches were even misidentified.  
 
Remarkably distinct for shorter hybridization times was the displacement of the 
maximum of the distribution of the relative intensity of the mismatches from 0.1 
towards 0.5. Hereby the distribution pattern clearly approached a Gaussian 
distribution, which was especially pronounced for the cover slip RIMM values at 15 
min (see figure 36a).  
 
 
 
 
Figure 35. (a) Net intensities (NIs) averaged from all SNP specific probes depending on the 
hybridization time (b) Specific intensities (SI) averaged from all SNP probe sets depending on 
the hybridization time for a diffusion dependent (cover slip) and agitation dependent (Lucidea 
Slide Pro) hybridization (n = 9). 
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The analysis of the RIMM standard 
errors did not yield conclusive results 
for favoring one of the tested methods 
(see figure 37). Generally, longer 
hybridization times led to a higher 
reproducibility, except for 30 min 
versus one hour hybridization in the 
Lucidea Slide Pro, which was 
attributed to a lower signal to noise 
ratio determined at one hour. This was 
most probably caused by incomplete 
probe injection and thus less applied 
target DNA in the hybridization taking 
one hour in comparison to the 
hybridization of 30 minutes. 
 
 
In conclusion, all perfect match positions were correctly identified using both methods 
for hybridization times as short as 30 minutes. For the cover slip hybridization one 
mismatch position at 30 minutes exceeded the predefined ID limit of 0.8, however 
considering the correct perfect match identification and the reliable identification of all 
the other positions, this could be neglected. For a hybridization time of 15 minutes 
both hybridization systems failed to deliver a reliable perfect match identification. By 
using the Lucidea Slide Pro, an enhancement of the discrimination efficiency could 
be observed, but no general increase in the net signal intensities or reproducibility 
was detected. The major difficulty observed while using the Lucidea Slide Pro was 
the probe injection step. To avoid the injection of air bubbles, sometimes not the 
whole sample could be loaded, which led to the observed aberrations in the assay 
results. 
Figure 36. Percentage of mismatch probes depending on the MM/PM ratio from an 
hybridization experiment of 75 ng DNA (75 NT/F) (a) in Corning hybridization chambers and (b) 
in the Lucidea Slide Pro for 1 h, 30 min and 15 min (n = 9)  
(a)
0
5
10
15
20
25
30
35
40
< 0.1 < 0.2 < 0.3 < 0.4 < 0.5 < 0.6 < 0.7 < 0.8 < 0.9 >0.9
RIMM = MM/PM
%
 o
f m
is
m
at
ch
 p
ro
be
s
1 h
30 min
15 min
Lucidea Slide Pro
(b)
0
5
10
15
20
25
30
35
40
< 0.1 < 0.2 < 0.3 < 0.4 < 0.5 < 0.6 < 0.7 < 0.8 < 0.9 >0.9
RIMM = MM/PM
%
 o
f m
is
m
at
ch
 p
ro
be
s
1 h
30 min
15 min
cover slip
Figure 37. Standard errors of relative 
mismatch intensities (RIMM) averaged from all 
SNP positions depending on the hybridization 
time for a diffusion dependent (cover slip) and 
agitation dependent (Lucidea Slide Pro) 
hybridization (n = 9). 
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
1 h 30 min 15 min
hybridization time
m
ea
n 
st
an
da
rd
 e
rro
r R
I M
M
Lucidea Slide Pro
cover slip
Results 
 78 
3.1.9.3 Tecan HS400 
The third tested hybridization device was the HS 400 from Tecan (Crailsheim 
Germany), which offered the possibility to automate the whole process starting from 
the hybridization up to the final drying step. The flow through chamber contained two 
membranes allowing an agitation of the sample by applying pressure alternately. The 
slides were dried automatically by N2 flow. Hybridization times from one hour, 30 and 
15 minutes were analyzed with 150 ng target DNA per array (136 NT/F). All 
experiments were performed in triplicate. An enhancement of the fluorescence 
signals by using the hybridization station could be observed as displayed in figure 38.  
30 min 1 h 15 min 
(b) 
(a) 
Figure 38. Fluorescence images of a hybridization experiment with 150 ng DNA 
(136 NT/F) used in a (a) diffusion dependent hybridization using standard cover slips 
in Corning hybridization chambers or (b) agitation dependent hybridization and wash 
in flow chambers of the HS400, for hybridization times of 15 min to 1 h. 
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The net signal intensities were increased by using the HS400 in average about 2.8 
times at one hour up to 3.5 times at 15 minutes in comparison to the cover slip 
hybridization (see figure 39). The average specific intensity was enhanced by the use 
of the hybridization station within the same range (approximately with a factor of  
1.2 -1.4 ) for all tested hybridization times.  
By using the HS400, all correct perfect match positions could be identified for the 
analyzed probe sets at one hour, 30 and even 15 minutes. (In the whole experiment 
position 182 had to be excluded from the data analysis, due to a spotting failure in 
the whole slide batch.) At one hour and 30 minutes in the cover slip hybridization also 
all perfect match positions could be identified, only at 30 minutes one probe 
exceeded the RIMM limit of 0.8 with an RIMM of 0.89. Two perfect matches were 
misidentified in the cover slip hybridization of 15 minutes.  
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Figure 40. Percentage of mismatch probes depending on the MM/PM ratio from an 
hybridization experiment of 150 ng DNA (136 NT/F) (a) in Corning hybridization chambers and 
(b) in the HS400 for 1 h, 30 min and 15 min (n = 9)  
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Figure 39. (a) Net intensities (NIs) averaged from all SNP specific probes and (b) specific 
intensities (SIs) averaged from all SNP probe sets depending on the hybridization time for a 
diffusion dependent (cover slip) and agitation dependent (HS400) hybridization (n = 9). 
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The mismatch to perfect match discrimination was enhanced by using the 
hybridization station at hybridization times shorter than one hour as can be seen in 
detail in figure 40. At one hour hybridization time the discrimination efficiency was 
almost equal for both methods. At 30 minutes while using the HS400 26 % of the 
relative intensities of the mismatches were below 0.1, in contrast to only 20 % of the 
mismatches in case of the cover slip hybridization. At 15 minutes hybridization time 
the divergent discrimination efficiency between the two methods was even more 
pronounced. By using the cover slip method, only 7 % of the RIMMs showed optimal 
discrimination efficiency with values below 0.1, in contrast to 17 % under agitation of 
the hybridization sample. In contrast to the coverslip method for the HS400 no RIMM 
values greater then 0.8 were detected for all analyzed hybridization times.  
 
 
The average RIMM standard errors for 
the HS400 hybridization remained 
almost at the same level (about 2 %) 
for a reduced hybridization time, 
whereas the RIMM standard errors for 
the cover slip hybridization showed a 
continuous increase (up to 4.5 % at 
15 min) as displayed in figure 41.  
 
 
 
 
 
 
 
 
 
Overall, the HS400 enhanced the net and the specific signal intensities and 
increased the reproducibility of experiments. It allowed a reliable perfect match 
identification at all tested hybridization times, even at times as short as 15 minutes. In 
the cover slip hybridization at one hour and 30 minutes all perfect match positions 
could correctly be determined, although one position exceeded the predefined ID 
limit. However, at 15 minutes the cover slip method failed to deliver an accurate 
perfect match identification in contrast to the HS400. 
Figure 41. Standard errors of relative 
mismatch intensities (RIMM) averaged from all 
SNP positions depending on the hybridization 
time for a diffusion dependent (cover slip) and 
agitation dependent (HS400) hybridization 
(n = 9). 
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3.1.9.4 Thermomixer slide adapter 
Additionally, two simple devices were tested for their effect on problems concerning 
the hybridization step. One was the application of sealing frames (Eppendorf, 
Hamburg, Germany) instead of cover slips, thereby forming an enclosed 
hybridization environment, so that the sample solution could not evaporate. 
Furthermore, it allowed to load a higher volume of the sample solution (65 µl instead 
of 30 µl for the cover slip hybridization). The second device was a slide adapter 
(Eppendorf, Hamburg, Germany), which allowed the heating and agitation of the 
array on a thermomixer, when a sealing frame was used for hybridization. The 
washing and the drying steps were performed manually. The applied target DNA 
(150 ng per array, 136 NT/F) stemmed from the target DNA batch used in the 
evaluation of the HS400, so that the data was directly comparable to the previous 
experiment. As before, hybridization times from one hour, 30 and 15 minutes were 
analyzed and all experiments were performed in triplicates.  
 
An enhancement of the fluorescence signals by using the thermomixer was not 
obvious from the fluorescence images (displayed in figure 42), but a slight increase in 
the average net fluorescence intensities (about 1.3 times) could be determined for 
hybridization times of one hour and 15 minutes as displayed in figure 43.  
30 min 1 h 15 min 
(b) 
(a) 
Figure 42. Fluorescence images of a hybridization experiment with 150 ng DNA 
(136 NT/F) used in a (a) diffusion dependent hybridization using sealing frames in 
Corning hybridization chambers or (b) agitation dependent hybridization in a 
thermomixer slide adapter, for hybridization times of 15 min to 1 h. 
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Although for the average net intensity calculated after 30 minutes hybridization time 
using the thermomixer a slight aberration could be observed, the average specific 
intensity was still increased compared to the sealing frame hybridization. The 
average specific intensity was enhanced by agitation from approximately 1.2 to 1.4 
times.  
 
 
On all slides tested in the thermomixer the discrimination efficiency for position 161 
was weak and at one hour hybridization time the perfect match of position 161 was 
even misidentified. Apart from that, under agitation all perfect matches could be 
identified correctly (except for position 182 due to the aforementioned spotting 
aberrations), but each time one mismatch exceeded the RIMM limit of 0.8 at 15 and 30 
minutes hybridization time. Without agitation, all analyzed perfect matches were 
detected correctly, but for the hybridizations lasting one hour and 30 minutes each 
time one mismatch exceeded the predefined RIMM limit of 0.8.  
 
Except for position 161 at one hour hybridization time, the mismatch to perfect match 
discrimination efficiency was enhanced for the agitation dependent hybridization as 
displayed figure 44. At 30 minutes, while using the thermomixer, 30 % of the relative 
intensities of the mismatches were below 0.1, in contrast to only 23 % of the 
mismatches in case of the hybridization without agitation. At 15 minutes hybridization 
time using the sealing frames only 8 % of the RIMMs showed optimal discrimination 
efficiency with values below 0.1, in contrast to 23 % under agitation of the 
hybridization sample.  
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Figure 43. (a) Net intensities (NIs) averaged from all SNP specific probes and (b) specific 
intensities (SIs) averaged from all SNP probe sets depending on the hybridization time for a 
diffusion dependent (sealing frames) and agitation dependent (thermomixer) hybridization 
(n = 9). 
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The average RIMM standard remained 
almost at the same level for a 
hybridization time of one hour and 30 
minutes, independent from 
hybridization with or without agitation, 
whereas the RIMM standard errors for 
the hybridization without agitation 
showed a slight increase at 15 min as 
displayed in figure 45. 
 
 
 
 
 
 
 
 
In summary, the use of the sealing frame alone (without agitation) increased the 
average net signal intensities, but the overall perfect match to mismatch 
discrimination as determined by the average specific signal intensities were 
comparable to those achieved by the application of the cover slip. In other 
experiments it was determined, that the use of a higher hybridization volume could 
lead to enhanced net signal intensities. Therefore, it was assumed, that the 
increased volume was the cause of the detected enhanced fluorescence signals 
compared to the cover slip hybridization. The agitation by thermomixer increased the 
average net and specific signal intensities, but in detail the discrimination was worse 
than observed for the results achieved by using the HS400. The integration of these 
devices into the assay would require an adaptation of the washing protocol, so that 
more stringent washing steps are applied. However, the aforementioned problem of 
the probability of experimental aberrations introduced through the non-automated 
washing and drying steps were not addressed by these devices. 
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Figure 45. Standard errors of relative MM 
intensities (RIMM) averaged from all SNP 
positions depending on the hybridization time 
for a diffusion dependent (sealing frames) and 
agitation dependent (thermomixer slide 
adapter) hybridization (n = 9). 
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Figure 44. Percentage of mismatch probes depending on the MM/PM ratio from an hybridization 
experiment of 150 ng DNA (136 NT/F) (a) in a diffusion dependent (sealing frames) and (b) 
agitation dependent (thermomixer slide adapter) hybridization for 1 h, 30 min and 15 min (n = 9)  
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3.1.9.5 Conclusion of assay time and hybridization device testing 
In conclusion, the evaluation of the different tested hybridization devices was as 
follows: The ArrayBooster performed best regarding the enhancement of the net and 
specific signal intensities and produced a good perfect match discrimination, but 
presented severe handling problems (e.g. probe injection, removing the hybridization 
chamber), which compromised the reproducibility of experiments. Furthermore, this 
device did not address the problem of the unreliability of the manual washing and 
drying steps.  
 
The Lucidea Slide Pro did not deliver very conclusive results regarding enhancement 
of the net intensities and the reproducibility. This was also partly attributed to 
problems with the probe injection. The discrimination was considerably enhanced in 
comparison to the cover slip hybridization, which was attributed to a more effective 
washing through automation of the wash step, but the slides still had to be dried 
manually, which was not satisfying for a hybridization station claiming a high level of 
automation.  
 
The Tecan HS 400 enhanced the net and specific signal intensities convincingly, as 
well as the perfect match discrimination and the reproducibility of the data. 
Furthermore, it offered the possibility to automate the whole process including 
hybridization and washing up to an effective final drying step. In combination with the 
easy handling, especially regarding the probe injection, this instrument was 
considered as the overall best performing hybridization device. 
 
The tested sealing frame in combination with the thermomixer slide adapter offered a 
simple solution for several points of concern of the hybridization. The use of the 
thermomixer led to increased average net and specific signal intensities, but the 
additional requirement of an effective perfect match discrimination for this assay 
proved to be the major drawback, which would require the adaptation of the washing 
protocol.  
 
In this experiment, it could be determined that by using the Tecan HS 400 the 
hybridization time could in principle be reduced to 15 minutes and the total assay 
time to less than 3.5 hours while keeping the discrimination power of the diagnostic 
array at a sufficient level. However, it was clearly determined that this reduction in 
hybridization time was only achieved at the expense of the specificity and the 
sensitivity of the analysis. To provide the possibility to achieve the most sensitive and 
specific results in an acceptable assay time, all following experiments were carried 
out using the Tecan HS400 with a hybridization time of one hour, which resulted in a 
reduction of the total assay time from initially 6 to 4 hours. 
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3.1.10 Mixed resistances 
To determine if the detection of an ESBL TEM variant in presence of a narrow 
spectrum variant was possible, blaTEM-8 and blaTEM-116 target DNA with identical 
incorporation ratios (NT/F=76) were mixed in different ratios: 1:0; 1:1; 1:5, 1:10; 
1:100, and 0:1.  
 
All perfect match positions could be identified correctly for pure blaTEM-116 with all 
relative intensities of the mismatches < 0.64 except for probe 258, which showed 
spotting errors and was thus not taken into account for the data analysis of all arrays. 
The standard deviations ranged from 0 - 0.23. For pure blaTEM-8 all perfect match 
positions could be identified correctly with RIMMs < 0.46 (standard deviations 0 -0.19), 
except for probe sets 163.1 and 235.2, where the net fluorescence intensities for the 
perfect match positions were below the detection limit and no relative intensities 
could be calculated. This was due to the correctly detected mutations at positions 
162.1 and 236.1, which represent an additional mismatch towards the target 
sequence for the probe sets with partially overlapping sequence. Thus the 
hybridization was for these positions disabled, but this did not affect the correct 
identification of blaTEM-8. For the whole test series the standard deviations of the 
relative intensities remained below 0.3.  
 
In figure 46 a-e the probe sets with perfect matches differing between blaTEM-116 and 
blaTEM-8 are displayed. In figure 46 f and g the perfect match positions of the 
displayed probes were identical. The blaTEM-8 perfect match signal pattern could be 
distinguished for positions 82 and 102 up to a ratio of 1:10, for 37, 162.1 and 236.1 
up to a ratio of 1:5 from the relative intensity signal pattern of a pure narrow spectrum 
variant (blaTEM-116) with differences from 0.11-0.24. The mixed pattern for 37, 162.1, 
236.1 at a ratio of 1:10 was still differing from the pure resistance pattern, but the 
difference of 0.06-0.07 was close to the inner variability of the system. The signal 
pattern of a ratio of 1:100 could not be distinguished from the pattern of pure  
blaTEM-116 target DNA. As can be seen in figure 46 f and g the variation for the relative 
intensities of the mismatches of a probe set with the same perfect match was less 
than 0.07.  
 
Due to the reproducibility of the relative intensities an identification of mixed 
resistances up to a ratio of 1:5 or even 1:10 should be possible, but for each probe 
set an individual RIMM threshold has to be defined. If this threshold is violated, a 
mixed resistance can be suspected. However, much more data has to be generated 
and more variants to be tested to ascribe an individual threshold to each probe set.  
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Figure 46. Mean relative (rel.) signal intensities 
for SNP position (a) 37, (b) 82, (c) 102, (d) 162, 
(e) 236, (f) 113, (g) 162.2 and corresponding 
probe (A, G, C and T refer to the central base 
position) from a hybridization experiment with 
blaTEM-8 and blaTEM-116 target DNA (total DNA 
amount 200 ng, 110 NT/F) mixed in different 
ratios: 1:0; 1:1; 1:5, 1:10; 1:100; 0:1; (n = 9). 
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3.1.11 Validation of the TEM-array with clinical samples from the NRCA 
To validate the TEM-array, a set of 61 
clinical isolates collected at four different 
Russian Hospitals (Moscow City Clinic 
No. 7, Central Russian Military Hospital, 
National Research Center for Pediatric 
Diseases, Tomsk City Hospital) was 
provided by the NRCA (National 
Research Center for Antibiotic 
Resistance, Moscow). Thirty of these 
isolates (displayed in table 7) contained 
a blaTEM gene, which was determined in 
a PCR prescreening with TEM-specific 
primers at the NRCA. The phenotypes 
and species identification were also 
carried out at the NRCA. By defining the 
MICs with broth microdilution tests, all 
isolates were classified as ESBL 
producers. An additional ESBL 
confirmatory disc diffusion test was 
performed at the Robert Bosch Hospital, 
Stuttgart. In this disk diffusion test a 
bigger than 5 mm increase in a zone 
diameter for ceftazidime, cefotaxime or 
cefpodoxime tested in combination with 
clavulanic acid versus its zone when 
tested alone confirmed an ESBL-
producing organism. The ESBL 
phenotype could be confirmed for 22 of 
the 30 isolates. For five isolates no 
inhibition effect of clavulanic acid could 
be observed, which indicates the 
presence of a mobilized AmpC gene 
causing the resistance. The presence of 
an ESBL gene in addition to this could 
not be determined by this test, since the 
AmpC phenotype might mask the ESBL 
phenotype. In two cases the isolates 
were susceptible to all tested antibiotics, 
so that an ESBL phenotype was 
excluded. One sample was not purely 
isolated, so that a correct confirmatory 
test could not be performed. The 
discrepancy between the MIC and 
confirmatory test results prove the 
problem of an unambiguous phenotypic 
ESBL identification independent from the 
used method (broth microdilution or disc 
diffusion) or the institution where the 
tests are performed.  
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Figure 47. Relative intensities of selected 
SNP positions in dependency of applied 
target DNA. Only the SNP positions (37, 82 
and 182) differing between blaTEM-1 and the 
detected variants are displayed. The 
identified blaTEM gene variants were (a) 
blaTEM-1 (n = 9) in 26 isolates (e.g. data 
displayed from isolate No 50) (b) blaTEM-2 
(n = 9) in isolate No 31 and (c) blaTEM-116 
(n = 9) in the control target DNA. The probe 
sets are indicated by their central base (A, 
G, C, T) in the legend. 
probe set number 
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The prescreening for and identification of CTX-M and SHV-type resistance was 
performed by coworkers at the NRCA. The DNA extracted from the isolates was 
prescreened by PCR for the occurrence of blaCTX-M and blaSHV genes in addition to 
the blaTEM genes. 24 of the isolates showed a PCR product with blaCTX-M -specific 
primers and 10 isolates showed a PCR product with blaSHV -specific primers. The 
blaCTX-M and blaSHV gene variants which could be subsequently identified by standard 
DNA sequencing are displayed in table 7. The detected variants comprised  
blaCTX-M -3, -14, -15 and blaSHV-2, -12, -38.  
 
All blaTEM genes could be amplified and fluorescently labeled from the extracted 
isolate DNA. PCR products of isolate 94 and 100 were lost during purification due to 
silica columns with manufacturing errors and thus could not be tested on the TEM-
array. With all other 28 PCR products an array analysis was performed. 26 tested 
genes of the clinical isolates were identified correctly by array analysis as blaTEM-1. 
Isolate 31 was identified to contain blaTEM-2. The positive control target DNA used in 
this experiment was an blaTEM-116 gene, which could also be correctly identified. 
Isolate 39 could not be identified correctly, because of the low quality of the 
generated data and thus had to be excluded from the further data analysis.  
 
The results of the identification of the different blaTEM gene variants (isolate 50 for 
blaTEM-1, isolate 31 for blaTEM-2 and the positive control for blaTEM-116) are displayed in 
figure 47 as relative intensities. Only the SNP positions differing between blaTEM-1, 
blaTEM-2 and blaTEM-116 are displayed. All these perfect match positions could be 
identified without ambiguity. In total 40 of 41 perfect match positions could be 
correctly identified for all analyzed isolates: SNP position 143 had to be excluded 
from the analysis, because of a spotting failure for this position within the whole slide 
batch. 95 % of the analyzed mismatch positions remained below a relative intensity 
of the mismatch value of < 0.6 (displayed in figure 48). 5 % showed a a relative 
intensity of the mismatch of 0.6 - 0.8. Two times the RIMM limit of 0.8 was violated by 
mismatch probes 122A (RIMM = 0.81) and 122T (RIMM = 0.87) of isolate No. 59: this 
could also be ascribed to sporadic aberrations in the spotting process. The standard 
deviations of the mean a relative intensities of the mismatches varied from 0 - 0.33, 
but 89 % remained below 10 % of the perfect match intensity (displayed in figure 
48b). The results of the array analysis were confirmed by standard DNA sequencing. 
The blaTEM gene variants of isolate 39, 94 and 100 were thereby also identified as  
blaTEM-1.  
  
(a) (b)
Figure 48. (a) Percentage of mismatch probes depending on the MM/PM ratio and (b) percentage of 
mismatch probes depending on the standard error of the MM/PM ratio of all identified SNP positions 
from 27 of in total 28 NRCA clinical isolate’s target DNA tested on the TEM-array (isolate No 39 was 
excluded, because of poor data quality). All hybridizations were performed in triplicates (n = 9). 
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All blaTEM variants detected in the Russian clinical isolates belonged to the TEM 
parental types, which do not cause an ESBL phenotype. Therefore, the detected 
ESBL phenotype must have been caused by the SHV or CTX-M variants displayed in 
table 7, which were detected in all isolates by PCR and sequencing analysis 
performed at the NRCA in addition to the TEM gene, except for isolate 67, 96 or 100. 
For isolate 67 and 96 this was analog to the findings of the phenotypic tests from the 
RBK, which suggested an AmpC type resistance. For isolate 100 an ESBL was 
excluded consistently in the phenotypic test performed at the RBK and genotypic 
analysis. In case of isolate 41, which was phenotypically classified as no ESBL by 
the RBK, no conclusive analysis could be made, because the CTX-M variant 
detected in the first PCR screening was not identified so far. 
 
Table 7. Results of testing of clinical isolates from the NRCA 
Genotype Origina Isolate No Species Phenotypeb  
blaCTX-M 
c blaSHV d blaTEM e 
M 25 E. coli ESBL +  TEM-1 
M 26 E. coli ESBL +  TEM-1 
M 31 P. mirabilis ESBL/AmpC + + TEM-2 
M 37 K. pneumoniae ESBL + + TEM-1 
M 39 Klebsiella spp. ESBL  SHV-2  (TEM-1) 
M 41 E. coli no ESBL +  TEM-1 
M 43 E. coli ESBL CTX-M-14  TEM-1 
C 50 K. pneumoniae ESBL + SHV-12 TEM-1 
C 52 E. aerogenes ESBL + SHV-12 TEM-1 
C 55 E. coli ESBL CTX-M-15 SHV-12 TEM-1 
C 57 E. coli ESBL CTX-M-15 SHV-12 TEM-1 
M 59 K. pneumoniae ESBL +  TEM-1 
M 64 K. pneumoniae ESBL CTX-M-15  TEM-1 
T 67 C. freundii ESBL/AmpC   TEM-1 
T 68 M. morganii ESBL +  TEM-1 
N 75 K. pneumoniae ESBL  SHV-38 TEM-1 
M 77 E. coli not pure CTX-M-15 + TEM-1 
M 79 E. coli ESBL CTX-M-15  TEM-1 
T 83 E. coli ESBL CTX-M-3  TEM-1 
T 86 C. freundii ESBL/AmpC  + TEM-1 
T 87 E. coli ESBL CTX-M-3  TEM-1 
T 90 P. vulgaris ESBL CTX-M-3  TEM-1 
N 92 K. pneumoniae ESBL CTX-M-3  TEM-1 
T 93 E. coli ESBL/AmpC +  TEM-1 
T 94 E. coli ESBL +  (TEM-1) 
T 95 K. pneumoniae ESBL CTX-M-3  TEM-1 
T 96 C. freundii ESBL/AmpC   TEM-1 
T 98 C. freundii ESBL +  TEM-1 
T 99 C. freundii ESBL CTX-M-3  TEM-1 
T 100 E. coli no ESBL   (TEM-1) 
 control 
target 
E. coli    TEM-116 
a Site of sample drawing: M-Moscow City Clinic # 7, C-Central Russian Military Hospital, N- National 
Research Center for Pediatric Diseases, T- Tomsk City Hospital. b The isolates were phenotypically 
tested at the NRCA and the RBK. Displayed here are the phenotypes detected by disk diffusion at the 
RBK. c,d blaCTX-M and blaSHV genotypes were identified by DNA sequencing, + indicates a detected 
product in a PCR prescreening with CTX-M and SHV specific primers, which has not been identified 
by sequencing up to date (analysis was performed by the NRCA). e blaTEM genotypes were determined 
by the TEM microarray for all isolates, except isolate 39, 94 and 100. For these isolates and all others 
the genotypes were determined and/or confirmed by standard DNA sequencing.  
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3.2 Results SHV-array 
In order to establish a system, which was as reliable as and easily compatible with 
the already designed TEM microarray (53), an allele specific hybridization format was 
also chosen for the SHV microarray. In case of the SHV probe design, however, the 
traditional allele specific probe design proved to be not sufficient, so that an 
alternative strategy had to be devised.  
 
3.2.1 Probe design I 
In contrast to the probes designed for the TEM-array, the SHV-array probes were 
equipped with an 5’ aminomodified 13T spacer, which allowed a directed 
immobilization on the epoxy substrate and should improve the accessibility of the 
probes. Since these modified probes were considerably more expensive than the 
unmodified ones, a strategy was devised to minimize costs of the probe design 
process. After the theoretical probe design, the first tested probe set consisted only of 
the probe perfectly matching blaSHV-1 and the probe perfectly matching the mutant 
blaSHV-X. If these probes performed satisfyingly in hybridization experiments the two 
mismatch probes completing the SNP probe set (with either A, G, C or T at the 
central base position) were ordered. Allele specific hybridization probe sets were 
designed covering 39 of the 40 SHV mutation positions displayed in table 8. The 
deletion at amino acid position 50 was omitted from the probe design, because of a 
highly unfavorable probe secondary structure as determined by in silico data analysis 
(data not shown). Furthermore, the SHV beta-lactamases (SHV-9, -10) carrying a 
mutation at the respective position could also be identified via position 136. 
 
In table 9 the results of the probe design for the probes complementary for blaSHV-1 
and the mutant blaSHV-x are displayed. The probe length was between 15-25 bases 
and the Tm values varied from 50.1 - 60.9 °C and the GC content was between 42.1 
and 86.7 %. Probes with stable secondary structures should be excluded, because of 
non-optimal accessibility for the target DNA. The applied software default probe 
design parameters excluded probes with a hairpin ∆G value of less than - 3 kcal/mol 
and self dimer ∆G values of < - 6 kcal/mol. All probes met these criteria for the 
hairpin secondary structures with ∆G values between 0 and - 2.8 kcal/mol, except 
probes 191C, 191A with a hairpin ∆G value of - 3.4 kcal/mol. 
 
For probes 115A, 136WILDTYPE, 136MUTANT, 201G, 201T, 202G, 222C, 234/5SEg, 238C 
the calculated dimer ∆G results for the first probe versions, which were designed (see 
∆G values table 9) violated the predefined probe design parameter limits. The dimer 
forming bases were in all cases in close proximity to the mutation position and 
shifting of the mutation position within the probe sequence only led to even worse 
secondary structures in silico or/and resulted in loss of discriminatory power (data not 
shown). For example at position 262, the mutation was already shifted from the 
center to the 5’ end of probe version 1, since with a central SNP a highly stable 
hairpin structure could be formed in silico in addition to the already existing dimer 
(data not shown). However, since this array should include the relevant mutation 
positions for unequivocal identification of all naturally occurring SHV variants, these 
probe sequences could not be excluded and were also tested in hybridization 
experiments. 
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Table 8. SHV beta-lactamase polymorphism sites and corresponding mutants 
Nucleotide Amino acida SHV-X with the following phenotypeb 
Codon in: Amino acid in :  
Positionc blaSHV-1 blaSHV-X 
 
 
Ambler 
position 
 
Position SHV-1 SHV-X 
 
 
ESBL 
 
IRT 
 
not defined 
8 TAT TTT 7 3 Y F   28 
10 
10 
ATT 
ATT 
TTT 
GTT 
8 
8 
4 
4 
I 
I 
F 
V 
7,14, 18, 34  
 
  
36 
40 ACC GCC 18 14 T A   25, 37 
61 GCC TCC 25 21 A S   42 
92 CTA CAA 35 31 L Q 2a, 12, 13, 15 , 
29 
11, 25, 35, 36, 37, 
40 
115 CGC AGC 43 39 R S 7, 14, 18, 29, 
34 
 
130 GAA AAA 48 44 E K 15   
148-150 GGC - 54 50 G Del 9 10  
180 GAA GGA 64 60 E G 34   
226 GTG ATG 80 76 V M 15   
253 GAA AAA 89 85 E K 15   35 
325 CTT TTT 113 109 L F   43 
343 GTC ATC 119 115 V I 48   
352 CTC TTC 122 118 L F 21   
365 GCC GTC 126 122 A V   32 
373 ATG GTG 129 125 M V 25  37, 42 
376 AGC GGC 130 126 S G  10  
406-408 GCC CGG 140 136 A R 9 10  
412 GTC TTC 142 138 V F   41 
422 CCC CTC 145 141 P L   51 
425 GCA GTA 146 142 A V   38 
433 ACT TCT 149 145 T S   43 
455 GGC GAC 156 152 G D   27, 32, 45 
462 AAC AAG 158 154 N K 22   
474-475  TGA...AC 
insert 
167-168 163-164  DRWET 
insert 
  16 
505 CTT TTT 173 169 L F 19, 20, 21   
512 GGC GCC 175 171 G A   51 
523 GAC AAC 179 175 D N 8   
524 
524 
GAC 
GAC 
GCC 
GGC 
179 
179 
175 
175 
D 
D 
A 
G 
6 
24 
  
547 GCC ACC 187 183 A T 26,   50 
564 AAG AAC 192 188 K N 9,10   
565 CTG GTG 193 189 L V 9,10   
572 
572 
ACC 
ACC 
AAC 
ATC 
195 
195 
191 
191 
T 
T 
N 
I 
46 
 
  
53 
602 CGG  CTG 205 201 R L 3, 4,   44 
606 CAG CAT 206 202 Q H   50 
664 CCG TCG 226 222 P S   33 
700-705 GGCGAG/A AGCGAA/G 
 
238/240 234/235 GEg SE 
 
2, 2a, 3, 20, 21, 
30, 34, 39 
 
700-705 GGCGAG/A AGCAAA/G 238/240 234/235 GEg SK 
 
4, 5, 7, 9, 12, 
15, 22, 45, 46, 
47, 48 
10  
700-705 GGCGAG/A GCCGAA/G 238/240 234/235 GEg AE 
 
29, 13    
700-705 GGCGAG/A GCCAAA 238/240 234/235 GEg AK 18   
713 GCG GGG 243 238 A G   35, 40 
784 ACC/G TCC 267 262 T S 39   
816 CAA CAT 278 272 Q H   37 
aAmbler position, position of the polymorphism in the amino acid sequence of SHV 
(http://www.lahey.org/Studies/shvtable.asp) according to Ambler et al. (3); position, position of the 
mutation according to SHV amino acid sequence (GenBank accession number CAA66727). The 
amino acids in the SHV-1 sequence and the mutated SHV (SHV-X) sequence are also indicated.  
b The numbers in the table body are the SHV types with an amino acid substitution at the indicated 
position. The ESBL and IRT phenotypes are as described by Bradford (16). c Position refers to the 
position of the mutation in the nucleotide sequence of the blaSHV gene (GenBank accession number 
X98099, region: 74-934).  
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Table 9. Probe design I results for the SHV specific microarray 
Probe 
name 
Probe sequence (5‘-3‘) Length 
 
(nt) 
Tm 
 
(°C) 
GC 
 
(%) 
Hairpin  
∆G 
(kcal/mol) 
Hairpin 
bond 
(nt) 
Dimer  
∆G 
(kcal/mol) 
Dimer 
bond 
(nt) 
Run/ 
repeat 
length (nt) 
03A ATGCGTTATATTCGCCTGT 19 50.2 42.1 -2.8 3 -2.8 3 2 
03T ATGCGTTTTATTCGCCTGT 19 51.3 42.1 -2.8 3 -2.8 3 4 
04A ATGCGTTATATTCGCCTGT 19 50.2 42.1 -2.8 3 -2.8 3 2 
04T ATGCGTTATTTTCGCCTGT 19 51.3 42.1 -2.8 3 -2.8 3 4 
14A CTGTTAGCCACCCTGCCG 18 55.5 66.7 0.0 0 0.0 0 3 
14G CTGTTAGCCGCCCTGCCG 18 58.6 72.2 0.0 0 0.0 0 3 
21G CGGTACACGCCAGCCC 16 54.6 75.0 0.0 0 -1.9 4 3 
21T CGGTACACTCCAGCCC 16 50.4 68.8 0.0 0 -1.9 4 3 
31T AGCAAATTAAACTAAGCGAAAGCC 24 55.4 37.5 0.0 0 -1.0 4 3 
31A AGCAAATTAAACAAAGCGAAAGCC 24 56.4 37.5 0.0 0 -1.0 4 3 
39C TGTCGGGCCGCGTAGG 16 56.0 75.0 0.0 0 -5.1 4 3 
39A TGTCGGGCAGCGTAGG 16 53.0 68.8 0.0 0 0.0 0 3 
44G GTAGGCATGATAGAAATGGATCTGG 25 55.8 44.0 -0.6 3 -2.2 4 3 
44A GTAGGCATGATAAAAATGGATCTGG 25 54.8 40.0 -0.5 3 -2.2 4 5 
60A CGCCGATGAACGCTTTCC 18 54.9 61.1 -0.5 3 -0.5 3 3 
60G CGCCGATGGACGCTTTCC 18 56.8 66.7 -1.3 3 -1.3 3 3 
76G CGGCGCAGTGCTGGC 15 55.9 80.0 0.0 0 -5.1 4 2 
76A CGGCGCAATGCTGGC 15 53.7 73.3 0.0 0 -5.1 4 2 
85G GCCGGTGACGAACAGCT 17 54.8 64.7 0.0 0 -4.2 4 2 
85A GCCGGTGACAAACAGCT 17 52.6 58.8 0.0 0 -4.2 4 3 
109C CGAAAAACATCTTGCCGACG 20 54.3 50.0 0.0 0 0.0 0 5 
109T CGAAAAACATTTTGCCGACG 20 53.1 45.0 -1.2 4 -1.2 4 5 
115G GCATGACGGTCGGCGAA 17 55.4 64.7 0.0 0 -2.2 4 2 
115A GCATGACGATCGGCGAA 17 52.8 58.8 0.0 0 -6.5 6 2 
118C GTCGGCGAACTCTGCG 16 52.7 68.8 0.0 0 -1.7 3 2 
118T GTCGGCGAATTCTGCG 16 50.7 62.5 0.0 0 -4.1 6 2 
122C CGCCGCCGCCATTACC 16 56.0 75.0 0 0 0 0 2 
122T CGCCGCCGTCATTACC 16 52.7 68.8 0 0 0 0 2 
125A GCCATTACCATGAGCGATAAC 21 53.2 47.6 -0.5 3 -2.2 4 2 
125G GCCATTACCGTGAGCGATAAC 21 55.5 52.4 0 0 0 0 2 
126A CCATTACCATGAGCGATAACAGC 23 56.2 47.8 -0.5 3 -2.2 4 2 
126G CCATTACCATGGGCGATAACAGC 23 58.2 52.2 -2.4 4 -6.0 6 3 
136WT CTGCTACTGGCCACCGTCGG 20 60.9 70 0 0 -7.1 6 2 
136MT CTGCTACTCCGGACCGTCGG 20 60.1 70 -2.3 3 -6.8 6 2 
138G GGCCACCGTCGGCGG 15 57.4 86.7 -2.4 3 -4.3 4 2 
138T GGCCACCTTCGGCGG 15 54.2 80 -2.4 3 -4.3 4 2 
142C GCGGCCCCGCAGGAT 15 56.1 80 -2.8 3 -4.7 4 4 
142T GCGGCCTCGCAGGAT 15 53.0 73.3 -2.8 3 -4.3 4 2 
143C CGGCCCCGCAGGATTG 16 55.0 75.0 0 0 -4.3 4 4 
143T CGGCCCCGTAGGATTG 16 50.9 68.8 0 0 -4.3 4 4 
145A CAGGATTGACTGCCTTTTTGC 21 54.3 47.6 -1.2 3 -1.2 3 5 
145T CAGGATTGTCTGCCTTTTTGC 21 54.3 47.6 -1.2 3 -1.2 3 5 
152G CCAGATCGGCGACAACG 17 53.2 64.7 0 0 -1.9 4 2 
152A CCAGATCGACGACAACG 17 50.1 58.8 0 0 -3.0 4 2 
154C CGGCGACAACGTCACCC 17 56.1 70.6 -1.1 3 -3.3 4 3 
154A CGGCGACAAAGTCACCC 17 53.2 64.7 -1.1 3 -1.1 3 3 
163WT CTGGGAAACGGAACTGAATG 20 52.4 50 0 0 0 0 3 
163MT CTGGGAAACTGACCGCTGGG 20 58.7 65 0 0 0 0 3 
169C ATGAGGCGCTTCCCGG 16 53.4 68.8 0 0 -5.1 4 3 
169T ATGAGGCGTTTCCCGG 16 50.7 62.5 0 0 -4.2 4 3 
171G GCTTCCCGGCGACGC 15 55.2 80.0 0 0 -4.2 4 3 
171C GCTTCCCGCCGACGC 15 55.2 80.0 0 0 0 0 3 
175.1G CGCCCGCGACACCAC 15 55.1 80 0 0 -5.1 4 3 
175.1A CGCCCGCAACACCAC 15 52.7 73.3 0 0 0 0 3 
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Table 9. continued 
175.2A GCCCGCGACACCACT 15 53.2 73.3 0 0 -5.1 4 3 
175.2C GCCCGCGCCACCACT 15 56.8 80 0 0 -5.1 4 3 
183G CCAGCATGGCCGCGAC 16 55.9 75.0 -1.4 3 -5.1 4 2 
183A CCAGCATGACCGCGAC 16 52.6 68.8 0 0 -5.1 4 2 
188/9WT GCGCAAGCTGCTGACCA 17 55.9 64.7 -1.9 3 -5.1 4 2 
188/9MT GCGCAACGTGCTGACCA 17 56.3 64.7 -1.9 3 -5.1 4 2 
191C GCTGCTGACCAGCCAGC 17 56.0 70.6 -3.4 4 -3.4 4 2 
191A GCTGCTGAACAGCCAGC 17 53.9 64.7 -3.4 4 -3.4 4 2 
201G GTTCGCAACGGCAGCTG 17 54.8 64.7 -0.6 3 -6.3 6 2 
201T GTTCGCAACTGCAGCTG 17 52 58.8 -0.6 3 -6.3 6 2 
202G GCAACGGCAGCTGCTG 16 54.0 68.8 -1.9 3 -11.0 8 2 
202T GCAACGGCATCTGCTG 16 50.7 62.5 -1.9 3 -1.9 3 2 
222C CGTGCTGCCGGCGGG 15 58.2 86.7 0 0 -8.9 6 3 
222T CGTGCTGTCGGCGGG 15 54.8 80 0 0 0 0 3 
234/5GEg GGAGCTGGCGAGCGGG 16 57.2 81.2 -1.7 3 -2.9 4 3 
234/5SEg GGAGCTAGCGAGCGGG 16 53.7 75 -1.7 3 -6.2 6 3 
238C GGGTGCGCGCGGGAT 15 57.0 80 0 0 -9.8 6 3 
238G GGGTGGGCGCGGGAT 15 55.6 80 0 0 -5.1 4 3 
262A GGGATACCCCGGCGA 15 50.8 73.3 -1.9 3 -4.2 4 4 
262T GGGATTCCCCGGCGA 15 51.5 73.3 -1.9 3 -4.2 4 4 
272A AAATCAGCAAATCGCCGGG 19 54.6 52.6 0 0 -4.2 4 3 
272T AAATCAGCATATCGCCGGG 19 53.5 52.6 0 0 -4.2 4 3 
a For each polymorphism site one probe complementary to blaSHV-1 (upper line) and one probe 
complementary to the mutated blaSHV-X (lower line) are displayed. The probes are named for the 
position in the amino acid sequence of blaSHV and the nucleotide at the central base position (either A, 
G, C or T). The probe length, the melting temperature (Tm), GC content (GC%), free energy of hairpin 
bonds (hairpin ∆G), the number of bases forming the hairpin bond (hairpin bond), free energy of 
dimers (dimer ∆G), the number of bases forming the dimer bond (dimer bond) were calculated by 
ArrayDesigner 2.0 software.  
 
 
3.2.2 Probe performance analysis I 
In a hybridization experiment with blaSHV-1 and blaSHV-2 target DNA the probe 
performance of a subset of the probes designed in the first step was tested. It should 
be determined, if a specific perfect match identification was possible and how the 
predetermined probe secondary structures affected the perfect match discrimination. 
In theory, secondary structures of perfect match probes lead to a decreased 
accessibility of the probe for hybridization of the target. If, in addition to this, the 
mismatch probe has no or a less stable secondary structure, the better accessibility 
of this probe could lead to a compensation of the duplex destabilising effect of the 
mismatched central base, so that high mismatch signals can occur and the 
discrimination of a perfect match towards a mismatch is impaired. The results for the 
hybridization of the SNP specific probes with blaSHV-1 are displayed in figure 49.  
 
All perfect match positions could be correctly identified, except for the perfect match 
positions 171G and 222C, which corresponded to an unfavorable perfect match to 
mismatch dimer ∆G difference of - 4.2 or - 8.9 kcal/mol respectively. Apparently, the 
more stable secondary structure of the perfect match in comparison to the mismatch 
probe resulted in less binding of the target DNA. Although perfect match probes 
191C, 201G and 202G also contained highly stable secondary structures, the correct 
perfect match positions were detected. For probes 191 and 201 this result can be 
explained by the fact that both probes contained in case of the probe perfectly 
matching blaSHV-1 and the probe perfectly matching the mutant blaSHV-x the same 
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secondary structures, so both probes should be equally accessible. However, in case 
of probe 202G, which contained the most stable secondary structure of the whole 
SHV specific probe set with a ∆G value of - 11.0 kcal/mol resulting in a difference 
between perfect match and mismatch self dimer ∆G of - 9.1 kcal/mol, the correct 
perfect match could be identified and the discrimination was unexpectedly 
pronounced with an experimentally determined relative intensity of the mismatch of 
only 0.29.  
 
Probes 39, 125, 145 and 238 showed a weak discrimination capability of the 
mismatch relative intensities with values greater than 0.5. A disadvantageous perfect 
match probe in contrast to the mismatch probe secondary structure could be 
assigned to probes 39 (difference between perfect match and mismatch self dimer 
∆G = - 5.1 kcal/mol), 125 (- 2.2 kcal/mol) and 238 (- 4.7 kcal/mol). For probe 145 the 
weak discrimination was caused by the fact that the net signal intensity of the perfect 
match probe approached the saturation level of the detection system. For position 
234/5 the identification of the correct blaSHV-1 codons (GEg) was possible (relative 
intensity values see figure 50a), but for blaSHV-2 the relative intensity of the GEg probe 
was almost as high as the correct SEg perfect match (figure 50b). This corresponds 
to a dimer ∆G of - 6.2 kcal/mol for the SEg probe in contrast to a ∆G of only - 2.9 
kcal/mol for the GEg probe. The probes 115A and 126G, which also contained 
secondary structures violating the predefined ∆G limits, could not be evaluated, since 
the SHV beta-lactamases bearing a perfect match at these positions (blaSHV-48 and 
blaSHV--10 respectively) were not available for testing. 
 
In conclusion, probe 222 had to be redesigned to allow a correct identification of the 
perfect match. Probes 39, 125, 234/5, 238 and 145 should also be reviewed to 
enhance the discrimination efficiency. Probe 171 could be excluded, since SHV-51, 
the only SHV variant bearing a mutation at this position, could also be specifically 
identified via position 141. 
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Figure 49. (a) Mean net signal intensities and (b) mean relative signal intensities for each 
SNP position and corresponding probe (A, G, C and T refer to the base at the central 
position) from a hybridization experiment with 200 ng blaSHV-1 (NT/F = 48) (n = 9). Probe 
sets No. 14, 21, 31, 44, 85, 109, 118, 122, 126 and 138 consisted of 4 probes, all other 
probe sets consisted only of the probe perfectly matching blaSHV-1 and the probe perfectly 
matching the mutant blaSHV-x in this experiment. 
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Figure 50. Mean relative (rel.) signal intensities of probe 234/5 hybridized with 200 ng (a) 
blaSHV-1 (NT/F = 48), (n = 9) and (b) blaSHV-2 (NT/F = 51), (n = 9). 
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3.2.3 Probe design II 
In a first probe performance analysis it was determined that probes 39, 125, 222, 
234/5, 238, and 145 should be redesigned to allow a correct or enhanced perfect 
match identification. The capture probe 262 also showed an insufficient mismatch to 
perfect match discrimination capability (see figure 52), when the complete probe set 
was tested (in the first experiment only oligos 262A and 262T were tested). The 
calculated hairpin and dimer ∆G results for the first capture oligonucleotide versions 
of the complete probe sets are displayed in table 10. Since with the usual probe 
design options the disadvantageous secondary structures could not be avoided, a 
new probe design concept had to be developed. It was assumed, that through 
introduction of an additional mismatched base the secondary structure could be 
dissolved, while retaining enough hybridization capability to allow the mismatch to 
perfect match discrimination (see figure 51). In table 11 the redesigned probe 
sequences and parameters are displayed. The bases, which were exchanged from 
version I to version II are underlined in table 10 and 11. Furthermore, the positions 
and length were adjusted for optimal accessibility of the new oligonucleotides. In 
case of probes 234/5 and 262, through introduction of a mismatched base, the 
secondary structures could be considerably reduced or as in case of probe sets 222 
and 238 even annihilated as shown in the corresponding ∆G values displayed in 
table 11.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In case of probe 145 only the probe length was shortened to yield diminished 
fluorescence signal intensities. For probe 39 the probe design options were limited, 
because at least two bases flanking the polymorphism site formed in silico a very 
unfavorable dimer structure for the probe 39C. If one of the bases was replaced by a 
different nucleotide, one of the secondary structures was released, but an almost as 
stable secondary structure was formed involving the other base. However, it was 
highly improbable, that a probe with two additional mismatches retains enough 
hybridization capability to yield a satisfactory hybridization signal (this was 
experimentally confirmed, data not shown). Due to this the probe 39NEW with one 
mismatch and the least unfavorable ∆G values was chosen. Probe 125 was first 
Figure 51. An application example for the new probe design concept is displayed. 
Through introduction of a mismatched base unfavorable probe secondary structures, 
such as dimers or hairpins are avoided, resulting in a better probe accessibility for 
target hybridization. 
5‘ 3‘
3‘ 5‘
5‘ 3‘
3‘ 5‘
position of polymorphism
position of artificial mismatch
introduction of artificial mismatch
strong secondary structure
weak secondary structure
GGGGTGCGTGCGGGAT
GGGGTGCGCGCGGGAT
TAGGGCGTGCGTGGGG
TAGGGCGCGCGTGGGG
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redesigned retaining the probe sequence position and length of probe version I and 
introducing the mismatched base at the marked position. This led to a considerable 
reduction of the probe secondary structure of probe 125A, but the fluorescence 
signal determined in a hybridization experiment (data not shown) was not sufficiently 
above background level. Although an elongation of the probe sequence (see  
version II in table 11) led to more stable secondary structures in the whole probe set  
(∆G = -2.8 kcal/mol), as displayed in table 11, this was the only option to gain enough 
fluorescence signal intensity for a sensitive data analysis (see probe performance 
analysis II). 
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Table 10. Probe version Ia 
Probe 
name 
Probe sequence (5‘-3‘) Length 
 
 
(nt) 
Tm 
 
 
(°C) 
GC 
 
 
(%) 
Hairpin  
∆G 
 
(kcal/mol)
Hairpin 
bond 
 
(nt) 
Dimer  
∆G 
 
(kcal/mol) 
Dimer 
bond 
 
(nt) 
Run/ 
repeat 
length 
(nt) 
39A TGTCGGGCAGCGTAGG 16 53.0 68.8 0 0 0 0 3 
39G TGTCGGGCGGCGTAGG 16 56 75 0 0 0 0 3 
39C TGTCGGGCCGCGTAGG 16 56.0 75.0 0 0 -5.1 4 3 
39T TGTCGGGCTGCGTAGG 16 53 68.8 0 0 0 0 3 
          
125A GCCATTACCATGAGCGATAAC 21 53.2 47.6 -0.5 3 -2.2 4 2 
125G GCCATTACCGTGAGCGATAAC 21 55.5 52.4 0 0 0 0 2 
125C GCCATTACCCTGAGCGATAAC 21 54.8 52.4 0 0 0 0 3 
125T GCCATTACCTTGAGCGATAAC 21 53.1 47.6 0 0 0 0 2 
          
145A CAGGATTGACTGCCTTTTTGC 21 54.3 47.6 -1.2 3 -1.2 3 5 
145G CAGGATTGGCTGCCTTTTTGC 21 56.9 52.4 0 0 -2.4 3 5 
145C CAGGATTGCCTGCCTTTTTGC 21 56.9 52.4 0 0 0 0 5 
145T CAGGATTGTCTGCCTTTTTGC 21 54.3 47.6 -1.2 3 -1.2 3 5 
          
222A CGTGCTGACGGCGGG 15 54.8 80 0 0 0 0 3 
222G CGTGCTGGCGGCGGG 15 58.2 86.7 0 0 0 0 3 
222C CGTGCTGCCGGCGGG 15 58.2 86.7 0 0 -8.9 6 3 
222T CGTGCTGTCGGCGGG 15 54.8 80 0 0 0 0 3 
          
234/5GEa GGAGCTGGCGAACGGG 16 54.6 75 0 0 -2.9 4 3 
234/5GEg GGAGCTGGCGAGCGGG 16 57.2 81.2 -1.7 3 -2.9 4 3 
234/5SEa GGAGCTAGCGAACGGG 16 51.1 68.8 0 0 -6.2 6 3 
234/5SEg GGAGCTAGCGAGCGGG 16 53.7 75 -1.7 3 -6.2 6 3 
234/5SKa GGAGCTAGCAAACGGG 16 48.7 62.5 0 0 -6.2 6 3 
234/5SKg GGAGCTAGCAAGCGGG 16 51.3 68.8 -1.7 3 -6.2 6 3 
234/5AEa GGAGCTGCCGAACGGG 16 54.6 75 0 0 -2.9 4 3 
234/5AEg GGAGCTGCCGAGCGGG 16 57.2 81.2 -1.7 3 -2.9 4 3 
234/5AK GGAGCTGCCAAACGGG 16 52.3 68.8 0 0 -2.9 4 3 
          
238A GGGGTGAGCGCGGGAT 16 56 75 0 0 -5.1 4 4 
238G GGGGTGGGCGCGGGAT 16 58.9 81.2 0 0 -5.1 4 4 
238T GGGGTGTGCGCGGGAT 16 56.7 75 0 0 -5.1 4 4 
238C GGGGTGCGCGCGGGAT 16 60.1 81.2 0 0 -9.8 6 4 
          
262A GGGATACCCCGGCGA 15 50.8 73.3 -1.9 3 -4.2 4 4 
262G GGGATGCCCCGGCGA 15 55.2 80 -1.9 3 -4.2 4 4 
262C GGGATCCCCCGGCGA 15 53.9 80 -1.9 3 -9.5 8 5 
262T GGGATTCCCCGGCGA 15 51.5 73.3 -1.9 3 -4.2 4 4 
a Probe secondary structure ∆G values, length, and sequences of oligonucleotide probes version I of 
probe 39, 125, 145, 222, 234/5, 238 and 262. The probe length, the melting temperature (Tm), GC 
content (GC), free energy of hairpin bonds (hairpin ∆G), the number of bases forming the hairpin bond 
(hairpin bond), free energy of dimers (dimer ∆G), the number of bases forming the dimer bond (dimer 
bond) were calculated by ArrayDesigner 2 software.  
b The exchanged nucleotide from probe version I to II (see table 11) is underlined. In probe 145 no 
nucleotide was exchanged, only the probe length was adjusted. 
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Table 11. Probe version IIa 
Probe 
name 
Probe sequence (5‘-3‘) Length
 
 
(nt) 
Tm 
 
 
(°C) 
GC 
 
 
(%) 
Hairpin  
∆G 
 
(kcal/mol) 
Hairpin 
bond 
 
(nt) 
Dimer  
∆G 
 
(kcal/mol) 
Dimer 
bond 
 
(nt) 
Run/ 
repeat 
length  
(nt) 
39ANEW TGTCGGGCAGCTTAGG 16 49.9 62.5 0 0 -2.9 4 3 
39GNEW TGTCGGGCGGCTTAGG 16 53 68.8 0 0 0 0 3 
39CNEW TGTCGGGCCGCTTAGG 16 53 68.8 0 0 -4.3 4 3 
39TNEW TGTCGGGCTGCTTAGG 16 49.9 62.5 0 0 0 0 3 
          
125ANEW CCGCCATTACCATTAGCGATAACAG 25 58.8 48 -2.8 3 -2.8 3 2 
125GNEW CCGCCATTACCGTTAGCGATAACAG 25 60.7 52 -2.8 3 -2.8 3 2 
125CNEW CCGCCATTACCCTTAGCGATAACAG 25 60.2 52 -2.8 3 -2.8 3 3 
125TNEW CCGCCATTACCTTTAGCGATAACAG 25 58.8 48 -2.8 3 -2.8 3 3 
          
145ANEW AGGATTGACTGCCTTT 16 43.1 43.8 0 0 0 0 3 
145GNEW AGGATTGGCTGCCTTT 16 46.6 50 0 0 -2.4 3 3 
145CNEW AGGATTGCCTGCCTTT 16 46.6 50 0 0 0 0 3 
145TNEW AGGATTGTCTGCCTTT 16 43.1 43.8 0 0 0 0 3 
          
222ANEW CCGTGCTGACTGCG 14 47.9 71.4 0 0 0 0 2 
222GNEW CCGTGCTGGCTGCG 14 51.5 78.6 0 0 0 0 2 
222CNEW CCGTGCTGCCTGCG 14 51.5 78.6 0 0 0 0 2 
222TNEW CCGTGCTGTCTGCG 14 47.9 71.4 0 0 0 0 2 
          
234/5GEaNEW GGAGCTGGTGAACGG 15 47.4 66.7 0 0 -2.9 4 2 
234/5GEgNEW GGAGCTGGTGAGCGG 15 50.2 73.3 -1.7 3 -2.9 4 2 
234/5SEaNEW GGAGCTAGTGAACGG 15 43.6 60 0 0 -2.9 4 2 
234/5SEgNEW GGAGCTAGTGAGCGG 15 46.4 66.7 -1.7 3 -2.9 4 2 
234/5SKaNEW GGAGCTAGTAAACGG 15 40.4 53.3 0 0 -2.9 4 3 
234/5SKgNEW GGAGCTAGTAAGCGG 15 43.3 60 -1.7 3 -2.9 4 2 
234/5AEaNEW GGAGCTGCTGAACGG 15 48 66.7 0 0 -2.9 4 2 
234/5AEgNEW GGAGCTGCTGAGCGG 15 50.8 73.3 -1.7 3 -2.9 4 2 
234/5AKNEW GGAGCTGCTAAACGG 15 44.8 60 0 0 -2.9 4 3 
          
238ANEW CGGGGTGAGTGCGGG 15 53.3 80 0 0 0 0 4 
238GNEW CGGGGTGGGTGCGGG 15 56.4 86.7 0 0 0 0 4 
238CNEW CGGGGTGCGTGCGGG 15 57.7 86.7 0 0 0 0 4 
238TNEW CGGGGTGTGTGCGGG 15 54.1 80 0 0 0 0 4 
          
262ANEW CTGCGTGATACCCCG 15 47.3 66.7 0 0 0 0 4 
262GNEW CTGCGTGATGCCCCG 15 51.6 73.3 0 0 0 0 4 
262CNEW CTGCGTGATCCCCCG 15 50.4 73.3 0 0 -1.9 4 5 
262TNEW CTGCGTGATTCCCCG 15 48.1 66.7 0 0 0 0 4 
a Probe secondary structure ∆G values, length, and sequences of oligonucleotide probes version II of 
probe 39, 125, 145, 222, 234/5, 238 and 262. The probe length, the melting temperature (Tm), GC 
content (GC), free energy of hairpin bonds (hairpin ∆G), the number of bases forming the hairpin bond 
(hairpin bond), free energy of dimers (dimer ∆G), the number of bases forming the dimer bond (dimer 
bond) were calculated by ArrayDesigner 2.0 software.  
b The exchanged nucleotide from probe version I to II (see table 10) is underlined. In probe 145NEW no 
nucleotide was exchanged, only the probe length was adjusted. 
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3.2.4 Probe performance analysis II 
The newly designed probe sets were compared with the former probe version in a 
hybridization experiment with 200 ng target DNA representing blaSHV-1, blaSHV-2 or 
blaSHV-4 genotypes. The net and relative intensities of probe versions I (e.g. probe 39) 
and version II (e.g. probe 39NEW) are displayed in figure 52 as relative and net 
intensities. In case of probe sets 222 and 262 only probe version II (222NEW and 
262NEW) allowed the identification of the correct perfect match positions (see figure 
52c and e). For probe set 238NEW, the discrimination of the perfect match from a 
mismatch was visibly enhanced with a reduction of the relative intensities of the 
mismatches from app. 0.7 in probe version I to values < 0.1 in probe version II. The 
net signal intensities of the probe version II were as expected for the majority of these 
probe sets considerably reduced (up to six times) compared to probe version I, but 
remained at a sufficient level (> 1000 arbitrary units) for a sensitive data analysis. 
These probes were included in the SHV-array instead of the former probe versions 
and were furtheron designated as probes 222, 238 and 262. 
 
The perfect match net probe signal intensity of probe 39NEW (figure 52a) was 
considerably reduced and approached the background level. The resulting relative 
intensities of probe 39NEW showed a low reproducibility and were not reliable for 
perfect match identification, so it could not be used for the SHV-specific microarray 
(figure 52b). The relative intensities of probe version I of probe 39 produced a higher 
mismatch fluorescence signal for probe 39T in comparison to the correct blaSHV-1 
perfect match position 39C. However the 39C perfect match of blaSHV-1 can be 
identified correctly, when compared to the relative intensity of probe 39A, which is the 
perfect match for the mutant blaSHV-x. Since all other probe design attempts produced 
no promising alternative, as explained above, a different data analysis strategy was 
devised. For a more comprehensive perfect match identification, in this case the four 
probe concept per single nucleotide polymorphism was skipped and only probe 39C 
(alias 39WILDTYPE) in comparison to 39A (alias 39MUTANT) was furtheron considered 
(see proof of concept). Thus a specific identification of the mutant blaSHV-X or blaSHV-1 
was possible (see section 3.2.6).  
 
The relative intensities of the mismatches of probe 125G in contrast to probe 
125GNEW was reduced about 0.2, but the redesign resulted also in an about 30 % 
reduced net signal intensity (see figure 52). The discrimination was also in probe set 
version I more specific than determined in the first experiment (relative intensity of 
the mismatch =0.53) with a value of 0.42. This was attributed to the fact that in this 
experiment the complete probe sets 125 and 125NEW were spotted in contrast to the 
first one where only probes 125A and G were spotted, so that more probes were 
competing within one reaction for the same target DNA region.  
The perfect match net signal intensity of probe 145NEW was reduced to 30 % of the 
perfect match net signal intensity of probe 145 (see figure 52). The perfect match 
discrimination of probe 145A towards probe 145T could be advanced, but as in case 
of probe 125 the discrimination of probe set version I was more specific in this 
experiment with a maximum relative intensity of the mismatches of 0.32 compared to 
0.55 as determined in the first experiment. In this case this could be attributed to the 
decreased amplitude of the perfect match net signal intensity (which was here not in 
the range of the saturation level) and the aforementioned increased competition for 
the target DNA. Probes 125NEW and 145NEW were included because of their increased 
discrimination potential in the SHV-specific microarray and furtheron designated as 
probes 125 and 145. 
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The results of the probe performance analysis of probe 234/5 are displayed in figure 
53a for hybridization with blaSHV-1 target DNA, in figure 53b for hybridization with 
blaSHV-2 target DNA and in figure 53c for hybridization with blaSHV-4 target DNA. With 
probe version I the identification of the correct blaSHV-1 codons (GEg) was possible, 
but for blaSHV-2 (SEg) and blaSHV-4 (SKg) the relative intensity of the GEg probe was 
as high or even higher as the correct perfect match. This corresponded to a more 
stable dimer structure with a ∆G of - 6.2 kcal/mol for the SEg or SKg probe in 
contrast to a less stable dimer structure with a ∆G of only - 2.9 kcal/mol of the GEg 
probe. In contrast, probe version II of probe set 234/5 allowed a highly specific 
identification of each correct perfect match due to minimized secondary structures. 
The perfect match net signal intensities were diminished due to the additional 
mismatched base, but remained at a sufficient level of at least ten times above 
background net signal intensity. Therefore, probes 234/5NEW were included in the 
SHV microarray and were furtheron designated as probe set 234/5. The complete 
probe set of the SHV specific microarray resulting from the probe design and probe 
performance analysis is displayed in table 12 and was applied in all following SHV-
array analyses. 
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Figure 52. Mean net intensities (right chart) and mean relative intensities (left chart) of probe version I 
(e.g. 39) and version II (e.g. 39N for 39NEW) are displayed. Results of a hybridization with 200 ng  
blaSHV-1 (NT/F = 48) with (a) probe set 39, (b) 125, (c) 222, (d) 238, (e) 262, (f) 145 are shown (n = 9). 
probe set number probe set number 
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Figure 53. Mean net (left chart) and mean relative (right chart) signal intensities of probe 
versions I (234/5) and version II (234/5N for 234/5NEW) hybridized with (a) blaSHV-1 (NT/F = 48), 
(b) blaSHV-2 (NT/F = 51) and (c) blaSHV-4 (NT/F = 85) are displayed (n = 9).  
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Table 12. Oligonucleotide probe sequences used in the SHV-specific microarraya 
Melting temp (°C) Length (bases) Name Probe sequence (5’-3’)b 
50.2 19 3 ATGCGTTNTATTCGCCTGT 
50.2 19 4 ATGCGTTATNTTCGCCTGT 
55.5 18 14 CTGTTAGCCNCCCTGCCG 
54.6 16 21 CGGTACACNCCAGCCC 
55.4 24 31 AGCAAATTAAACNAAGCGAAAGCC 
56.0 16 39 TGTCGGGCNGCGTAGG 
55.8 25 44 GTAGGCATGATANAAATGGATCTGG 
54.9 18 60 CGCCGATGNACGCTTTCC 
55.9 15 76 CGGCGCANTGCTGGC 
54.8 17 85 GCCGGTGACNAACAGCT 
54.3 21 109 TCGAAAAACACNTTGCCGACG 
55.4 17 115 GCATGACGNTCGGCGAA 
52.7 16 118 GTCGGCGAANTCTGCG 
56.0 16 122 CGCCGCCGNCATTACC 
58.8 25 125 CCGCCATTACCNTTAGCGATAACAG 
56.2 23 126 CCATTACCATGNGCGATAACAGC 
60.9 
60.1 
20 
20 
136WILDTYPE 
136MUTANT 
CTGCTACTGGCCACCGTCGG 
CTGCTACTCCGGACCGTCGG 
57.4 15 138 GGCCACCNTCGGCGG 
56.1 15 141 GCGGCCNCGCAGGAT 
55.0 16 142 CGGCCCCGNAGGATTG 
43.1 16 145 AGGATTGNCTGCCTTT 
53.2 17 152 CCAGATCGNCGACAACG 
56.1 17 154 CGGCGACAANGTCACCC 
52.4 
58.7 
20 
20 
163WILDTYPE 
163MUTANT 
CTGGGAAACGGAACTGAATG 
CTGGGAAACTGACCGCTGGG 
53.4 16 169 ATGAGGCGNTTCCCGG 
55.1 15 175.1 CGCCCGCNACACCAC 
53.2 15 175.2 GCCCGCGNCACCACT 
55.9 16 183 CCAGCATGNCCGCGAC 
55.9 
56.3 
17 
17 
188/9WILDTYPE 
188/9MUTANT 
GCGCAAGCTGCTGACCA 
GCGCAACGTGCTGACCA 
56.0 16 191 GCTGCTGANCAGCCAGC 
54.8 17 201 GTTCGCAACNGCAGCTG 
54.0 16 202 GCAACGGCANCTGCTG 
51.5 14 222 CCGTGCTGNCTGCG 
50.2 
47.4 
43.6 
46.4 
40.4 
43.3 
48.0 
50.8 
44.8 
15 
15 
15 
15 
15 
15 
15 
15 
15 
234/5 GEg 
234/5 GEa 
234/5 SEa 
234/5 SEg 
234/5 SKa 
234/5 SKg 
234/5 AEa 
234/5 AEg 
234/5 AK 
GGAGCTGGTGAGCGG 
GGAGCTGGTGAACGG 
GGAGCTAGTGAACGG 
GGAGCTAGTGAGCGG 
GGAGCTAGTAAACGG 
GGAGCTAGTAAGCGG 
GGAGCTGCTGAACGG 
GGAGCTGCTGAGCGG 
GGAGCTGCTAAACGG 
57.7 15 238 CGGGGTGNGTGCGGG 
47.3 15 262 CTGCGTGATNCCCCG 
54.6 19 272 AAATCAGCANATCGCCGGG 
54.9 21 process control TTTAAAGTAGTGCTCTGCGGC 
46.0 18 negative hybridization control TCTAGACAGCCACTCATA 
53.1 19 positive hybridization control GATTGGACGAGTCAGGAGC 
46.0 18 spot control TCTAGACAGCCACTCATA-Cy3 
a For the SNP specific probes, four probes for each SNP position were used. The 
probes are named for the position in the amino acid sequence of blaSHV. The four 
probes had either A, G, C or T at the central base position (designated N in the probe 
sequence). The probe length and the melting temperatures calculated for the probes 
matching the blaSHV-1 sequence by ArrayDesigner 2.0 software are also provided. The 
probes 234/5 are designated by the targeted amino acids at position 234/5 (GE, SE, 
SK, AE, AK) and the nucleotide at the third codon position for amino acid 235 (e.g. 
GEa or GEg). For probes where more than one neighboring nucleotide differs in the 
mutant sequence from the wildtype sequence, one probe (136WILDTYPE, 188/9WILDTYPE, 
163WILDTYPE) matching the wildtype sequence (blaSHV-1) and one probe (136MUTANT, 
188/9MUTANT, 163MUTANT) matching the mutant sequence blaSHV-x were designed.  
bThe triplet with the amino acid substitution is underlined. All probes carried a 13T 
spacer and a C6- aminomodification at the 3’end. 
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3.2.5 Proof of concept 
As a proof of concept it was shown, that all perfect match positions could be 
identified for a hybridization with 200 ng blaSHV-1 target DNA, which was derived from 
a laboratory culture of E. coli DH5α bearing a pCCR9 plasmid. The target DNA with a 
incorporation ratio (NT/F) of 55 was hybridized for one hour under medium agitation 
in a hybridization station (see figure 54) . It was the aim to assess the specificity and 
the reproducibility of the perfect match detection of the SHV-array under standard 
conditions. All perfect match positions for blaSHV-1 were correctly identified. The 
absolute net signal intensities ranged from 2400 to 46000 for the probes with perfect 
matches (displayed in figure 55 a,c,e). The relative intensities were calculated to 
investigate the discriminatory power of the system. The mean relative intensities and 
standard deviations for all mutation positions are shown in figure 55 b,d,f. Up to 97 % 
of the relative intensities of the mismatches remained < 0.5, more than 92 % of the 
mismatch signal intensities remained even below 10 % of the perfect match signal 
intensities (see figure 56). The highest relative intensity of a mismatch was detected 
for probe 39MUTANT with 0.67. The standard deviations for the mean relative intensities 
of the mismatches ranged from 0 to 0.17. 
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Figure 54. On the left, the layout of the mutation capture probes of the SHV microarray is displayed. 
All mutation specific capture probes were spotted in triplicates. The mutation position is indicated 
above each triplicate. For the SNP specific probes the nucleotide at the central base is indicated on 
the left side of each row as A, G, C or T. For probe No 234/5 the probes are designated by the 
targeted amino acids at position 234/5 (GE, SE, SK, AE, AK) and the nucleotide at the third codon 
position for amino acid 235 (GEa or GEg) as indicated in the legend. For position 136, 188/9, 163 one 
probe triplet (WT) matching the wild type sequence (blaSHV-1) and one probe triplet (MT) matching the 
mutant sequence (blaSHV-x) are spotted. Negative and positive hybridization controls are indicated as 
neg. hyb. and pos. hyb. controls respectively. On the right the fluorescence image of a hybridization 
experiment with 200 ng target DNA blaSHV-1 (NT/F = 55) for 1 h in an HS 400 hybridization station is 
shown. The signal intensity is shown in false color. Blue corresponds to the lowest signal intensity and 
red to white depict the highest signal intensities. 
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Figure 55. Mean net signal intensities (a) and mean relative signal intensities (b) for each SNP position 
and corresponding probe (A, G, C and T refer to the base at the central position) from a hybridization 
experiment with 200 ng blaSHV –1 (NT/F = 55) (n = 9). Mean net signal intensities (c) and mean relative 
signal intensities (d) for mutation position and corresponding probe No. 39, 136, 188/9, 163 WT 
matching the wildtype sequence (blaSHV-1) and MT matching the mutant sequence (blaSHV-x). Mean net 
signal intensities (e) and mean relative signal intensities (f) for mutation position and corresponding 
probe 234/5 designated by the targeted amino acids at position 234/5 (GE, SE, SK, AE, AK) and the 
nucleotide at the third codon position for amino acid 235 (GEa or GEg).  
Results  
  107
 
 
(a) (b)
0
10
20
30
40
50
60
70
80
90
<0.05 <0.1 <0.2 <0.3 <0.4 <0.5 <0.6 <0.7 <0.8 <0.9 <1 >1.00
standard error RIMM=MM/PM
 m
is
m
at
ch
 p
ro
be
s 
%
0
5
10
15
20
25
30
35
40
45
50
<0.1 <0.2 <0.3 <0.4 <0.5 <0.6 <0.7 <0.8 <0.9 <1 >1
 RIMM=MM/PM
m
is
m
at
ch
 p
ro
be
s 
%
 
Figure 56. (a) Percentage of mismatch probes depending on the MM/PM ratio (b) Percentage 
of mismatch probes depending on the standard error of the MM/PM ratio from a hybridization 
experiment with 200 ng blaSHV-1 (NT/F = 55), (n = 9). 
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3.2.6 Identification of SHV variants 
The performance of the array was tested with a set of genetically and phenotypically 
well characterized SHV gene variants (131). More precisely the investigated SHV 
variants were SHV-1, -2, -3, -4, -5, -7 and -8. The results of the hybridization of 
blaSHV-1, blaSHV-2, blaSHV-3, blaSHV-4 , blaSHV-5, blaSHV-7 and blaSHV-8 are given as 
fluorescence images in figure 58. The resulting relative intensity values are displayed 
in figure 59. Only the mutation positions, which varied in comparison to blaSHV-1 are 
shown. All correct perfect matches were identified without ambiguity. The relative 
intensity of the mismatches remained for 97 % of the mismatch positions below a 
limit of 0.5. Only 3 % of the relative intensities of the mismatches ranged from 0.4 to 
0.7 (see figure 57). Two times the value of 0.7 was exceeded by probe 39MUTANT with 
values up to 0.79 for the identification of blaSHV-2 and blaSHV-4. This was due to the 
aforementioned unfavorable secondary structure of the 39WILDTYPE probe. However, a 
reliable differentiation between a mutated and wildtype variant at this position was 
still possible, since as shown for the identification of blaSHV-7, the detection of a 
mutated position 39 in the target was highly specific with a relative intensity of the 
39WILDTYPE probe of only 0.02 (see figure 59f). The standard deviations of the mean 
relative intensities of the mismatches varied from 0 to 0.33, but 93 % of the values 
remained below 10 % of perfect match intensity (see figure 57).  
 
Probe sets with probe net signal intensities below background level were excluded 
from the data analysis. This was the case for probe set 262: probe 262A was 
perfectly complementary to the blaSHV-1 codon (ACC) and probe 262T was perfectly 
complementary to the codon of blaSHV-39 (TCC). A probe perfectly complementary to a 
silent mutation ACG present for example in blaSHV-2, -3, -4, -5, -7, -8 was so far not 
included in this probe set. Therefore, the perfect match position of probe 262 could 
only be identified for blaSHV-1 (data not shown), since the probe net signal intensities 
for the other not perfectly complementary variants were not above background level. 
Variants blaSHV-3 and blaSHV-4 carry a mutation at position 201. The neighboring probe 
202 does therefore not perfectly match those variants and thus, the net signal 
intensities were not above background level and were also excluded from the 
calculation of the relative intensities. However, all the directly targeted positions were 
detected and allowed an unequivocal identification of each tested SHV variant.  
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Figure 57. (a) Percentage of mismatch probes depending on the MM/PM ratio, (b) percentage of 
mismatch probes depending on the standard error of the MM/PM ratio from a hybridization 
experiment with 200 ng of each blaSHV-1, blaSHV-2, blaSHV-3, blaSHV-4, blaSHV-5, blaSHV-7 and blaSHV-8 
(n = 9). 
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Figure 58. Fluorescence images of selected SHV arrays hybridized with target DNA originating from 
different variants from diverse reference strains. The SNP positions varying towards blaSHV-1 (4, 39, 
175.1, 201, 234/5) are highlighted. The identified variants were (a) blaSHV-1, (b) blaSHV-2 , (c) blaSHV-3, 
(d) blaSHV-4, (e) blaSHV-5, (f) blaSHV-7 and (g) blaSHV-8 as indicated in the right corner of the fluorescence 
images. The signal intensity is shown in false color. Blue corresponds to the lowest signal intensity, red 
to white depict the highest signal intensities (as output by ImaGene 3.0). In (h) the SNP capture probe 
layout of the SHV microarray is displayed (for details see also figure 49). 
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Figure 59. Relative (rel.) intensities of the signals for selected mutation positions according to 
the target DNA applied. Only the mutation positions (4, 39, 175.1, 201, and 234/5) differing 
between the tested variants: (a) blaSHV-1, (b) blaSHV-2, (c) blaSHV-3, (d) blaSHV-4, (e) blaSHV-5, 
(f) blaSHV-7  and (g) blaSHV-8  are displayed (n = 9). For the SNP specific probes, the probe sets 
are indicated in the legend by their central base (A, G, C or T), for mutation position 39WILDTYPE 
(39WT) is indicated in the legend for the probe matching the wildtype sequence (blaSHV-1) and 
39MUTANT (39MT) for the probe matching the mutant sequence (blaSHV-X). For probe 234/5 the 
probe set is designated by the targeted amino acids at position 234/5 (GE, SE, SK, AE, AK) 
and the nucleotide at the third codon position for amino acid 235 (GEa or GEg). 
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3.3 Validation of the SHV- and TEM-array with clinical isolates collected in 
Croatia  
To validate the TEM and SHV-array a set of 35 isolates, as displayed in table 13, 
collected during 02/2001-10/2003 at the Zadar Hospital in Zadar, Croatia was 
provided by Dr. Susa (Department of Clinical Microbiology, Robert-Bosch Hospital, 
Stuttgart). These isolates were classified as possible ESBL producers through a 
standard phenotypic screening carried out at the Zadar Hospital. An additional 
phenotypic ESBL screening and species identification was performed at the Robert 
Bosch hospital using the MicroScan system (an automated microdilution test). The 
identified isolates species included 22 K. pneumoniae, 10 E. coli, one K. 
ornithinolytica, one K. terrigena and one K. oxytoca. By analyzing the antibiogram, 28 
of the isolates were classified as ESBL producers. A reference antibiogram for 
identification of ESBL, AmpC, K1 (only for K. oxytoca) and CTX-M according to 
Livermore et al.  (97) is given at the bottom of table 13. For isolates 13, 21 and 32 the 
results did not indicate an ESBL phenotype and an ESBL confirmatory test did 
support these results. For isolate 36 no phenotype clearly matching the 
aforementioned ones was detected, since it was tested as being resistant to cefoxitin, 
excluding an ESBL phenotype as ESBLs are susceptible to cephamycins. It also 
appeared to be susceptible to several cephalosporins, thereby contradicting an 
AmpC resistance type, so that no clear classification was possible. The antibiogram 
of isolate 20 matched an AmpC resistance type, since it was resistant to the tested 
cephalosporins and cefoxitin, however this does not exclude an ESBL, since this 
phenotype might be masked by the dominant AmpC phenotype. The  
K. ornithinolytica isolate 2 matched a CTX-M resistant phenotype according to 
Livermore, because of the susceptibility to ceftazidime (at a concentration of 8 
µg/ml), while being resistant to all other cephalosporins except cefoxitin. The 
antibiogram and the identified species (K. oxytoca) of isolate 26 matched the 
guidelines for identification of a K1 type resistance.  
 
3.3.1 TEM-array 
The plasmidic DNA 
extracted from the isolates 
was used in PCR labeling 
reactions as a template. For 
all samples a PCR product 
with TEM specific primers 
could be obtained 
corresponding to the correct 
blaTEM amplicon size of  
861 bp. With all generated 
PCR products an array 
analysis was performed. The 
hybridizations were carried 
out in triplicates for the TEM-
array analysis. The identified 
blaTEM - genes are displayed 
in table 14. Eight isolates 
contained a blaTEM-1 gene, in 
all others blaTEM-116 genes 
were detected. The differing 
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Figure 60. Representative identification of (a) blaTEM-1 in 
isolate No. 3 and (b) blaTEM-116 in isolate No. 5 from 
clinical isolates collected in Croatia. Only the relative 
intensities (RIs) of SNP positions (82, 182) differing 
between blaTEM-1 and blaTEM-116 are displayed. The probe 
sets are indicated by their central base (A, G, C, T) in the 
legend (n = 9). 
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polymorphism positions are displayed for 
isolates 3 (TEM-1) and 5 (TEM-116) as 
relative intensity values in figure 60. All 
correct TEM perfect match positions could 
be identified for 34 of the 35 isolates. Only in 
isolate 21 the probe set 235.2 had to be 
excluded from the analysis due to a spotting 
failure. Over 99 % of the analyzed perfect 
match positions could be unambiguously 
identified, since their relative intensities of 
the mismatches remained below a limit of 
0.8 (see figure 61a). Only for 0.16 % of the 
analyzed values this limit was violated with 
relative intensities of the mismatches up to 
0.88, which was attributed to sporadic 
aberrations during the spotting process. The 
standard deviations of the mean relative 
intensities of the mismatches varied from 0 
to 0.38, whereby 78 % remained below 10 % 
of the perfect match intensity (see figure 
61b). Usually about 90 % of the standard 
deviations of the mean relative intensities of 
the mismatches remained below this limit, 
but in this case two slide batches with 
differing production parameters were used 
(new spotting pins and a new microtiterplate 
as probe source had to be applied). Since 
the standard deviations still remained within 
a range of 0 - 0.4, the results were 
considered reliable enough for a significant 
analysis.  
 
 
 
3.3.2 SHV-array 
Except for isolates 2, 21, 26, 27 and 36 a SHV amplicon with an expected amplicon 
size of 932 bp could be obtained for each isolate. All hybridizations were carried out 
in duplicates for the SHV-array analysis. The SHV-variants could be identified 
successfully by the SHV microarray analysis for 29 of the 30 SHV-amplicons. For two 
isolates a blaSHV-1 gene, for six isolates a blaSHV-5 gene, for one isolates a blaSHV-12 
gene was detected. In the other isolates the coexistence of two blaSHV variants was 
detected, four times blaSHV-1 and blaSHV-12, 16 times blaSHV-1 and blaSHV-5 (see table 
14). Exemplary hybridization results of detected SHV-variants are displayed in figure 
62 as fluorescence images. The differing polymorphism positions are displayed for 
each detected genotype: blaSHV-1 (e.g. isolate 32), blaSHV-5 (e.g. isolate 23), blaSHV-12 
(e.g. isolate 3), blaSHV-1 and blaSHV-5 (e.g. isolate 1) and blaSHV-1 and blaSHV-12 (e.g. 
isolate 11 or 20) as relative intensity (for position 31) and net intensity (for position 
234/5) values in figure 63.  
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Figure 61. (a) Percentage of mismatch probes 
depending on the MM/PM ratio (b)  Percentage 
of mismatch probes depending on the standard 
error of the MM/PM ratio from the TEM-array 
analysis of 35 clinical samples collected in 
Croatia. 
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Figure 62. Fluorescence images of selected SHV-arrays hybridized with target DNA 
presenting different genotypes originating from clinical isolates collected in Croatia. The 
varying SNP positions 31, 234/5 are highlighted with white boxes. The identified variants 
were (a) blaSHV-1 in isolate No. 32, (c) blaSHV-5 in isolate No. 23, (d) blaSHV-5 + blaSHV-1 in 
isolate No. 1 (e) blaSHV-12 in isolate No. 3, (f) blaSHV-12 + blaSHV-1 in isolate No. 11. The 
signal intensity is shown in false color. Blue corresponds to the lowest signal intensity, 
red to white depict the highest signal intensities (as output by ImaGene 3.0). In (b) the 
capture probe layout of the SHV-microarray is displayed (for details see also figure 52). 
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Figure 63. Representative identification of (a) blaSHV-1 in isolate No. 32, (b) 
blaSHV-5 in isolate No. 23, (c) blaSHV-12 in isolate No. 3, (d) blaSHV-5 +  blaSHV-1 in 
isolate No. 1, (e) blaSHV-12 + blaSHV-1 in isolate No. 11, (f) blaSHV-12 + blaSHV-1 in 
isolate No. 20 from clinical isolates collected in Croatia (n = 6 for all isolates). 
Only the mutation positions differing between blaSHV-1 and the other SHV 
variants are displayed as relative intensities (RIs) for SNP position 31 and as 
net intensities (NIs) for mutation position 234/5. Probe set 31 is indicated by 
the central base (A, G, C, T) in the legend. Probe set 234/5 is designated by 
the targeted amino acids at position 234/5 (GE, SE, SK, AE, AK) and the 
nucleotide at the third codon position for amino acid 235 (GEa or GEg). 
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For the detection of more than one blaSHV variant, the net intensities of position 234/5 
had to be considered. SHV-1 has at this position the amino acids GE, in contrast to 
the ESBL variants SHV-5 and SHV-12 carrying the amino acids SK. In case of the 
detection of a blaSHV-5 or blaSHV-12 alone, net signal intensities between approximately 
700 and 2300 arbitrary units (a.u.) for the perfect match probe SKg could be 
detected, in contrast to net signal intensities between approximately 28,000 and 
34,000 a.u. for the perfect match probe GEg in pure blaSHV-1. This corresponded to a 
diminished melting temperature of the SKg probe (43.3 °C) in comparison to the GEg 
probe (50.2 °C) due to a lower GC content (see table 11). For the detection of a SK- 
in presence of a GE-carrying variant this difference in signal intensities has to be 
taken into account. Therefore, the net signal intensities of 234/5 had to be closely 
analyzed. In figure 63 a-f the differing net signal intensities of probes SKg in contrast 
to probe Geg or GEa can be noticed easily.  
 
To clarify the specific detection of a mixed in contrast to a pure SHV-genotype, the 
net signal intensities of probe 234/5SKg of all different genotypes for all analyzed 
isolates are given in figure 64a. In case of the detection of pure blaSHV-1 (detected in 
isolate 13, 32 and the positive control target DNA) SKg net signal intensities of 
maximal 50 a.u. could be detected, which was not above net intensity background 
level. In all other tested SHV amplicons the presence of an ESBL variant could be 
detected by SKg net intensity values between 561 and 2236 a.u., which were at least 
six times above background net intensity. For the detection of blaSHV-12 in presence of 
another blaSHV -variant, the relative intensities of position 31 had to be considered. In 
contrast to a wild type T, a mutated position 31 carried an A at the concerned 
position. The presence of a pure blaSHV-12 or a blaSHV-12 in presence of blaSHV-1 could 
be confirmed by 31A relative intensities of > 0.83. The non blaSHV-12 genotype 31A 
relative intensities remained all below 0.6 (see figure 64b). The unusually high 
variation in between 31A relative intensities within the non-blaSHV-12 genotypes was 
attributed to the aforementioned changes in the spotting routine. 
 
Figure 64. (a) Net intensities of probe 234/5 SKg and (b) relative intensities of probe 31A 
depending on the detected genotype (blaSHV-1 (N = 3), blaSHV-5 (N = 6), blaSHV-5 + blaSHV-1 (N = 16), 
blaSHV-12 (N = 1), blaSHV-12 + blaSHV-1 (N = 4) from the SHV array analysis of 29 of 30 SHV 
containing clinical samples collected in Croatia and the positive control target DNA (blaSHV-1), 
(N= Number of samples). The RI or NI limit value discriminating between the differing genotypes 
is displayed as a red line. 
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All blaSHV perfect match positions 
could be identified correctly for the 
analyzed SHV samples, except for 
position 202, which could not be 
analyzed for six of the tested samples 
due to incorrect spotting of this 
position in one batch of the slides. 
For isolate 34 the generated data was 
not sufficient for an unambiguous 
identification, therefore it was omitted 
from the further data analysis. Over 
99% of the analyzed perfect match 
positions of the remaining 29 SHV 
containing isolates could be identified 
correctly, since their relative 
intensities of the mismatches 
remained below a limit of 0.8 (see 
figure 65a). Only for 0.23 % of the 
analyzed values this limit was 
violated with relative intensities up to 
0.93, which was in six of eight cases 
caused by the mismatch position 
39MUTANT. The unfavorable mismatch 
to perfect match ratio of this probe 
has already been described before 
(see section 3.2.5 and 3.2.6) and can 
be attributed to the unfavorable 
secondary structure of the perfect 
match probe 39WILDTYPE. The other 
two cases of an relative intensities of 
the mismatches > 0.8 were attributed 
to sporadic aberrations during the 
spotting process. The standard 
deviations of the mean relative 
intensities of the mismatches varied 
from 0 to 0.42, whereby 83 % 
remained below 10 % of the perfect 
match intensity (see figure 65b). 
Hereby the problematic of two slide 
batches with differing production 
parameters has to be reconsidered, 
since usually about 90 % of the 
standard deviations of the mean 
relative intensity of the mismatch 
values remained below 10 %.  
 
When comparing the phenotypic and the genotypic data, it has to be noted that in all 
K. pneumoniae and in one K. terrigena isolates a blaSHV-1 gene was found either 
alone or in combination with a blaSHV -ESBL gene variant. In contrast to that no E. coli 
isolate contained a blaSHV-1 type gene. 
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Figure 65. (a) Percentage of mismatch 
probes depending on the MM/PM ratio (b)  
Percentage of mismatch probes depending 
on the standard error of the MM/PM ratio 
from the SHV array analysis of 29 of 30 SHV 
containing clinical samples collected in 
Croatia. 
Results  
  119
For all isolates (except isolate 27), which were resistant or showed intermediate 
resistance against all cephalosporins except cefoxitin, an SHV-type ESBL variant 
(either blaSHV-5 or blaSHV-12) was detected alone for E. coli, or in combination with 
blaSHV-1 for K. pneumoniae. It is remarkable, that all other isolates, which were 
susceptible to one or more of the cephalosporins displayed in table 13, did not 
contain such a gene variant. In case of isolates 13 and 32 only blaTEM-116 in 
combination with blaSHV-1 and in case of isolate 21 only blaTEM-116 was detected. 
These isolates were confirmed to be no ESBL producers by a phenotypic 
confirmatory test. The K. oxytoca isolate No. 26, which could be phenotypically 
classified as a likely K1 producer, also contained only a blaTEM-116 gene variant. As 
has already been mentioned before, it is not clear, whether TEM-116 can confer an 
ESBL phenotype or not (see also section 3.1.7). According to these results, it 
appears not to be an ESBL conferring gene variant. Isolate 2 and 36 contained only a 
blaTEM-1 gene and no blaSHV variant. The phenotype of isolate 2 suggested a CTX-M-
type resistance, for which was not genotypically screened in this study. As 
aforementioned, isolate 36 could phenotypically not be classified as an ESBL 
producer.  
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Table 13. Properties and phenotypic data of samples collected in Croatia 
Antibiograme Origina #b Samplec Speciesd 
AZT CAX CAZ CFT CRM CFX CPD CAZ1 IMP 
Enzymef 
P 1 urine K. pneumoniae R R R R R S R R S ESBL 
P 4 urine K. pneumoniae R R R R R S R R S ESBL 
P 5 urine K. pneumoniae R R R R R S R R S ESBL 
P 6 urine K. pneumoniae R R R I R S R R S ESBL 
P 7 urine K. pneumoniae R R R R R S R R S ESBL 
n.s. 8 n.s. K. pneumoniae R R R R R S R R S ESBL 
n.s. 11 n.s. K. pneumoniae R R R R R I R R S ESBL 
S 12 w. swab K. pneumoniae R R R R R S R R S ESBL 
n.s. 13 n.s. K. pneumoniae S S S S R S S R S no ESBL 
P 14 blood K. pneumoniae R R R R R S R R S ESBL 
P 16 urine K. pneumoniae R R R R R S R R S ESBL 
P 19 urine K. pneumoniae R R R R R S R R S ESBL 
P 20 urine K. pneumoniae R R R R R R R R S AmpC/ESBL 
P 25 urine K. pneumoniae R R R R R S R R S ESBL 
P 28 urine K. pneumoniae R R R R R S R R S ESBL 
P 29 urine K. pneumoniae R R R R R S R R S ESBL 
n.s. 30 n.s. K. pneumoniae R R R R R S R R S ESBL 
N 31 urine K. pneumoniae R R R R R S R R S ESBL 
P 32 urine K. pneumoniae S S S S S S S R S no ESBL 
P 33 urine K. pneumoniae R R R R R S R R S ESBL 
n.s. 34 n.s. K. pneumoniae R R R R R S R R S ESBL 
n.s. 35 n.s. K. pneumoniae R R R R R S R R S ESBL 
              
S 2 w. swab K. ornithinolytica R R S R R S R R S CTX-M 
P 9 urine K. terrigena R R R R R S R R S ESBL 
Ga 26 urine K. oxytoca R R S I R S R S S K1 
              
n.s. 3 n.s. E. coli R R R R R S R R S ESBL 
P 10 urine E. coli R I R I I S R R S ESBL 
P 15 urine E. coli R R R I R S R R S ESBL 
Gy 18 urine E. coli R R R R R S R R S ESBL 
P 21 urine E. coli S S S S R S R  S no ESBL 
P 22 blood E. coli R R R I R S R R S ESBL 
Gy 23 v. swab E. coli R R R R R S R R S ESBL 
n.s. 24 n.s. E. coli R R R R R S R R S ESBL 
n.s. 27 n.s. E. coli R R R R R S R R S ESBL 
n.s. 36 n.s. E. coli S S R S R R R R S not clear 
   V V R V V S R R S ESBL 
   R R R R R R R R S AmpC 
   R V/R S V R S R S S K1,  
(K. oxytoca) 
   
 
gE. coli and 
Klebsiellae 
V R V R R S R R S CTX-M 
a Site of sample drawing: P-Department of Pediatry, S-Department of Surgery, Gy-Department of 
Gynecology, Ga-Department of Gastrology, N-Department of Nephrology at Zadar Hospital, Zadar 
Croatia; n.s. = no specification. 
b Isolate No.  
c Sample type: w. swab - wound swab, v. swab - vaginal swab, n.s. = no specification 
d, e Species identification and ESBL screening were performed at the RBK using an automated 
microdilution test system (WalkAway 5105, MicroScan, Neg Breakpoint Combo Panel Type 30). AZT-
Aztreonam (R > 16 µg/ml, S <= 8 µg/ml, I = 16 µg/ml), CAX-Ceftriaxone (R > 32 µg/ml, S <= 8 µg/ml, I 
= 32 µg/ml), CAZ-Ceftazidime (R > 16 µg/ml, S <= 8 µg/ml, I = 16 µg/ml), CFT-Cefotaxime (R > 16 
µg/ml, S <= 4µg/ml, I = 16 µg/ml), CFX-Cefoxitin (R >16 µg/ml, S <= 8 µg/ml, I = 16 µg/ml), CRM-
Cefuroxime (R >32 µg/ml, S <= 16 µg/ml, I = 32 µg/ml) , CPD-Cefpodoxime (R > 4 µg/ml, S < 4 µg/ml) 
CAZ1-Ceftazidime (R > 1 µg/ml, S < 1 µg/ml), IMP-Imipenem (R > 8 µg/ml, S <= 4 µg/ml, I = 8 µg/ml) 
f Enzyme type defined by antibiogram according to Livermore et al. (see g) 
g Antibiogramm of Klebsiellae and E. coli with potent beta-lactamases, R-resistant, S-Susceptible, V-
variable with type and amount of enzyme, see Livermore et al. (97) 
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Table 14. Phenotype-genotype correlation of samples collected in Croatia 
Phenotypea Genotype(blaTEM or blaSHV)b Isolate No. Species 
Enzyme TEM-array SHV-array 
1 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
4 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
5 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
6 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
7 K. pneumoniae ESBL TEM-116 SHV-1 SHV-12 
8 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
11 K. pneumoniae ESBL TEM-1 SHV-1 SHV-12 
12 K. pneumoniae ESBL TEM-1 SHV-1 SHV-12 
13 K. pneumoniae no ESBL TEM-116 SHV-1  
14 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
16 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
19 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
20 K. pneumoniae ESBL/AmpC TEM-1 SHV-1 SHV-12 
25 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
28 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
29 K. pneumoniae ESBL TEM-1 SHV-1 SHV-12 
30 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
31 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
32 K. pneumoniae no ESBL TEM-116 SHV-1  
33 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
34 K. pneumoniae ESBL TEM-116 (SHV-1 SHV-5) 
35 K. pneumoniae ESBL TEM-116 SHV-1 SHV-5 
      
2 K. ornithinolytica CTX-M TEM-1   
9 K. terrigena ESBL TEM-116 SHV-1 SHV-5 
26 K. oxytoca K1 TEM-116   
      
3 E. coli ESBL TEM-1  SHV-12 
10 E. coli ESBL TEM-116  SHV-5 
15 E. coli ESBL TEM-116  SHV-5 
18 E. coli ESBL TEM-116  SHV-5 
21 E. coli no ESBL TEM-116   
22 E. coli ESBL TEM-116  SHV-5 
23 E. coli ESBL TEM-116  SHV-5 
24 E. coli ESBL TEM-116  SHV-5 
27 E. coli ESBL TEM-1   
36 E. coli not clear TEM-1   
a Phenotype: Phenotypic resistance detection was performed at the RBK using an 
automated microdilution test system. Enzyme type definition by antibiogram 
according to Livermore et al. (97) (see also table 13). b Genotype was determined 
by TEM- (n = 9) and SHV-array (n = 6) analysis (except for SHV genotype of 
isolate No. 34) and was confirmed by standard DNA sequencing. 
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3.4  Ongoing developments 
3.4.1 Transfer of the TEM-array to a marketable array format 
Through the cooperation partner Eppendorf Array Technology (EAT, Namur, 
Belgium) an alternative not disclosed immobilization method and labeling technique 
was available, which would allow the development of a marketable ESBL chip. As a 
proof of concept for the feasibility of the transfer of the developed TEM- or SHV-array 
to the EAT proprietary format a small subset of probes used for the TEM-array was 
immobilized on the EAT array format and hybridized with different amounts (25-150 
ng) of biotinylated blaTEM-116 target DNA. The hybridized targets were detected using 
fluorescence and silver based (1) post-labeling techniques.  
 
In figure 66 some of the resulting fluorescence and silver images are displayed. 
Perfect match positions of all probe sets could be identified correctly with both 
systems. The resulting net fluorescence signal intensities are also displayed in figure 
66 a and b. The detected signal intensities and the discrimination efficiency on the 
new format after fluorescence labeling were decreased compared to the currently 
used system. The silver labeling resulted in visibly enhanced signals compared to the 
fluorescence labeling, although six times less target DNA was used. It has to be 
noted that the quantified data resulting from the fluorescence and silver labeling 
process were not directly comparable, since different detection systems (for detection 
of transmitted light or emitted fluorescence) had to be used. The overall 
discrimination of the perfect matches towards the mismatches was in case of the 
silver staining drastically reduced and high background signals were observed. 
However, in principle SNP detection was possible with both formats, but further 
optimization is needed. 
.
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Figure 66. Transfer of a subset of probes of 
the TEM-array from (a) a standard 
oligonucleotide array format (150 ng target 
DNA applied, spot size 150 µm) to (b) EAT 
immobilisation technology (150 ng target 
DNA, spot size 400 µm) and (c) silver 
staining procedure (25 ng target DNA, spot 
size 400 µm). In (d) the spotted array layout 
is displayed (n = 3). The net signal intensities 
of probe set 143 were not analyzed, since 
the probes spotted on the different surfaces 
were not identical and thus the differing 
format characteristics not comparable 
regarding this probe. 
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3.4.2 Link of the resistance to the pathogenic bacteria 
The assignment of the resistance to the 
pathogenic bacteria is a crucial step during 
resistance analysis, because otherwise the 
occurrence of resistance traits of a non 
pathogenic organism could result in errors in 
treatment. In a proof of principle experiment 
Escherichia coli were enriched from a urine 
sample by hybridization to species specific 
polynucleotide probes, which were subsequently 
immobilized in microtiterplate wells. Afterwards a 
PCR reaction with TEM-specific primers was 
carried out. These steps were performed by 
Kathrin Fichtl (Department of Microbiology, 
Technical University of Munich). At our institute 
the generated amplicon was used as a template 
in a labeling PCR and the resulting product was 
analyzed on the TEM-array. The identification of 
a TEM-1 resistance gene by array analysis was 
successful. The corresponding fluorescence 
image is displayed in figure 67. All analyzed 
perfect match positions were correctly identified 
(except probe set 122, which was not correctly 
spotted) within the predefined limits by 
calculation of the relative intensities as displayed 
in figure 68. Thus, a resistance detection by TEM 
microarray analysis after a species specific 
enrichment by polynucleotide probes was shown 
in this experiment. This experiment delivers the 
proof of principle, that the culture dependent and 
therefore time consuming preisolation step can 
be replaced by a molecular enrichment method. 
 
 
Figure 67. Fluorescence image 
of an identification of blaTEM-1 
originating  from a specific 
enrichment of E. coli from a 
urine sample.  
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Figure 68. (a) Relative intensities of blaTEM-1 target DNA originating from a specific enrichment of 
E. coli from a urine sample (n = 6). The four probe sets are indicated by their central base (A, G, C, T) 
in the legend. The labeling efficiency of the hybridized sample DNA was 178 NT/F; 200 ng of target 
DNA was applied. Probe set 122 was not analyzed, since it was not correctly spotted. 
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4 Discussion 
The increased occurrence of microorganisms, which are resistant to commonly used 
antibiotics, enhances the need for a faster diagnostic and a strict monitoring of the 
spread of resistances throughout the hospital and the community. In average the 
phenotypic standard methods of resistance detection take two to three days, before a 
resistance profile is provided. This situation is unacceptable regarding the current 
resistance situation. The resulting empiric antibiotic treatment is one of the major 
causes of the further development and spread of resistances. Therefore, new 
strategies allowing a predictive diagnostic in contrast to a retrospective one for an 
early and accurate resistance detection and monitoring have to be developed. The 
molecular antibiotic resistance tests devised in this study target a group of the 
clinically most relevant and problematic resistances: the extended spectrum beta-
lactamases. These enzymes are especially difficult to detect with phenotypic 
standard methods. The emphasis of this work was to develop a method allowing the 
sensitive and specific detection, identification and monitoring of the majority of the 
numerous resistance traits causing the ESBL and IRT phenotype. Furthermore, this 
test system should be fast, reliable and manageable in a clinical diagnostic 
laboratory. 
 
4.1 Phenotypic resistance tests 
Phenotypic tests are still the standard method of resistance detection, since they are 
cost-effective, applicable for the detection of a wide range of antibiotic resistances 
caused by different mechanisms and test the microorganisms directly regarding their 
in vitro activity against the antibiotics most commonly used to treat those infections. 
On the one hand the spectrum of detectable resistances in phenotypic screening 
tests is broad, on the other hand the lack of a specific identification of the responsible 
resistance trait makes a closed monitoring of emerging or spreading resistances and 
the underlying mechanisms impossible. The results obtained by the commonly 
applied agar diffusion tests used in clinical routine diagnostic rely on subjective 
interpretation of growth inhibition zones, requiring experienced personnel. 
Misinterpretation can still occur and result in treatment failures (95,97). Furthermore, 
some resistances might remain undetected for example for uncultivable organisms or 
if an inappropriate selection of antibiotics or a too low inoculum is used to perform the 
test. Low-level-expression of the resistance gene or the expression of resistance 
genes, which mask effects of another resistance are also disadvantageous for 
detection. A major drawback is also the need for preisolation and cultivation of the 
bacteria, which prolongs the analysis time. Automated broth microdilution methods 
such as the MicroScan (Dade MicroScan, West Sacramento, US), Vitek (bioMérieux, 
Nürtingen, Germany) or BD Phoenix (Becton Dickinson, Heidelberg, Germany) for 
speeding up the cultivation and resistance testing have been developed, but these 
analyses still need a preisolation and up to 9 to 11 h of analysis time 
(39,93,137,138). Since serious infections have to be treated as early as possible, the 
antibiotic treatment often has to start before the resistance is unequivocally identified. 
Due to this fact the current phenotypic antibiotic resistance diagnostic is more 
retrospective than predictive. To avoid treatment failures more extended spectrum 
antibiotics are prescribed than necessary, which enhances the development of new 
resistances.  
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In case of the detection of enterobacteriacae producing ESBLs the standard 
phenotypic tests have several pitfalls, which have to be considered. An ESBL does 
not always increase the MICs to levels high enough to be called resistant by NCCLS 
interpretive guidelines. A variety of cephalosporins has to be tested, otherwise about 
one third of the organisms might be reported to be susceptible in broth microdilution 
and disc diffusion tests, although carrying an ESBL-type beta-lactamase (42,70). 
Furthermore, the MICs of most cephalosporins increase dramatically, when the 
inoculum is raised in susceptibility tests (108). These effects can lead to susceptible 
test results in vitro, whereas in vivo the infection is not stopped, if treated with the 
false negatively tested antibiotic. 
 
Several studies evaluated the reliability of the current phenotypic ESBL detection 
methods. The test methods included disc diffusion methods as well as automated 
broth microdilution testing. Errors were encountered with both automated and disc 
diffusion methods. In a survey of 38 laboratories in Connecticut in 1999 only 18 % of 
the tested institutions categorized at least one of the four tested isolates (one AmpC 
and three ESBL) as potential ESBL producers (163). In 2000 a proficiency test 
assessing the ability of hospital laboratories participating in the project ICARE 
(Intensive Care Antimicrobial Resistance Epidemiology) to detect specific types of 
antimicrobial resistances, it was reported, that up to 58 % of the laboratories failed to 
detect and report ESBL isolates correctly (158). In a study conducted by the WHO in 
2001, 130 laboratories were tested with a TEM-3 producing Klebsiella pneumoniae 
challenge strain. 5.4 % of the tested laboratories using disc diffusion tests reported 
this strain to be susceptible to all cephalosporins. Only two of 130 laboratories 
specifically reported the isolate as an “ESBL producing strain” (164). 
 
Apart from the need for a reliable prescreening method, also the ESBL confirmatory 
methods pose an important issue. In an evaluation of the NCCLS ESBL confirmation 
methods for E. coli in 2003 with isolates collected during the project ICARE it was 
determined, that after a prescreening according to NCCLs criteria, it is indispensable 
to perform additional confirmatory methods for ESBL detection, since otherwise a 
large percentage of false resistance results was reported. In this study only 16 % of 
131 E. coli isolates identified as potential ESBL producers by the NCCLS screening 
criteria were confirmed as ESBL producers. Changing the interpretation of extended-
spectrum cephalosporins and aztreonam results from the susceptible to the resistant 
category after prescreening, without confirming the presence of an ESBL phenotype, 
would lead to a large percentage of false resistance results and is not recommended. 
However, 45 % of the false-positive results were due to a cefpodoxime MIC 
screening breakpoint of 2 µg/ml, by increasing the breakpoint to 8 µg/ml, these false-
positive results could be eliminated. NCCLS has incorporated this change in the 
cefpodoxime screening breakpoint in its recent documents (165). 
 
These reports confirm the dilemma of phenotypic ESBL detection. Infections with 
ESBL producing organisms in E. coli and K. pneumoniae are associated with 
significantly longer hospital stays and increased hospital costs (85). These facts in 
combination with the increased prevalence of ESBLs worldwide has prompted the 
search for more accurate tests to detect the presence of ESBLs in clinical isolates. 
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4.2 Genotypic resistance tests 
Genotypic analysis of resistant microorganisms has the potential to offer a more 
rapid and reliable solution, providing an increased information depth for antimicrobial 
resistance testing than the conventional susceptibility methods. The advantages of a 
genotypic resistance analysis are the following. (i) The test can in principle be 
performed directly starting with DNA isolation from clinical samples without the need 
for preisolation or cultivation of the bacteria. (ii) Genotyping is faster, especially 
regarding tests of slow growing organisms. (iii) Even uncultivable organisms can be 
assessed. (iv) The risk of propagation of the pathogenic organisms due to prolonged 
exposition of laboratory personal to bacterial cultures is minimized. (v) Resistances 
are detectable genotypically even if their phenotypic pattern is not conclusive due to 
a not induced state, low-level expression, masking phenotypes, inoculum effect, etc.. 
(vi) Genotypic test results can be more objective through in silico data analysis than 
comparable phenotypic methods relying on visual determination of growth inhibition 
zones.  
 
However, genotypic analysis also has several potential drawbacks compared to 
conventional phenotypic analysis (30). (i) They might lack sensitivity if only few 
organisms are present in a higher volume of clinical sample. This problem can be 
solved by appropiate concentration methods. (ii) Due to low multiplexing capability of 
some genotypic methods, a separate test has to be developed for each tested 
resistance trait. (iii) Resistance can be caused by different mechanisms and a wide 
variety of genes or single nucleotide polymorphisms. Therefore, the development of a 
genetic test targeting a specific resistance problematic might turn out to be very 
complex. (iv) The detection is usually limited to specifically targeted and thus known 
resistances, so emerging resistances might remain undetected. This problem might 
also occur in case of the phenotypic analysis, if resistances emerge with a substrate 
spectrum widely differing from the conventionally tested ones. (v) The molecular 
background of some antibiotic resistance mechanisms might still be unknown. (vi) 
Genotypic testing might not differentiate between low-level and high-level expression 
and therefore between clinical relevance or irrelevance of the resistance. (vi) False 
positive results might occur due to the presence of nonpathogenic organisms which 
might carry a resistance gene or due to contamination of the sample prior the nucleic 
acid amplification step. (vii) No standards exist so far for performing molecular 
methods for resistance detection. (viii) Clinical trials to assess the accuracy, 
reproducibility and utility of these methods were only conducted for few of these 
tests. (iX) Genotypic tests are usually more expensive compared to standard dilution 
or disc diffusion tests. 
 
4.3 Methods for molecular ESBL detection  
One of the first methods for molecular detection of different ESBL variants was the 
determination of the isoelectric point of the enzymes. This procedure is labour 
intensive and not specific enough, since at the present time multiple variants with 
similar isoelectric points are observed. The use of oligonucleotide probes for the 
detection of different TEM variants was first described in 1988 for discrimination 
between TEM-1 and TEM-2 (120), in 1990 for TEM-1, TEM-3 and TEM-6 (166) and 
in 1991 for discrimination of TEM-1 to TEM-7 (101). These probes were labeled with 
radioisotopes or biotin and were used in southern blotting or in colony hybridization 
experiments. The combination of different hybridization patterns from the 12 
radiolabeled primers developed by Mabilat and Courvalin allowed the identification of 
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previously unknown enzyme variants with a novel combination of known 
polymorphisms (101). However, southern blotting and colony hybridization 
experiments are time-consuming and restricted to the analysis of a limited number of 
features, since multiple separate hybridization reactions have to be performed. 
Radioactively labeled intragenic fragment probes were also used in colony 
hybridization experiments to differentiate between different beta-lactamase families 
such as TEM or SHV, but these probes were not specific for the identification of 
polymorphisms leading to an extended substrate range (5). 
 
Another approach for the detection of different ESBL variants is the analysis of 
restriction fragment length polymorphisms in combination with PCR (PCR-RFLP). 
After amplification by PCR the generated amplicons are digested by restiction 
enzymes, producing different fragment lengths due to the presence or absence of a 
restriction site caused by a mutation. The fragment sizes are then analyzed by 
agarose gel electrophoresis. Thereby a limited number of different TEM or SHV 
ESBL variants could be detected (4,119). The major limitation of the RFLP method is 
the requirement of polymorphisms in specific restriction sites. It is impossible to find 
an analyzable feature for each relevant mutation position, thus numerous TEM or 
SHV variants can not be detected by this method (26). Additionally the resolution of 
different fragment lengths by agaose gel electrophoresis is limited. Furthermore, 
restriction length polymorphism can also be caused by a silent mutation and 
therefore false interpretation of the results can occur. 
  
The analysis of single strand conformational polymorphisms (PCR-SSCP) was also 
applied for characterization of ESBL variants. After amplification of the target region 
and restriction with a restriction enzyme the fragments are denatured and analyzed 
on a polyacrylamide gel. This method allowed the detection of 12 different inhibitor 
resistant TEM variants (155) and six different SHV variants (100,114). The 
simultaneous detection of different SHV-types within one strain also was possible. 
However, some mutations leading to different variants are difficult to differentiate, 
hence the resolution of this method and the specificity of the discrimination is limited. 
 
To increase the spectrum of detectable SHV variants a combination of PCR-SSCP 
and PCR-RFLP was described by Chanawong et al. (25). It theoretically allowed the 
discrimination of up to 17 SHV variants. After digestion with two different restriction 
enzymes the genes could be differentiated by the aforementioned methods. Although 
the combination of these methods was applicable to the identification of a wider 
range of variants, the problem of a limited detectable and differentiable variant 
spectrum of the assay persists. The same group developed a restriction site insertion 
PCR to extend the identification of SHV beta-lactamases by the aforementioned 
methods (26). Hereby the amplification primers were designed to create a restriction 
site specific to blaSHV-1 at five different restriction sites. If a mutation was present, the 
amplified fragments could not be digested by the endonucleases and displayed a 
restriction pattern differing from blaSHV-1 in the agarose gel electrophoresis. However, 
the resolution of the differing fragment sizes in the displayed results was not very 
high, so that correct interpretation of the results might be difficult. Furthermore, the 
primer design was not applicable for all mutation positions and a combination of the 
different methods as suggested by the authors is not really appropriate for the 
application in clinical microbiology laboratories. 
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The use of the ligase chain reaction (LCR) has also been described for SHV 
detection. Niederhauser et al. described the detection of the glycine to serine 
mutation at Ambler position 238 by the use of two adjacent oligonucleotides, which 
contained template independent tails (117). After the ligation reaction a PCR reaction 
was performed with two primers that match the tails of the oligonucleotides. The 
products were detected by agarose gel electrophoresis. It was shown that this 
method was very sensitive, since it allowed the detection of a point mutation in a 
background of 100,000 wild-type bacteria. Kim et al. described a LCR method for the 
detection of four different mutation positions (79). The LCR product was detected by 
an enzymatic reaction using NADPH-alkaline phosphatase in a microtiterplate format. 
 
Real time PCR and melting curve analysis was applied by Randegger et al. for the 
detection of three SHV polymorphism positions relevant for the ESBL phenotype 
(129). This assay applies fluorescently labeled oligonucleotide hybridization probes. 
Mutations are differentiated by the detection of diverging melting profiles. This assay 
allowed a rapid and sensitive discrimination between SHV ESBL and non-ESBL type 
beta-lactamases and the categorization of SHV ESBL producers in three 
phenotypically relevant groups.  
A minisequencing-based assay for the discrimination of SHV ESBL or non-ESBL 
type beta-lactamases was reported by Howard et al (64). The method interrogates 
two polymorphic ESBL relevant sites through primer annealing immediately upstream 
of the polymorphic site followed by a primer extension reaction and determination of 
the identity of the incorporated base.  
Nucleotide sequencing remains so far the standard for determination of the specific 
beta-lactamase gene present in the isolate. However, results can still vary depending 
on the method used (15) and the presence of more than one gene variant is also 
difficult to detect by this method. Furthermore, this method is still time-consuming 
and technically demanding for high throughput screening purposes. 
 
A major drawback of most of the aforementioned methods remains the application of 
agarose gel electrophoresis for detection of the different gene variants. They are 
therefore difficult to adapt to automation and high throughput analysis. The detection 
in a microtiterplate format increases the throughput, but for all reported methods so 
far the number of simultaneously analyzable polymorphisms was limited. Thus, not 
all polymorphisms relevant for identification of the numerous variants were detected 
and only a minor number of TEM or SHV variants could be discriminated. A 
genotyping assay detecting the majority of the relevant mutation positions for TEM or 
SHV-type beta-lactamases for rapid high throughput analysis has - to our knowledge 
- not been described up to date. DNA microarray technology offers in contrast to 
most other genotypic methods the possibility to analyze a high number of features 
simultaneously. All resistance and variant specific mutations can be identified, so that 
a conclusion about the substrate spectrum and the responsible genotype can be 
drawn. Only this makes a closed monitoring of spreading resistances possible.  
 
4.4 DNA microarrays for molecular resistance detection  
Due to the urgent need for faster and more precise test methods for species 
identification and antimicrobial resistance detection for clinical microbiology diverse 
DNA microarrays were already described. Troesch reported in 1999 the development 
of an allele specific high density DNA probe array for the identification of 
Mycobacterium species and mutations in rpoB, which are responsible for rifampicin 
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resistance (171). Mikhailovich also reported an assay for the identification of mutant 
variants of the rpoB gene in Mycobacterium tubercolis strains (110). Here allele 
specific hybridization, PCR and ligase detection reaction on oligonucleotide chips 
were applied. A microelectronic chip array for the detection of diverse resistances in 
E. coli, Salmonella, Campylobacter, Staphylococcus and Chlamydia was described 
by Westin et al. (179). DNA microarrays for detection of quinolone resistant Neisseria 
gonorrhoeae (14) or E. coli (183) have also been described. Volokhov et al. reported 
a microarray for the analysis of erythromycin resistance in Staphylococcus and 
Streptococcus species (175).  
 
DNA microarrays allowing the detection of beta-lactamase resistance genes were 
only reported twice so far. Call et al. developed an oligonucleotide DNA microarray 
for the detection of tetracycline resistance genes in E. coli (22). This array also 
contained one probe specific for blaTEM-1. Lee et al used spotted PCR products for 
detection of various beta-lactamase genes (PSE, OXA, FOX, MEN, CMY, TEM, SHV, 
OXY, AmpC) (88). ESBL or non-ESBL variants could not be identified and 
discriminated with these arrays, since the detection of the single nucleotide 
polymorphisms relevant for the discrimination of the different phenotypes and 
variants was not possible. The genotyping arrays developed in this work fills this gap 
for the identification and discrimination for 96% of the TEM and 100% of the SHV 
variants known up to date. 
 
4.5 Implementation of the system  
To produce oligonucleotide microarrays for a reproducible, specific and sensitive 
analysis, the surface for immobilization, the spotting technique and buffer, as well as 
the method of probe immobilization have to be carefully chosen (12). However, also 
the budget for the numerous experiments necessary for implementation of the 
system has to be considered. Therefore, in the beginning the most cost-effective 
alternatives were tested. 
 
It was reported that unmodified oligonucleotides can be efficiently immobilized 
without comprimising hybridisation effieciency (23). Hence, the system was first 
implemented on low-priced poly-L-lysine slides, which allow to immobilize 
oligonucleotide probes without an amino-modification or spacer. This undirected 
immobilization of the oligonucleotide probes is done via the formation of a covalent 
bond between a base from within the probe sequence to the surface (see section 
1.3.4.3). A DMSO-based spotting buffer was chosen, since it was reported that this 
buffer provides uniform spot shapes and allows long spotting rounds, because of low 
evaporation rates (12). 
  
However, after hybridization of the target on the poly-L-lysine slides the observed 
signal intensities were low and the spot shapes irregular. Furthermore, multiple 
failures of experiments due to high background signal intensities occured.The low 
signal intensities and irregular spot shapes resulted in high standard deviations of up 
to 68 % in between signal intensities of replicate spots. The regularity of the spot 
shapes depends on the spotting equipment and process, the surface, the spotting 
buffer and the spotting parameters, such as surrounding humidity (27). Since the 
surrounding humidity could be monitored during spotting and remained constantly at 
54 %, it was assumed that the spotting buffer and the chosen surface were mainly 
responsible for the varying spot shapes. Another possible source of variation was the 
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use of different pins to spot the replicate spots. To avoid variation inherent in the 
spotting process with multiple pins replicate spots should be spotted with the same 
pin (12).  
 
The most probable reasons for the overall low signal intensity were either a low 
immobilization or hybridization efficiency of the probes. The surface density of the 
probes obtained in the immobilization procedure is an important parameter of the 
system. A low surface coverage can result in low hybridization signals. Conversely, 
high surface densities might result in steric interference, impeding access to the 
target DNA strand (55,125). The hybridization efficiency of the target DNA to the 
immobilized oligonucleotide probes is influenced by several parameters. The binding 
capacity of the surface bound probes, secondary structure of the target DNA (151), 
the position of the short capture probe on the target nucleic acid (127), as well as 
steric interactions are important. Steric hindrance is influenced by the probe density, 
spacer length, as well as hydrophobicity and charge of the solid support (28). The 
steric hindrance is enhanced, the closer the target sequence has to hybridize to the 
surface (126). Since in an undirected immobilization of the capture probes the 
surface is very close, an increased steric hindrance could occur resulting in low 
hybridization yields. 
 
Consequently, due to the observed low reproducibility and sensitivity of the 
microarray analysis on the poly-L-lysine support, the immobilisation chemistry and 
the spotting process had to be reviewed. Therefore, a new surface in combination 
with various spotting buffers and a new spotting strategy was tested to determine 
whether (i) the used unmodified oligonucleotide probes were the major cause of low 
hybridization efficiency or (ii) if the surface characteristics of the poly-L-lysine support 
were responsible for an inefficient immobilization and uneven background intensities, 
and (iii) if the variability could be reduced by changing the spotting strategy and 
buffers. Slides coated with epoxy groups were therefore tested with three different 
spotting buffers and replicate spots were spotted with the same pin. These 
parameters had a major effect on sensitivity and reproducibility. No unfavorable 
background effects were observed as with the previous system, which was attributed 
to a higher quality of the surface. By using a phosphate based spotting buffer the 
reproducibility of spot shapes and the regularity of the signal distribution within the 
spot was generally improved. The net signal intensities after hybridization were 
increased about more than three times, although target DNA with less fluorescence 
label was applied. This was an indication of most probably an enhanced 
immobilization efficiency and/or better accessibility of the probes on the epoxy 
surface. The combination of a new spotting strategy, surface and buffer led to a 
reduction of the mean variability in between replicate spots from 68 % on one array 
to 18 % in between three arrays.  
 
4.6 Probe design and performance  
4.6.1 Sequence analysis  
The occurrence of extended spectrum beta-lactamases was reported since 1985 
(171) and since then the number of registered amino acid exchanges with a potential 
influence on the substrate spectrum grew rapidly. To standardize the nomenclature 
of the new beta-lactamase variants Bush and Jacoby created a data base registering 
all naturally occurring ESBL conferring and related enzymes and their amino acid 
exchanges versus TEM-1 or SHV-1 (http://www.lahey.org/Studies/). Usually the 
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corresponding nucleotide sequences are available in GenBank, but sometimes only 
the amino acid exchanges are published. First steps of this work were to align all 
available nucleotide sequences of the classified TEM or SHV variants, to identify and 
confirm the mutation positions and to combine amino acid and nucleotide exchange 
information.  
 
Many of the substitutions affect enzyme structure and activity and lead to the widely 
differing substrate spectra of the numerous variants. However, there are also 
substitutions for which no functional change is currently evident, but most enzymes 
will have been sequenced because of a change in properties, and these substitutions 
might still affect the interaction with a future substrate or inhibitor (51). Furthermore, 
the concept of this array was to provide a tool for the identification and detection of all 
the known TEM or SHV variants and not merely the classification in ESBL, non-ESBL 
or IRT categories. Therefore, even substitutions which do not alter the substrate 
spectrum are considered as useful epidemiological markers and were included in the 
design of the probe set. Thus, the developed arrays should allow a monitoring of the 
occurrence of TEM or SHV gene variants and the consideration of a predetermined 
substrate spectrum of previously characterized enzymes for treatment options. 
 
DNA arrays allow the simultaneous detection of a high number of features. However, 
the analysis is still limited to amplifiable sequences. In the case of this work, the 
regions which sequences matched the primer sequences could not be included in the 
genotyping test, resulting in the exclusion of the ability to detect TEM-97, -98, -99,  
-102. TEM-108, which also shows point mutations in the primer specific regions, 
could theoretically be identified by the SNPs at position 194.2 and 78. The four other 
TEM variants are seldom described and may be considered as exceptional or 
endemic variants (S. Fanning and coworkers have directly submitted the TEM-97,  
-98, -99, and -108 to GenBank, which can be found under accession numbers 
AF397066, AF397067, AF397068, and AF506748, respectively). For TEM-87 and  
-92 the mutation at amino acid exchange position 4 is not detectable, since the probe 
set 4 included on the array is overlapping the sequence of the currently used primer 
set. However, these variants also carry other mutation positions, which can be 
detected with the presented array (see also table 3). The design of a different primer 
set outside the open reading frame (ORF) to circumvent the problematic of the 
detection of end-standing SNPs was presently not advisable, since for a considerable 
part of the published TEM variants no ORF flanking sequences are available. 
Methods to circumvent the problem arising from the consensus primer regions still 
have to be investigated and create the need for alternative amplification strategies. 
 
4.6.2 Performance analysis 
An important premise for the probe sets developed for a SNP detection microarray is 
an equal hybridization efficiency of all capture probes under the applied hybridization 
conditions (55). Therefore, the probes should have similar melting temperatures, 
similar lengths and as little secondary structures as possible (12). To design a probe 
set for all relevant SNP positions, sometimes a compromise between these 
parameters had to be found to achieve similar hybridization efficiencies. For 
example, to avoid unfavorable secondary structures, some probes were designed 
shorter resulting in lower melting temperatures, or some probes had to be designed 
longer to gain sensitivity. However, although algorithms for calculating probe 
parameters, such as melting temperatures and secondary structures facilitate probe 
design in silico, the probes have to be optimized empirically after the theoretical 
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probe design, since certain target DNA effects have already been identified (127), but 
remain difficult to predict for probe design.  
 
Although the probes for the TEM-array were not immobilized in a directed way, all 
polymorphisms could be identified correctly with a good mismatch to perfect match 
discrimination efficiency. Even though some perfect match probes had an 
unfavorable secondary structure in comparison to the mismatch probes, the perfect 
match probes were accessible enough for the hybridization of the target sequence to 
yield a specific perfect match detection signal. Generally, no distinct linkage between 
optimal probe design parameters and optimal discrimination and performance could 
be determined for the TEM-array probe sets. This might be due to the fact that the 
undirected immobilization and the proximity of the surface (since no spacer was 
used) further influenced the accessibility of the probes, so that secondary structures 
might not have the impact as determined by ∆G values, which were calculated for 
hybridization in solution. Solid-phase hybridization is a more complex process than 
solution hybridization (90). The aforementioned assumptions are also supported by a 
study from Peterson and coworkers (126). In this study it was determined that 
hybridization for surface immobilized DNA is quite different from the well-studied 
solution-phase reaction. Surface hybridization strongly depended on the target 
sequence and probe density. Steric crowding at high probe density had a negative 
influence on the hybridization efficiency. Furthermore, it was shown that hybridization 
kinetics were slower, the closer the hybridization of the target sequence to the probe 
sequence occurred to the surface. This was explained by the fact that the target must 
penetrate into the probe DNA film before hybridization can take place. These steric 
effects also have to be considered in case of the undirectly immobilized probes used 
on the TEM-array. 
 
In case of the SHV probe sets amino-modifications were applied for a directed 
immobilization and spacers were used to achieve a higher hybridization efficiency 
through increased accessibility (55,144,151). The extension of the distance between 
the surface and the probe sequence led to an approximation of the hybridization 
conditions to a hybridization in solution. Generally, the predetermined parameters of 
the probe design of the SHV-array probe set were more concordant with the detected 
hybridization results of the designed probes than observed for the TEM probe set. 
The results of an incorrect perfect match identification or a weak perfect match to 
mismatch discrimination efficiency could usually be ascribed to a more stable 
secondary structure of the perfect match probe in comparison to the mismatch probe 
- as determined during probe design. It is well known, that secondary structures can 
lead to a diminished accessibility of the capture probe to the target DNA (111,112). 
The resulting decreased hybridization efficiency of the perfect match probe is 
unfavorable for a clear perfect match/mismatch discrimination. However, there were 
also exceptions from the observation that secondary structure had an unfavorable 
effect on hybridization efficiency. The greatest difference in ∆G values in the whole 
SHV probe set between the perfect match and the mismatch probes secondary 
structure was observed for probe 202 with a difference of the ∆G values of  
- 9.1 kcal/mol. Nevertheless, the discrimination of the perfect match was distinct. It 
could not be determined why less stable probe secondary structures were in some 
cases more unfavorable towards discrimination efficiency than in case of probe 202. 
As mentioned before, the sequence context of the target DNA might play also a role 
(127). 
 
Discussion 
 134 
4.6.3 New probe design strategy 
For five SHV probe sets perfect match secondary structures led to high mismatch 
probe hybridization signals. Here a redesign of the probe sets was necessary. Since 
the bases forming the secondary structures were close to the central mismatch, a 
shifting or shortening of the probe sequence to avoid the secondary structure was not 
possible. Therefore, a new probe design concept had to be developed. In order to 
enhance specificity of polymorphism detection, enzymatic reactions (ligase detection 
reaction, primer extension) (170), structured DNA probes (13) (molecular beacons) or 
gold nanoparticle probes (161), have been developed. Unfortunately, all these 
approaches require new materials or complex processes and are not easily 
adaptable to the chosen allele specific hybridization format.  
 
A simpler approach described by Guo et al. involves the introduction of artificial 
mismatches in the short oligonucleotide probes to enhance the discrimination of 
SNPs (56). They reported that the effect of the artificial mismatches on hybridization 
stability depends strongly on the relative position of the mismatches, with the 
greatest destabilization occurring with a centralized mismatch and a three to four 
base distance between the true and artificial mismatches. However, they introduced 
artificial nucleotides. Such probes are usually more expensive and not generally 
available from conventional suppliers. Lee et al. provided guidelines for designing 
non-perfectly matched probes by the introduction of mismatches using conventional 
nucleotides in order to increase the specificity of the target hybridization (86). Their 
data indicated that the position of the artificial mismatch is less significant than the 
identity of the nucleotides involved in the exchange, excluding the three positions at 
either end of a oligo probe with a length of 19 nucleotides. The mutation of a not 
centered G produced a significantly greater effect on hybridization efficiency than 
more centered mutations from A or T to G. However, their study was limited to 
properties in solution and in microarray analysis the distance from the mismatch to 
the solid support might also effect hybridization efficiency (126). 
 
Both approaches were designed to generally improve probe specificity to inhibit cross 
hybridization. In this work additional mismatches had to be introduced to avoid the 
formation of unfavorable probe secondary structures in order to allow SNP 
identification at specific target DNA sites. Therefore, the choice of the nucleotide to 
be exchanged was very limited and the results of the aforementioned publications 
were not generally applicable for this purpose. An approach to release secondary 
structure by introduction of additional mismatches in oligonucleotide probes used for 
SNP detection has - to our knowledge - not been reported so far.  
 
In case of four of five probes this design strategy proved to be successful. Although, 
as expected, the resulting net intensities were considerably diminished due to the 
steric hindrance of the additional mismatch, the resulting discrimination efficiency 
was generally increased, slightly in case of probe 125 and distinctively for probe 238. 
In case of probe 222 and 262 only the new probe version allowed the identification of 
the correct perfect match position. The decrease of the perfect match net signal 
intensities could be avoided by designing longer oligonucleotide probes, but as 
shown in case of probe 125, this also implies a higher probability of other secondary 
structure formation. Therefore, in this study the probes were, if possible, designed 
with a length identical to the first version.  
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For probe 39 the new probe design strategy could not generate an improvement, 
since here two highly stable dimer structures could be formed flanking the central 
polymorphism position in the probe sequence at either side. If one was resolved by 
introduction of a mismatched base, the other one persisted. Probes designed with 
one or two additional mismatches to resolve one or both of the dimer structures did 
not produce enough hybridization signal to discriminate the perfect match correctly. 
However, a specific differentiation between mutant and wild type SHV sequences 
was possible in spite of the unfavorable wild type probe secondary structure, since 
the mutant probe was well accessible and the observed hybridization patterns for the 
detection of a mutated versus a wildtype sequence were clearly distinguishable (see 
section 3.2.6). 
 
In conclusion, the new probe design concept of releasing secondary structures by 
introduction of additional mismatched bases proved to be successful in the majority 
of the newly designed probe sets by increasing the specificity of the discrimination, 
but can not be applied to every problematic sequence, as shown in case of probe 39. 
Careful analysis of the different secondary structures and the loss of sensitivity 
through mismatch introduction have to be considered. 
 
4.7 Array performance 
4.7.1 Discrimination efficiency 
The overall discrimination efficiency of allele specific hybridization array for SNP 
detection is depending on an almost equal hybridization efficiency of all used probes 
under the applied experimental conditions (55). Therefore, not only the probe design 
parameters, such as secondary structure (112) or melting temperature are important, 
but also the sequence context (151) and fragment length (78) of the target DNA, the 
immobilization strategy, hybridization and washing conditions as well as the 
hybridization time (55). To achieve similar hybridization efficiencies for a set of 
different probes interrogating specific SNP positions in an allele specific hybridization 
format is thus very complex and needs experimental optimization. Alternatively 
multiplex allele specific oligonucleotide hybridization reactions are performed using 
arrays carrying a highly redundant set of probes (31). However, these analyses are 
complex, laborious and expensive and are not applicable for clinical routine 
diagnostics. Furthermore, not all genotypes can be identified correctly, in spite of the 
complex analysis (29,178).  
 
The diverse probe sets displayed different hybridization efficiencies, which could be 
observed by analysing the absolute signal intensities of the perfect matches in the 
proof of concept. The absolute signal intensities of the perfect matches exhibited a 
wide range from 1500 to 20000 for the TEM-array and 2400 to 46000 arbitrary units 
for the SHV-array. This was to be expected, since it is well known that probes with 
differing sequences display different hybridization behavior (151,154). However, all 
targeted polymorphism positions could be distinctively identified. The highest 
mismatch signal intensities reached only 52 % (TEM-array) or 67 % (SHV-array) of 
the perfect match signal intensity in these experiments. The identification of all tested 
blaTEM - or blaSHV - variants originating from reference strains was also shown. In all 
cases the differing nucleotides present at the polymorphism positions could be 
identified distinctively, because all intensities of the mismatches remained below a 
value of maximal 80 % of the perfect match signal intensity. Although the 
hybridization efficiency of each probe can be influenced by changing the 
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hybridization conditions, such as temperature or salt concentration, it was not 
possible to do this for each probe individually in the currently chosen microarray 
format, since here all hybridizations were carried out simultaneously in one 
hybridization compartment. A promising alternative would be to set the hybridization 
condition for each probe individually, which has already been shown in microarray 
systems using electric field control (41,150). 
 
The measured hybridization signal in microarray experiments is time dependent (55). 
This due to the fact that the target DNA has to diffuse towards the probes. Mixing of 
the hybridization solution can therefore enhance the rate of hybridization (151). 
These parameters should hence also affect the discrimination level. A dependency of 
the discrimination level from the hybridization time and agitation level was clearly 
observed during the testing of the different hybridization devices and times. The 
efficiency of the mismatch to perfect match discrimination was analyzed by reviewing 
the distribution of all mismatches in dependency of the mismatch to perfect match 
ratio (the relative intensity of the mismatches, RIMM). The discrimination was the more 
efficient the lower the mismatch to perfect match ratio was. The better the 
discrimination level, the more the distribution of the relative intensity of the 
mismatches was shifted towards lower relative intensity values. Lower RIMM values 
were observed for hybridizations under agitation or for longer incubation times. In 
comparsion to that - at shorter hybridization times and without agitation - the 
maximum of the RIMM distribution was shifted towards higher RIMM values and the 
distribution approached a Gaussian standard distribution (see section 3.1.9.2). This 
observation proved that the discrimination level was depending on the number of 
meeting events between probe and target molecules. By increasing the number of 
meeting events by agitation or longer incubation times, the discrimination level was 
as expected enhanced.  
 
Furthermore, a dependency of the discrimination level to the incorporation ratio of 
fluorescence label, the amount of target DNA and fragment sizes could be shown (for 
a detailed discussion see below). 
 
4.7.2 Reproducibility  
The reproducibility of the microarray analysis is an important premise for the 
development of a microarray as a diagnostic tool. Sources of variation are numerous 
in microarray experiments, starting from manufacturing of the array, to PCR 
amplification and labeling of the targets, to differences in hybridisation efficiencies of 
probes (12). The current state of the art provides 5 - 10 % variation in signal 
intensities among replicate array elements, and 10 - 30 % variation among 
corresponding array elements on different (self manufactured, cDNA) microarrays for 
expression analysis (157,185). Unfortunately a comparable evaluation study, 
evaluating variations in self manufactured oligonucleotide microarrays for genotyping 
purposes could not be found. 
 
In this study the inter-array variation was determined in the proof of concept by 
calculation of the standard error of the relative mismatch intensities between three 
repetitive hybridizations of a blaTEM or blaSHV reference sample. The detected 
standard errors were between 0 - 12 % or 0 - 17 % respectively. However,  
98 % (for TEM) or 92 % (for SHV) of the standard errors remained below 10 % 
variation among replicate relative intensities. To determine the inter-sample variation 
five blaTEM-1 samples were analyzed, originating from different isolates, amplification 
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and fragmentation reactions. Although the overall net signal intensities after 
hybridization varied due to different incorporation ratios of fluorescent label from the 
different target DNA batches, the detected mismatch to perfect match ratios 
remained fairly reproducible with standard errors up to 21 %. Thus, it was determined 
that the observed inter-array and inter-sample variations were in the range of 
reported values for the current state of the technology. Therefore, the identification of 
the same genotype originating from differing samples was reproducible and a reliable 
detection of different genotypes was rendered possible with the presented microarray 
system. 
 
Unexceptionally high variations in between replicate signal intensities, which were 
detected from time to time, were mostly attributed to problems of the spotting 
process. A problem occurring repeatedly during the microarray analysis was the 
misidentification of a perfect match caused by aberrations in the spotting process. 
These aberrations were identified by hybridization of one or more arrays of a 
produced slide batch to a known reference target. These positions were then 
excluded from the further data analysis. A complete exclusion of the concerned 
slides was generally not possible due to cost reasons. Multiple features of the contact 
printing process can be the cause of these spotting failures (27,102). Among the 
most frequent sources of error were the clogging of the split pin by dust particles or 
crystallized salt, the obstruction of the pin movement by contamination of the pin 
holder, the incomplete loading of the probe solution due to inhomogeneous well 
content, insufficient filling level or solution attached to the walls of the wells. 
Furthermore, aberrations on the slide surface can also inhibit probe deposition or 
attachment. Although extensive optimization regarding spotting protocols and 
preparation of the probe source plate were made, the sporadic occurrence of these 
spotting failures could not be excluded. An on-line monitoring of the probe deposition 
process and automatic exclusion or correction of erroneous arrays would be a 
necessary feature for the commercial production of microarrays for the use in clinical 
diagnostics. 
 
4.7.3 Sensitivity 
The sensitivity of the hybridization on the DNA microarray was determined regarding 
the necessary quantity of target DNA, which is needed for analyzing all perfect 
matches correctly. The amount of target DNA needed depends on multiple 
parameters: characteristics of the surface, such as background intensity and 
immobilization efficiency, nature, quantity and accessibility of the probe DNA, as well 
as target DNA characteristics, such as content of fluorescence label and fragment 
length, as well as the hybridization parameters and the signal detection method (27). 
Therefore, it is quite challenging to compare the results to other systems. 
 
The sensitivity was determined testing the minimum amount of target DNA for two 
different incorporation ratios (87 or 166 NT/F), which is needed for a correct detection 
of all polymorphism positions of the TEM-array. The detection limit of the array was 
not fully exploited with the applied target DNA amounts, since even with the smallest 
amount tested (25 ng equivalent to app. 0.04 pmol) for both incorporation ratios all 
perfect matches could be discriminated from the mismatches. it has to be noted, that 
these results were obtained in a conventional cover slip hybridization for three hours. 
In comparable microarray experiments sensitivity limits of 0.125 pmol (10 minutes 
with agitation of the hybridization solution) (184), or 1 pmol in 30 min (182) were 
obtained. In terms of quantity of detectable DNA amount our developed system can 
Discussion 
 138 
be considered therefore as very sensitive. As has been shown in the results part the 
hybridization time can still be reduced to at least one hour by using an automated 
hybridization station without a significant loss of sensitvity for the analysis (see 
section 3.1.9.1). Although all perfect matches were detected with the lowest amount 
of target DNA tested, the negative effects on the discrimination and the 
reproducibility of a low signal to noise ratio were already obvious. Therefore, it was 
determined that for an optimal specificity and reproducibility the incorporation ratio 
should amount to at least 100 nucleotides per fluorophore and at least 50 ng (app. 
0.09 pmol) of target DNA should be applied. 
 
A dependency of the discrimination efficiency from the amount of applied target DNA 
was clearly determined in case of the target DNA with a higher content of 
fluorescence label (87 nucleotides/fluorophore). By increasing the amount of target 
DNA molecules with an incorporation ratio of 87 the discrimination level was 
enhanced. In contrast to that the discrimination efficiency for an incorporation ratio of 
166 nucleotides/fluorophore was almost independent from the amount of applied 
target DNA and the level of discrimination was decreased compared to all tested 
amounts of target DNA for an incorporation ratio of 87. A probable explanation for 
this observation is an increased competition between unlabeled and labeled 
fragments in case of the target DNA containing less fluorescence label. To reach an 
optimal discrimination between a perfect match and a mismatch, a sufficient number 
of target molecules has to reach the probe. This is depending on the time and the 
amount and size of the available target molecules. In case of the higher content of 
fluorescence label, more labeled target fragments are available, when the amount of 
target DNA is increased, so that the number of probe/target meeting events is 
increased and thus the discrimination level enhanced. In case of the lower content of 
fluorescence label more unlabeled fragments than labeled fragments are available. 
The duplexes with unlabeled fragments are more stable due to steric reasons, since 
the Cy molecule has a relatively big size in comparison to the bases of the DNA (see 
figure 9) and presents a steric hindrance for duplex formation. The stability of the 
heteroduplex products also determines dissociation rates (112). Therefore, the 
hybridization of unlabeled target DNA molecules in case of the target DNA with the 
lower content of fluorescence label is favored in comparison to the labeled ones and 
probably counteracts the enhancement of the discrimination level by increasing 
probe/target meeting events.  
 
In this study the arrays were validated with DNA extracted from clinical isolates, and 
due to an effective DNA extraction step performed at the Robert Bosch Hospital 
sufficient template DNA was present to achieve satisfactory amounts of target DNA 
for all tested isolates (unpublished results). The sensitivity of the system was so far 
not determined regarding the quantity of template DNA needed for the amplification 
of sufficient target DNA for the detection on the microarray. Hereby it has to be noted 
that the PCR, used for target DNA production in this study, was more optimized 
towards cost effectiveness (with low concentrations of dNTPs, fluorescence labels 
and a relatively low priced Taq polymerase) than towards optimal sensitivity. 
Furthermore, a direct labeling approach was used, which was very effective for 
implementation of the system, since it was time-saving and allowed to monitor the 
incorporation ratio of fluorescence label easily, but also lead to a less effective target 
DNA production, since the relatively large size of the fluorescent dye was 
disadvantageous for the polymerase reaction (184). These parameters would have to 
be optimized for increased sensitivity of the target DNA production. 
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An optimization of the PCR protocol is only reasonable in combination with the 
species specific molecular enrichment step  and the development of a multiplex PCR 
approach or an alternative DNA amplification strategy for the simultaneous 
amplification of all ESBL or IRT relevant target genes. This was beyond the scope of 
this study, but will be the subject of subsequent research for implementation of a 
complete ESBL chip. 
 
4.8 Parameters influencing the hybridization 
4.8.1 Fragmentation 
The fragmentation of the target DNA for analysis with an oligonucleotide microarray 
is usually performed to minimize secondary structure and to allow the hybridization of 
different sequence parts independently from each other on the microarray (78). 
Although single stranded targets promise a better accessibility for duplex formation 
(55), in our approach double stranded, directly labeled and fragmented target DNA 
was used for hybridization without prior denaturation. DNA hybridization is a reaction 
process, where ssDNA and dsDNA are present in an equilibrium. The shorter the 
fragments are and the closer their Tm is to the surrounding temperature the more 
strand exchanges can occur, thus probe/target duplex formation also takes place, if 
short dsDNA fragments are used. In this study the denaturation prior hybridization to 
produce single stranded target DNA could be omitted, because, as proven by the 
results of the hybridization, strand exchange could occur within the applied 
hybridization condition. This target DNA preparation method yielded in our approach 
fast, sensitive and specific hybridization results. 
 
The fact that long target DNA strands prevented the accessibility of the target DNA 
could be observed for target DNA batches containing mostly unfragmented target 
DNA. Hereby the capture probes targeting the 3’ end of the targeted DNA strand 
delivered close to background signals when hybridized with unfragmented target 
DNA in contrast to probes targeting the 5’ end. A higher amount of secondary 
structures at the 3’ end of the target molecule compared to the 5’ end could be an 
explanation for this observation.  
 
Another reason could be interactions between the two strands of the target molecule 
during hybridization to the probe sequence. The group of Bergeron, reported that  
5’ immobilized capture probes gave stronger hybridization signals when the  
5’ overhanging tail of the bound target strand was short and showed near 
background signals when the 5’ tail reached a length over 600 nucleotides (127). The 
increase of the 3’ end had no major effect on the hybridization signals. This was a 
counterintuitive result, since one would expect a weaker hybridization signal when a 
5’ end immobilized probe binds a target molecule close to its 5’ end, because of 
steric hindrances caused by a longer 3’ overhanging tail directed towards the 
surface. This observation was explained by the fact that when a probe recognize an 
area close to the 3’ end of the captured target strand most of the overhanging 5’ end 
of nonhybridized DNA is exposed to the liquid phase above.The protruding tail of the 
target molecule can thus interact with the complementary strand, which destabilizes 
the probe target complex. The capture probe sets used in this study presented the 
same kind of behavior as the probe sets used in the study from the group of 
Bergeron, although undirectly immobilized probes were used. This result is 
surprising, since the theories of the group of Bergeron are not applicable, when the 
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probes are immobilized in an undirected way. Most probably other target molecule 
effects have to be considered. One possible explanation could be, that in case of the 
TEM target strand the 5’ end is more accessible for reassociation of the 
complementary target strand than the 3’ end. However, if this hypothesis is valid, 
could not be discerned within the scope of this study.  
 
As expected, best results regarding identification of the perfect match positions were 
achieved for conditions, where - according to the determined incorporation ratio of 
fluorescence label - a majority of the fragments should still bear a fluorescence label. 
Although shorter fragments might still perform better regarding accessibility of the 
target sequence, it could be observed that target DNA with smaller fragment sizes 
(15-50 bp) performed less well regarding sensitivity of the perfect match detection. 
This was most probably due to the presence of an increased number of unlabeled 
target DNA fragments. 
 
The method chosen for fragmentation was the digestion by DNaseI enzyme. This 
enzyme cleaves internal phosphodiesterbonds independently from the DNA 
sequence (173). The major advantage of this procedure was the rapidness of the 
reaction (15 min) and the fact that no purification prior hybridization was necessary. 
The reaction conditions for obtaining a specific size range of fragments has to be 
determined empirically and can be quite diverse, depending on the enzyme batch, 
enzyme activity and the initial target DNA size. Crucial was, as observed during the 
tests of the clinical isolates, the exact timing of the reaction, which was sometimes 
problematic, when multiple fragmentation reactions were performed simultaneously. 
Furthermore, exposure of the enzyme to room temperature could quickly lead to 
inactivation of the enzyme. This could cause incomplete fragmentation, which led to 
a poor discrimination efficiency. To avoid the variations introduced through the use of 
different enzyme batches or decreasing enzyme activity during the multiple utilization 
of one enzyme batch, other enzyme-independent methods for DNA fragmentation 
are also available. The fragmentation can also be performed chemically (78,128) or 
mechanically (68). Among the disadvantages of a chemical fragmentation is the fact 
that harsh reaction conditions (such as alkali or acid treatment) can make the target 
DNA unsuitable for direct hybridization, so that prior purification or neutralization is 
necessary. It also might interfere with the fluorescence label, so that only indirect 
labeling can be used. Most chemical treatment protocols make a more elaborate 
purification necessary and require more time. The mechanical fragmentation of target 
DNA is difficult to control for the used low sample volumina and DNA concentrations. 
 
4.8.2 Assay time and hybridization devices 
For a clinical application the assay time is of crucial importance. The major limitations 
hereby are the amplification and hybridization steps with two and initially three hours. 
Also the manual washing steps with 30 minutes additional assay time offer a 
potential for improvement. A shortening of the amplification time can cause a loss of 
sensitivity of the detection. As mentioned before, the optimization of the amplification 
regarding sensitivity and also assay time involves the combination with the specific 
enrichment method and was beyond the scope of this work. The focus in the here 
presented approach was on optimization of the hybridization process, regarding 
reaction time, sensitivity and reproducibility. Therefore, different devices for the 
improvement of specific features of the hybridization step or for automation of the 
whole process were applied. The different parameters influencing the hybridization 
results were described in detail in the results part. Hereby, it was shown that an 
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automation of the hybridization, washing and drying steps had an advantageous 
effect on the sensitivity and the specificity of the analysis. The tested devices 
performed variably and required different levels of skillfulness from the user. Since 
one prerequisite was to perform the assay as user-independently as possible, the 
most user-friendly equipment with the most convincing assay results was chosen 
(HS400 from Tecan). In an application note from Tecan it was shown, that the 
hybridization station improved the reproducibility and homogenity of the hybridization 
results in comparison to a manual hybridization method (162). This was confirmed by 
the results obtained in this study. With this device a shortening of the hybridization 
time to only 15 minutes was successfully shown. Furthermore, the washing steps 
were also reduced to two times two minutes and one time 1.5 minutes, but the 
automated exchange of solutions, pumping and complete drying process did still add 
up to 30 minutes in total. However, a decreased hybridization time did also result in a 
reduced discrimination efficiency and sensitivity of the analysis. To achieve a 
compromise between optimal results of the analysis and decreased time 
requirements, the hybridization time was shortened to one hour and the HS400 was 
used for all following experiments. 
 
Alternative methods for speeding up hybridization is the use of electronic forces for 
annealing or dissociation of the target. The duplex formation and dissociation can 
then be done in seconds. This method requires special carriers with individually 
addressable electrodes for each probe site. First prototypes of electronic microarrays 
have already been developed (45), but up to date a limitation regarding the number 
of individual probe sites is still observed. However, the principle is quite promising 
and presuming a more complex layout with a high number of electrodes in 
combination with a flow cell and on-line monitoring could allow the sequential 
hybridization, detection and removal of multiple samples within a short period of time. 
 
4.9 Detection of mixed resistances 
The coexistence of different beta-lactamase variants from the same family in a single 
strain has already been reported for TEM- (17) and SHV-type beta-lactamases (43). 
There is not much known so far about the frequency of occurrence of these 
resistance gene patterns especially in case of TEM beta-lactamase. However, it is 
known that TEM-1 (95) and SHV-1 (8) are widespread enzymes and in case of SHV 
the coexistence of SHV-1 and an ESBL variant of this enzyme has been observed 
(64). The possibility for a molecular detection assay to detect and identify an ESBL 
variant in presence of a non-ESBL variant in an isolate therefore is of crucial 
importance. Due to the high level of reproducibility of the mismatch to perfect match 
signal intensity ratios as shown in section 3.1.6, it was assumed that hybridization 
patterns diverging from the usually observed ones can be interpreted regarding 
mixed resistance patterns. The results of a model experiment for the TEM array 
showed, that the level of discrimination between a mixed genotype and a non-mixed 
genotype was differing, depending on the analyzed polymorphism position. A 
detection of mixed resistance patterns was possible for some probe sets up to a ratio 
of 1:5 of target DNA from differing variants, in some cases up to a ratio of 1:10. There 
is not much known about the relative copy number of the different genes in one 
isolate, so that no definite conclusion can be made, whether this range of detection is 
relevant or not. Howard et al. reported a relatively equal copy number of different 
SHV variants in two of three cases, but they did not mention actual ratios (64). The 
detection of the coexistence of different SHV beta-lactamase variants in real clinical 
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isolates with the presented system was possible as shown for the isolates collected 
in Croatia.  
 
However, if this assay system should be used without prior isolation of the resistant 
bacteria, the observed discrimination level is insufficient, because the presence of a 
resistant bacteria in a high excess of non-resistant bacteria in a crude sample is 
definitely possible. Higher discrimination levels (up to one ESBL producing bacterium 
in a background of 100,000 wild-type bacteria) can be achieved by LDR (ligase 
detection reaction) based methods as described by Niederhauser et al. (117). In this 
study only a single polymorphism position was detected and the presented system 
showed only limited multiplexing capacity. LDR-based methods on the microarray 
have already been described (35,38), but these procedures require more complex 
assay features than the allele specific hybridization method and the adaptation of this 
concept to an analysis of a higher number of features is challenging. Generally, 
methods with increased discrimination level (e.g. primer extension, LDR) also require 
more complex protocols, which is a clear disadvantage for clinical application. In the 
future on-line monitored and electronically directed dissociation and association 
profiles could also be used to advance the discrimination level while applying 
traditional allele specific hybridization probes. 
 
4.10 Test of clinical isolates 
In total 113 clinical isolates were provided by the cooperation partners for validation 
of the TEM- or SHV-array. Seventy-two blaTEM -gene containing isolates were 
analyzed on the TEM-array. Seventy of these variants could be identified by the 
TEM-microarray analysis. Two variants exhibited insufficient discrimination pattern, 
which were attributed to incomplete fragmentation. Thirty of the 35 clinical isolates 
collected in Croatia contained blaSHV variants and 29 of these could be identified by 
the microarray analysis. One variant was not identified due to the aforementioned 
problem of insufficient fragmentation. The observed problem during the 
fragmentation step was caused by the simultaneous manual preparation of multiple 
samples, leading to a premature inactivation of DNaseI for these samples. In a 
clinical application this step should be automated or a restricted number of samples 
should be prepared simultaneously to avoid such aberrations. All genotypes detected 
by microarray analysis were confirmed by standard DNA sequencing.  
 
The correlation to the phenotypic data could only be made in a limited scale, since 
not all ESBL or IRT relevant genes were detected. In case of the analysis of all 
blaTEM- genes, only blaTEM-1, blaTEM-2 and blaTEM-116 were found. BlaTEM-1 and blaTEM-2 
are parental types, which do not confer an ESBL phenotype. For blaTEM-116 the 
phenotypic characteristics are not clearly defined. Although Jeong et al. (74) stated, 
that a transconjugant bearing this gene exhibited an ESBL phenotype, it was not 
definitely proven, that this was the only resistance gene present. Furthermore,  
blaTEM-116 bears only two mutations towards TEM-1 at position 82 and 182, which 
have not been found in any other TEM ESBL gene variant so far. It still has to be 
determined whether there is a functional advantage in such changes, so currently no 
conclusion can be drawn if the ESBL phenotype might be caused by this variant. The 
results from the analysis of the samples collected in Croatia suggest a non-ESBL 
phenotypic substrate pattern for variants carrying this genotype. Thus, in the isolates 
tested in this study the ESBL phenotype was probably not caused by TEM variants.  
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In case of the analysis of the SHV genotypes from the isolates collected in Croatia 
blaSHV-1 and blaSHV-5, blaSHV-12 alone or in presence of blaSHV-1 were detected. Hereby 
it was shown that the differentiation of mixed and pure resistance patterns is possible 
and that an ESBL variant can be identified in presence of a non-ESBL variant by 
SHV-array analysis. The fact that in all K. pneumoniae and the K. terrigena isolates a 
blaSHV-1 gene was found either alone or in combination with a blaSHV -ESBL gene 
variant (in contrast to the E. coli isolates, which did not contain a  
blaSHV-1 type gene), could be explained by the frequent occurrence of a 
chromosomally encoded blaSHV-1 in K. pneumoniae (8). Although the template DNA 
consisted of extracted plasmid DNA, the presence of a background of chromosomal 
DNA could not be excluded (64) and was the most probable cause of the blaSHV-1 
genotype detection in the K. pneumoniae isolates.  
 
The correlation of the genotypic analysis to the phenotypic data was for the isolates 
from Crotia consistent for 34 of the 35 isolates. The isolates phenotypically classified 
as ESBL producers contained an SHV-type ESBL variant, except for isolate 27, 
which must contain a non-SHV- or TEM-type ESBL variant, which was not 
genotypically identified. Isolates clearly classified as non-ESBL producers (isolates 
13, 21, 32) or showing substrate patterns corresponding to K1 (isolate 26) or CTX-M 
(isolate 2) type resistance contained only parental variants (SHV-1, TEM-1) or  
TEM-116 and no SHV-ESBL variant. A final conclusion could not be drawn for 
isolates 2 or 26, since it was not genotypically screened for CTX-M or K1 type 
resistances within this study. Isolate 36 showed an unusual resistance pattern (see 
section 3.3) and could not be classified phenotypically as an ESBL, AmpC or other 
usual beta-lactamase producer and contained according to the genotypic analysis no 
blaTEM or blaSHV –ESBL variant. Thus, the reliability of the array analysis for ESBL 
detection and identification could be validated, but the need for an extension of the 
detectable spectrum of ESBL variants to other families than TEM or SHV also was 
observed, since otherwise no definite correlation to the phenotypic data can be 
made.  
 
4.11 Ongoing developments 
4.11.1 Transfer to a marketable format 
The identification of the perfect match positions was possible with the EAT propietary 
system, but further optimization to achieve comparable discrimination and sensitivity 
levels, as for the well-characterized currently used system, still has to follow for a full 
implementation of the new format. The use of the silver label (1) showed very 
promising enhancements of the sensitivity of the detection, but the necessity to 
improve the wash protocol for reduced background signals and improved 
discrimination efficiency was observed. Since the transfer of the system to the EAT 
format was in principle successful, the development of a marketable product for 
clinical microbiology is considered as possible. 
 
4.11.2 Link of the resistance to the pathogenic bacteria 
In this proof concept experiment a blaTEM-1 gene could be amplified after a species-
specific enrichment by polynucleotide probes of E. coli from a urine sample in 
microtiter wells. This amplificate could be used as a template in a labeling PCR and 
was used for a successful identification of blaTEM-1 with the TEM-microarray. In the 
future the labeling PCR should be carried out directly after enrichment. So far this 
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direct amplification and labeling was not successful (data not shown), but an 
optimization of the PCR protocol should solve this problem. However, the proof that 
the combination of both systems can establish a link between a genotypic species 
detection and resistance identification was rendered by this experiment. A culture 
independent preisolation of the pathogenic organism could be a considerable time 
advantage for the clinical application. 
 
4.11.3 Extension of the detection spectrum of the ESBL chip 
The developed TEM- and SHV-arrays yield a clear identification of the known TEM 
and SHV resistance determinants, enabling a monitoring of the occurrence of 
different variants in the clinical setting. Furthermore, the ESBL relevant 
polymorphisms are identified, so that the choice of antibiotics for treatment can be 
facilitated by considering existing resistance profiles of previously characterized 
variants. However, a major advantage of the phenotypic diagnostic remains that a 
wider variety of resistance determinants can be detected. To enable the ESBL chip to 
compete with phenotypic standard methods, the majority of the ESBL resistance 
determinants have to be covered. The third major ESBL causing genotype is 
attributed to genes from the CTX-M gene family (13). These resistances are of 
increasing importance especially in eastern Europe and belong to the most rapidly 
growing groups. Therefore, a CTX-M array is currently developed as a 
complementary feature to the TEM- and SHV-arrays in cooperation with coworkers 
from the National Research Center of Antibiotics in Moskow (NRCA). In contrast to 
SHV and TEM the different CTX-M variants present a high level of polymorphism 
with only up to 70% of sequence identity within the gene family. A prototype array 
has already been developed, conferring a hierarchic identification, where family, 
group and subtype specific probes are combined in an allele specific hybridization 
format. So far 11 of the 37 classified CTX-M variants can be specifically identified by 
these probes. Seven group specific probes allow the correct classification of the 
tested CTX-M variants according to their different subgroups. The development of 
family specific and the missing subtype specific probe sets is still in progress. To 
design microarrays for the detection of AmpC and OXA-type beta-lactamases is 
projected.  
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4.12 Conclusion 
The ultimate goal in this project was the development of an ESBL-Chip for the rapid, 
sensitive and reliable detection and identification of the clinically relevant ESBL and 
IRT producing beta-lactamases for application in clinical microbiology diagnostics as 
well as epidemiologic studies. This was achieved for the majority of the most relevant 
ESBLs, the TEM and SHV beta-lactamases. The developed assay systems allow the 
detection of 96 % of the currently known TEM-variants and 100 % of the known SHV-
variants. The assay enabled the detection and identification of 99 % of the relevant 
polymorphisms for TEM beta-lactamases and 100 % of the mutations of SHV beta-
lactamases. Consensus primers were developed and used for target amplification 
covering the majority of the known variant sequences. The sensitivity, reproducibility 
and identification capability of the developed arrays was validated with numerous 
reference samples and clinical isolates. The simultaneous detection of an extended 
spectrum-variant in presence of a narrow spectrum-variant was shown in a model 
system for TEM up to a ratio of 1:10, as well as in clinical isolates for SHV. Starting 
from the isolated DNA, the assay could be performed in less than 3.5 hours. The 
discrimination level, the sensitivity and the reproducibility were enhanced by 
automation of the hybridization procedure. The extension of the developed system 
towards the detection of other beta-lactamase families is possible and is already in 
progress. 
 
The rapid detection of resistant bacteria by genotypic resistance testing at a 
competitive price should reduce the emergence of drug resistances. The prescription 
of antibiotics could be more targeted and thus more effective, since expected 
substrate profiles could be deducted from the genotypic profile and considered 
before treatment. The use of broad spectrum antibiotics could be limited to severe 
infections and a spread of resistances could be averted by an early isolation of 
infected patients. The developed genotypic resistance tests could therefore have a 
major impact on the clinical management of infectious diseases and health care 
costs. 
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6 Appendix 
6.1 List of abbreviations 
A, G ,C , T  Adenine, Guanine, Cytosine, Thymine 
AmpC   name of beta lactamase 
APEX    arrayed primer extension 
APS   ammonium persulfate 
ASPE   allele specific primer extension 
a. u.   arbitrary unit 
BAL   bronchoalveolar lavage 
BLAST   basic local alignment tool 
BES   name of beta-lactamase 
bp   base pair 
CCD   charge-coupled device 
CFU   colony forming unit 
CME    name of beta-lactamase 
CMY   name of beta-lactamase 
CTX-M   cefotaxime resistant (beta-lactamase) 
Cy   cyanin dye 
ddH2O   double distilled water 
ddNTP   didesoxynucleotidetriphosphate 
DMSO   dimethylsulfoxide 
DNA   desoyxribonucleic acid 
dNTP   desoxynucleotidetriphosphate 
dsDNA   double stranded DNA 
EARSS   European Antbiotic Resistance Surveillance System 
EAT   Eppendorf Array Technology 
E. amnigenus  Enterobacter amnigenus 
E. cloacae  Enterobacter cloacae 
E. coli   Escherichia coli 
EDTA   ethylendiamintetraacetate 
EGTA   ethylene glycol bis(2-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 
ESBL   extended spectrum beta-lactamase 
FEC    name of beta-lactamase 
FDA   US Food and Drug Administration 
FOX    name of beta-lactamase 
∆G   free energy 
GES    name of beta-lactamase 
h   hour 
HPLC   high performance liquid chromatography 
ID limit   identification limit 
ICU   intensive care unit 
IRT   inhibitor resistant TEM (beta-lactamase) 
K1   name of beta lactamase 
kb   kilobase 
K. oxytoca  Klebsiella oxytoca 
K. ornithinolytica Klebsiella ornithinolytica 
K. pneumoniae  Klebsiella pneumoniae 
K. terrigena  Klebsiella terrigena 
MALDI-TOF  matrix assisted laser desorption/ionization-time of flight detector 
MEN   name of beta-lactamase 
MIC   minimum inhibitory concentration 
min   minute 
MM   mismatch 
MT   mutant 
NCCLS   National Committee for Clinical Laboratory Standards 
NI    net intensity 
NRCA   National Research Center for Antibiotic Resistance, Moscow 
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n. s.   no specification 
NT/F   number of nucleotides per fluorophore 
ORF   open reading frame 
OXA   oxacillin resistant (beta-lactamase) 
OXY   name of beta-lactamase 
PBP   penicillin binding protein 
PCR   polymerase chain reaction 
PER    name of beta-lactamase 
PSE    name of beta-lactamase 
PLL   poly-L-lysine 
PM   perfect match 
P. mirabilis  Proteus mirabilis 
PMT   photomultiplier 
PNA   peptide nucleic acid 
RFLP   restriction fragment length polymorphism 
RI    relative intensity 
RIMM    relative intensity of the mismatch 
RIPM    relative intensity of the perfect match 
RNA   ribonucleic acid 
rRNA    ribosomal RNA 
SDA   strand displacement amplification 
SDS   sodium dodecyl sulfate 
SFO    name of beta-lactamase  
SHV   sulphydryl variable (beta-lactamase) 
SI   specific intensity 
SNP   single nucleotide polymorphism 
SSC   sodium chloride sodium citrate buffer 
SSCP   single strand conformational polymorphism 
ssDNA   single stranded DNA 
SSPE   sodium chloride sodium phosphate EDTA buffer 
STR   short tandem repeats 
TAE   Tris acetate EDTA buffer 
TE   Tris EDTA buffer 
TEM   Temoniera (name of beta-lactamase) 
TLA    name of beta-lactamase 
Tm   melting temperature 
TPase   transpeptidase 
Tris   Tris-(hydroxymethyl) aminomethan 
U   unit 
UK   United Kingdom 
US   United States 
UV   ultra violet 
VEB    name of beta-lactamase 
WT   wild type 
 
Appendix 
 164 
6.2 Acknowledgements 
 
I would like to thank Prof. Rolf D.Schmid for providing this interesting project and the 
opportunity to work in his institute with an excellent equipment, as well as for his help 
and motivational support during the whole time.  
 
A special thanks goes to my supervisor PD Dr. Till T. Bachmann for my introduction 
into the subject, his untiring support, scientific advice and help for writing this thesis 
and publications, as well as the management of an inspiring and agreeable working 
group. 
 
I would also like to thank Beate Rössle-Lorch for proofreading, as well as scientific 
discussions, her readiness to help and good work together. 
 
I thank Dirk Leinberger for the agreeable work together, discussions and his support 
for creating some of the images displayed in this thesis. 
 
A special thanks goes also to all the present and former lab members, with whom I 
had the opportunity to work: Dr. Xiao Lei Yu, Dr. Holger Schulze, Jutta Secker, Marco 
Hofmann, Susanne Münch, Carolina Soekmadji, Kristina Knösche, Timo Barl, Katja 
Kurr, Dr. Flaubert Mbeunkui, Stefanie Häfele. They were always helpful, ready to give 
good advice and made my stay in the lab an enjoyable experience.  
 
I would like to thank Dr. Satoshi Ezaki for the introduction into the subject and the 
work preceeding this study, which paved the way for the development of the here 
presented arrays. 
 
I also want to thank Christina Onaca, whose work accomplished within the scope of a 
Studienarbeit delivered some data for this thesis and Marlies Fischer for an 
agreeable time of work together during her Studienarbeit. 
 
This work was done in cooperation with academic and industry partners. Therefore, I 
would like to thank Prof. Dr. Cornelius Knabbe, Dr. Milorad Susa and Jan Weile, the 
coworkers at the Robert-Bosch Hospital in Stuttgart, for performing the phenotypic 
testing, support of the strain collection and providing advice concerning the clinical 
microbiology point of view.  
 
My thanks go also to Prof Dr. Witte and coworkers at the Wernigerode branch of the 
Robert Koch Institute for delivering reference strains and knowledge regarding 
importance and prevalence of diverse antibiotic resistance traits.  
 
I thank PD Dr. Wolfgang Ludwig and Katharina Fichtl for providing access to a 
method for the species-specific enrichment of pathogenic bacteria in order to test a 
combination with the resistance arrays.  
 
I thank the industry partner Eppendorf AG, who supported this work with technical 
equipment and promotes the transfer of the developments to a marketable format.  
 
Appendix 
  165
I also thank Maya Rubtsova from the National Research Center for Antibiotics in 
Moscow, Russia for her work on the CTX-M-array, which is an important step for the 
development of a complete ESBL-chip. 
 
Since this thesis was accomplished at the Insitute of Technical Biochemistry within 
the scope of the GenoMik (Genome research on microorganisms) project, I would 
like to thank the BMBF for funding this work.  
 
Furthermore, I would like to thank my parents and my husband Thomas for their 
irreplaceable help, patience and support during my whole time of studies. 
Appendix 
 166 
6.3 Curriculum Vitae 
 
Surname: Grimm, née Jung 
First names: Verena, Ulrike 
Date of Birth:  21 November 1975 
Place of Birth: Herten in Westfalen 
Marital status: married 
Nationality: German 
 
 
Education/Studies 
Nov. 01 - Oct. 05 Doctorate  
Institute of Technichal Biochemistry,  
University of Stuttgart, Prof. R. D. Schmid 
Development of a diagnostic microarray for the rapid detection 
of Extended Spectrum Beta-Lactamases for the use in clinical 
microbiology 
 
Jan. 01 - Sept. 01 Diplomarbeit 
Department of Microbiology and Immunology, 
University of Michigan USA, Prof. M. Imperiale 
Development of Adeno-Associated Virus Vectors for gene 
therapy of the nervous system 
 
Sept. 98 - Sept. 01 Preparation of a trinational diploma in Biotechnology  
at the Ecole Supérieure de Biotechnologie de Strasbourg 
Degree: Diplom d’Ingénieur en Biotechnologie, 
              Diplom Biotechnologin 
conferred by the European Confederation of the 
University Louis Pasteur in Strasbourg (France), 
University of Basel (Switzerland), Freiburg and Karlsruhe 
(Germany) 
 
Sept. 95 - May 98 Vordiplom in Chemistry  
University of Karlsruhe  
 
Sept. 86 - Jun. 95 Abitur  
Städtisches Gymnasium Herten, Westfalen 
 
Sept. 82 - Jul. 86 Primary school 
Comenius Grundschule in Herten, Westfalen 
Appendix 
  167
6.4 Declaration 
 
Herewith I declare that the presented work was accomplished independently and only 
by the use of the specified resources and literature. 
 
Stuttgart, 12 October 2005 
 
